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Abstract 
In a mouse model of radiation-induced acute myeloid leukaemia (rAML), the CBA/H 
strain, copy loss of Sfpi1 is found in up to 90 % of cases. The gene codes for the 
transcription factor PU.1, an important regulator of haematopoiesis, which acts as a 
tumour suppressor. Point mutations specifically in the DNA sequence encoding the 
binding domain of the protein are found at a high frequency, suggesting that the 
transcription factor has a reduced function in leukaemic blasts.  
    Transgenic CBA/H mice expressing green fluorescent protein (GFP) under the 
control of the Sfpi1 promoter allowed the use of flow cytometry to, for the first time, 
study copy loss of Sfpi1 in cases of rAML by analysing the expression levels of GFP. 
Analysis of mRNA levels of Sfpi1 showed there probably is a different mechanism for 
leukaemogenesis in cases with point mutations in the sequence encoding the DNA 
binding domain compared to cases with a wild type Sfpi1, the former potentially 
through lack of function in the transcription factor PU.1 and the latter through 
suppression of Sfpi1 gene expression. 
    Fluorescent activated cell sorting was used to isolate immature bone marrow cells 
(BMC) containing Sfpi1 deletions from previously irradiated mice. The isolated cells 
were transplanted into myeloablated hosts with some success, although this new 
approach to study radiation-induced leukaemogenesis needs refinement. 
    A population of immature BMCs was found to be less radiosensitive in the CBA/H 
strain compared to the C57BL/6 strain, which is not susceptible to rAML. This gave 
an indication of where the target cell population for the initial leukaemic events may 
occur.   
    The work in this thesis presents novel ways of studying early events in rAML 
induction in the CBA/H mouse and gives new insights into the mechanisms of 
leukaemogenesis in the model. 
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Chapter 1. Introduction 
 
1.1 Ionising radiation and sources of exposure   
    Electromagnetic (EM) radiation consists as a continuous spectrum where the waves 
can be described according to the relationship between the frequency and wavelength. 
The radiation includes for example x-rays, ultraviolet and visible light, microwaves 
and radio waves. EM radiation with a short wavelength and high frequency is ionising 
radiation, where examples are x-rays and γ-rays. X-rays are produced by an x-ray tube 
and are produced extranuclearly by accelerating electrons to a high energy and 
stopping them with a target, usually tungsten. In contrast, γ-rays are produced 
intranuclearly and emitted by radioactive isotopes through nuclear fission. Apart from 
how they are produced, they have similar properties. Other forms of ionising radiation 
are particulate radiation, such as α-particles, neutrons, protons or heavy charged 
particles. Particulate radiation is naturally occurring as well as being produced 
experimentally or through radiation therapy (Hall 2000; Lehnert 2008).  
    Exposure to ionising radiation is from a mixture of natural- and medical sources 
and nuclear accidents. Natural sources include radiation from space, the sun and from 
the earth itself. The estimated world wide average exposure due to natural sources is 
estimated to be 2.4 mSv (UNSCEAR 2008a). The annual exposure in excess of 
natural sources due to occupational sources is 37260 man Sv, which is the collective 
effective dose. Examples of such occupations are aircrew and people working in the 
mining or nuclear industry (UNSCEAR 2008a). Ionising radiation is also used in 
diagnostic radiology, nuclear medicine and radiation therapy. The annual exposure, 
expressed as an estimated collective dose is 4200000 man Sv (UNSCEAR 2008b). 
Further exposure occurs from nuclear accidents, such as Chernobyl in 1986 where 
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directly exposed staff and emergency workers had high dose direct exposure, but also 
exposure to the general public through contamination of milk by 131I (UNSCEAR 
2008c).  
    Ionising radiation, such as x-rays and γ-rays, is a well known carcinogen in 
humans. Epidemiological studies of mortality and incidence of cancer have shown an 
increased risk of cancer for the atomic bomb survivors, therapy using ionising 
radiation and workers in the nuclear industry (Gilbert, 2009; Sill et al., 2011). In 
survivors of the atomic bombs of Hiroshima and Nagasaki an excess risk in solid 
cancers was found and an approximately 5-fold increase in leukaemias, including 
acute lymphocytic leukaemia, chronic myeloid leukaemia and acute myeloid 
leukaemia (AML) was seen (Pierce et al., 1996).  
 
1.2 Chemical and physical effects of exposure 
    Radiation can be divided into directly ionising and indirectly ionising radiation. 
Directly ionising radiation, charged particles such as protons and heavy ions, has 
sufficient energy to interact directly with atoms to cause chemical damage and 
biological effects. Indirectly ionising radiation, such as x-rays, is absorbed by tissues 
where energy from the radiation is dispersed. This produces fast, charged particles 
through the interaction with atoms. In the case of x-rays, these are electrons. The 
excitation of electrons, if sufficient energy is provided, can then lead to ionisation 
through the removal of electrons (Tubiana et al., 1990; Hall, 2000). X-rays are 
composed of photons, which can be seen as energy packets. When an electron is 
removed, this leads to the breaking of chemical bonds. The absorbed dose is measured 
in the SI unit Gray (Gy), where 1 Gy = 1 J/Kg). Tissues absorb the individual energy 
packets and the energy they contain could have an effect on the absorbing tissues 
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(Hall, 2000). The total energy absorbed by a dose of 4 Gy, which is approximately the 
LD50 in humans, (Anno et al., 2003) is equivalent to the energy absorbed by drinking 
a cup of coffee. The important difference between ionising radiation and non-ionising 
radiation is the energy in each packet and not the total energy absorbed (Hall 2000).  
    Radiation has direct and indirect actions on deoxyribonucleic acid (DNA). Direct 
action is caused by charged particles, such as α-particles, protons or electrons. In this 
process, the ionised molecule caused by radiation interacts directly with the DNA to 
cause DNA damage. The second scenario is DNA damage caused by free radicals 
produced by the interactions of ionising radiation with particularly water molecules in 
a cell and the subsequent formation of charged particles, which can then interact and 
damage DNA (Tubiana et al., 1990; Lehnert 2008).  
 
 
1.3 DNA- and chromosome damage 
 
    The DNA molecule in cells is the most important target of radiation and can cause 
various types of damage, such as chromosome aberrations, DNA single- and double-
strand breaks (Table 1.1) (Goodhead, 1994).  
    Single-strand breaks in DNA lead to the recruitment of replication protein A 
together with the Rad9-Rad1-HUS (9-9-1) complex to the damaged site. In the case of 
double-strand breaks, the Mre11/Rad50/NBS1 (MRN) complex is recruited to the site 
of DNA damage (Seviour and Lin, 2010). The DNA damage response (DDR) can 
then continue through a signalling network through two pathways, either the protein 
kinase ataxia-telangiectasia, mutated (ATM) or ATM Rad3-related (ATR). Both 
pathways need the function of BRCT-repeat inhibitor of hTERT (BRIT1) since both 
ATM and ATR are unable to localise to the site of DNA damage if BRIT1 is absent 
(Rai et al., 2006). The DDR signalling pathway then varies depending on where in the  
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Number of DNA 
lesions/cell      
          after a dose of 1-2 Gy     
                
  Double-strand breaks     40     
                
  Single-strand breaks     approx 1000     
                
  Base damage     > 1000     
               
        
Damage in 
mammalian cell 
nucleus  
from 1Gy of x-ray 
radiation 
     
          
 
Type of initial 
physical damage      
                
  
Number of 
ionisations in cell 
nucleus       ~100 000     
                
  
Number of 
ionisations directly 
in DNA       ~2000     
                
  
Number of excitations 
 directly in DNA   ~2000     
 
Table 1.1. Damage in the mammalian cell nucleus caused by ionising radiation. 
 (Goodhead, 1994 and Hall, 2000) 
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cell cycle the damaged cell is (Shiloh, 2001). At the G1/S checkpoint, ATM and ATR 
can phosphorylate a Serine residue (Ser15) on the transcription factor p53, an 
important tumour suppressor (Meek, 2009), whereas other serine residues on p53 are 
indirectly phosphorylated via other proteins activated by ATM. This leads to the 
upregulation of p21 and cell cycle arrest through the inhibition of cyclin-dependent 
kinases (CDKs) that prevent the progression through the cell cycle (Shiloh 2001). 
ATM and ATR can also activate the protein kinases Chk2 and Chk1 respectively at 
the G2/M checkpoint. This leads to the inactivation of CDC25 and prevent cells from 
entering mitosis (Zhou and Elledge, 2000). 
Single-strand breaks caused by ionising radiation are mainly repaired by base excision 
repair. It involves the interaction between several factors that detect, excise the 
damaged base and then replaces it. Single-strand breaks are detected by Poly (ADP-
ribose) polymerase proteins. After the damaged ends have been processed by among 
other proteins DNA Polymerase β (Pol β), AP endonuclease-1 and x-ray repair 
complementing defective repair in Chinese hamster cells 1 (XRCC1), the gap is filled. 
This is either done by Pol β, XRCC1followed by ligation for single base pair 
replacements. For longer stretches up to 10-12 base pairs, the action also involves 
proliferating cell nuclear antigen (PCNA) further polymerases and flap endoculease-1 
(Caldecott, 2007).  
    DNA double-strand breaks (DSBs) are a common type of damage caused by 
ionising radiation and more serious since just one break can be lethal to a cell. The 
main mechanisms of DSB repair are homologous recombination (HR) and non-
homologous end joining (NHEJ) (Khanna and Jackson, 2001). During HR the sister 
chromatid is used as a template. The Rad52 group of proteins binds to the DNA and 
Rad52 and Rad51 co-operate with several other proteins to mediate the strand 
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exchange. Thereafter, the repair process continues through the formation of a 
Holliday junction and is then completed by the action of DNA polymerases for 
synthesis and ligation of the new DNA (Helleday et al., 2007). While HR is used to 
repair DSBs in DNA in mammalian cells, NHEJ is more commonly used. NHEJ is 
initiated by the binding of the Ku complex of proteins that associates with DNA-
protein Kinases (DNA-PK). The DNA-PK catalytic subunit (DNA-PKCS) is then 
activated and recruits the XRCC4- DNA ligase IV (X4-L4) complex. Before the 
damaged DNA can be processed, another important protein, Artemis is needed for the 
processing of DNA ends. After this has been achieved, the X4-L4 complex can ligate 
the DNA ends together (Burma et al., 2006; Mahaney et al., 2009). NHEJ exists as 
two different pathways, one accurate described above and one error-prone. In the 
error prone pathway, Ku is not of the same importance as in the canonical pathway. 
The alternative pathways is thought to involve a mechanism where short stretches of 
nucleotides, or microhomologies, close the DSB acts as a primer for NHEJ (Pfeiffer et 
al., 2000; Bennardo et al., 2008). The mechanisms of the alternative-NHEJ is still 
under investigation, but the transcription factor carboxy-terminal binding protein 
interacting protein (CtIP) has been found to have an important role (Bennardo et al., 
2008) and also in the formation of translocations resulting from alternative-NHEJ 
(Zhang and Jasin, 2010). 
 
1.4 Ionising radiation, cancer and leukaemia 
    DNA DSBs can lead to chromosomal aberrations if not properly repaired (Hall 
2000; Lehnert 2008) and there is a well established link between radiation and 
chromosomal aberrations (Sax, 1938). Chromosomal aberrations are commonly found 
in tumour cells and lead to losses and gains of genetic material (Heim and Mitelman, 
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1995). The changes resulting from the chromosomal aberrations in tumour cells can 
range from chromosome translocations, changes in the number of chromosomes and 
amplifications or deletions of parts of chromosomes, to smaller mutations such as 
deletions, insertions or base pair substitutions of the DNA sequence (Kinzler and 
Vogelstein, 2002).  
     Cancer is a multi-stage process, where normal cells are turned into malignant by 
mutations that enhance the proliferation of the cell or create a genetic instability in the 
cell. This means the mutated genes causing the progression towards cancer can be 
seen as either accelerating the process (oncogenes) or keeping it under control 
(tumour suppressors) (Strachan and Read, 1999). Mutations of oncogenes can lead to 
excessive proliferation due to the normal version of the gene, called a proto-
oncogene, being involved in progression through the cell cycle, cell division or 
differentiation. Examples include genes for growth factors, growth factor receptors 
and families of nuclear transcription factors involved in proliferation or 
differentiation. A feature of oncogenes is that a single mutated allele of the gene can 
have an effect (Park, 2002).  
    Tumour suppressor genes are linked to a variety of functions. These are for 
example cell-cycle control, differentiation, apoptosis and maintenance of genome 
integrity. A common feature is that the genes are involved in conserved signalling 
pathways and are part of a network of other tumour suppressors and proto-oncogenes 
(Fearon, 2002). In contrast to oncogenes, both alleles of the gene need to be mutated 
for an effect to be noticed (Strachan and Read, 1999). Alfred Knudson’s work on 
retinoblastoma, a rare, aggressive tumour of the retina, led him to propose a two-hit 
model of carcinogenesis (Knudson, 1971). A rare genetic spontaneous mutation in 
one allele of the gene RB1 does not lead to retinoblastoma, but a second mutation in 
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the other allele is needed for progression of the disease. The work of Cavenee et al. 
then gave some possible mechanisms for how such a two-hit model would work, by 
showing how recessive heterozygous mutations can become homozygous by loss of 
the wild-type allele (Cavenee et al., 1983). 
    Apart from the direct mechanism of a tumour suppressor through a mutation in the 
gene, another indirect mechanism is the methylation of CpG dinucleotides of 
promoter regions. This has been noticed in several forms of cancers, including breast 
cancers and leukaemias.  There is furthermore evidence of hypomethylation of DNA 
in cancer that could lead to activation of genes or chromosome instability (Das and 
Singal, 2004). Other epigenetic modifications of DNA that are involved in normal 
gene regulation as well as cancer are modifications such as acetylations, methylations 
and ubiquitinations of histones. These modifications control gene expression by the 
fact that they change the conformation of the chromosomes and the availability of 
binding sites for transcription factors. The modifications are made possible through 
the aberrant recruitment of histone-modifying enzymes by repressive or activating 
fusion proteins (Cheung and So, 2011).  
    In a study of AML patients, a higher incidence of chromosome aberrations 
involving chromosome 5 and 7 was seen in AML patients that were atomic bomb 
survivors compared to non-exposed patients with AML (Kamada et al., 1991). In a 
further study of patients that were atomic bomb survivors, a higher frequency of 
deletion of chromosome 7 was seen in AML. Deletions of chromosome 20 were seen 
in myeloprolferative disease at a higher rate than in AML. Deletions were seen on 
chromosome 5 and 13 at a higher rate and also amplifications on chromosome 17 
(Nakanishi et al., 1999). 
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    AML has also been found in patients previously treated with alkylating agents or 
radiotherapy. In a study of 140 patients, the frequency of internal tandem duplications  
of the gene Flt3 was seen as well as rearrangements of the MLL gene, point mutations 
were also found in the KRAS and NRAS genes (Pedersen-Bjergaard et al., 2008). 
Another study found deletions of chromosome 5 and 7 as well as trisomy of 
chromosome 8. Translocations (t(9;11) and t(v;11)(v;q23)) were also seen at a higher 
rate in therapy-related AMLs compared to primary AMLs (Kayser et al., 2011). 
    Point mutations are a common type of mutation in cancers, particularly through the 
deamination of CpG dinucleotides caused by methylation (Antonarakis et al., 2002). 
It is not generally thought that ionising radiation directly causes these mutations 
(Breimer, 1988), but that they are part of the multi-step process of cancer 
development. Ionising radiation can however cause the formation of reactive oxygen 
species, which could then cause DNA base damage (Hall, 2000; Bregeon and 
Doetsch, 2011). Contributing factors, including genetic disposition, are deficiencies in 
proofreading by DNA polymerases and misrepair of DNA (Preston et al., 2010; 
Lange et al., 2011).  
 
1.5 Haematopoiesis  
    The formation and development of red and white blood cells is referred to as 
haematopoiesis (Figure 1.1). Haematopoietic cells differentiate from haematopoietic 
stem cells (HSCs) via progenitors, with varying capacity to develop into either 
myeloid or lymphoid cells, to immature lineage-restricted progenitors and finally 
mature effector cells (Bryder et al., 2006). In adult mammals, the site of 
haematopoiesis is the bone marrow, however in the adult mouse some haematopoietic 
activity is still present in the spleen (Morita et al., 2011). The HSCs reside in niches 
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in the bone marrow where they mostly exist in a quiescent state. (Wilson and Trumpp, 
2006). The HSCs give rise to various progenitor cells that can later mature into 
effector cells of various lineages, lymphoid, myeloid and erythroid. The lymphoid 
cells originate in the bone marrow, but whereas B-lymphocytes continue their 
maturation in the bone marrow, T-lymphocytes mature in the thymus. Cells of the 
myeloid lineage and erythrocytes continue their maturation in the bone marrow 
(Janeway et al., 2001). 
    HSCs have the capability to self-renew, can differentiate into all lineages and cell 
types of the haematopoietic system. A test for proving a particular type of cell is a 
true HSC is to transplant them into immunocompromised or lethally irradiated 
animals. If the animals receiving the transplanted cells show long-term reconstitution 
of all haematopoietic lineages, usually for a minimum of 16 weeks, the transplanted 
cell type is considered a HSC (Purton and Scadden, 2007). Since similar experiments 
cannot be performed in humans due to ethical reasons, it is difficult to definitely say 
whether a particular phenotype of human HSC would reconstitute humans long-term. 
In the mouse, a multipotent progenitor (MPP) was found that has a limited capacity 
for self-renewal, but still has the potential to develop into all cell types (Morrison et 
al., 1997). A similar cell type has not been found in humans. Further downstream the 
MPP in mice and from the human HSC, the progenitor cells start to branch and 
become either lymphoid or myeloid progenitors. The commitment to either the 
myeloid or lymphoid lineage is through the common myeloid progenitor (CMP) 
(Akashi et al., 2000; Manz et al., 2002) and common lymphoid progenitor (CLP) 
(Galy et al., 1995; Kondo et al., 1997).  In mouse, a suggested lymphoid primed 
multipotent progenitor (LMPP) with some capability of myeloid differentiation has 
also been found (Adolfsson et al., 2005; Lai and Kondo, 2006). Even though dendritic  
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Figure 1.1. An overview of the development of cells in the haematopoietic 
system.   
Haematopoietic stem cells (HSCs) give rise to all cells of different lineages. In mouse 
a multipotent progenitor (MPP) has been suggested, which develop into the common 
lymphoid progenitor (CLP) and the GMP through a lymphoid primed multipotent 
progenitor (LMPP). The MEP can also develop into a megakaryocyte-erythrocyte 
progenitor (MEP) and the common myeloid progenitor (CMP), which can divide into 
the granulocyte-macrophage progenitor (GMP). The CMP has also been suggested to 
be able to differentiate into the MEP. The progenitors then mature into more lineage 
restricted progenitors and finally the mature effector cells. 
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 Mouse  Human 
    
 
LSK Thy-1 lo 
 
LSK   
LT-
HSC 
Thy -1 lo  flt3 – 
 
LSK   CD34+ CD38- CD90+ 
 
LSK CD38+ 
 
Endo+ Sca-1+ Rholo 
 
CD150+ CD244- CD48- 
   
    
ST- 
HSC 
LSK 
Thy-1lo Flt3+   
    
 LSK  Not proven 
MPP Thy -1 - CD34+ flt3 +   
    
 ILR7α+ Sca-1lo  CD34+ CD38+ 
CLP   CD45RA+ CD10+ 
    
 IL7Rα- Lin- Sca-1- c-kit+ CD34+ CD38+ 
CMP FcγRIII/II lo CD34+  CD45RA- IL3Rα =/- 
    
 IL7Rα- Lin- Sca-1- c-kit+ CD34+ CD38+ 
GMP FcγRIII/II hi CD34+  CD45RA+ IL3Rα lo 
    
 IL7Rα- Lin- Sca-1- c-kit+ CD34+ CD38+ 
MEP FcγRIII/II lo CD34-  CD45RA- IL3Rα - 
    
 
Table 1.2. Proposed phenotype of immature BMCs in mouse and human.  
(Bryder et al., 2006; Iwasaki and Akashi, 2007b and further references in the text). 
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cells are usually derived from the myeloid branch of haematopoietic development via 
the CMP, some dendritic cells also develop from the CLP in mice (Traver et al., 
2000). The lymphoid development further progresses to more lineage-restricted 
progenitor and finally fully differentiated lymphoid cells, ie T-cells, B-cells and 
natural killer cells (Iwasaki and Akashi, 2007a). The CMP can differentiate into a 
granulocyte-macrophage progenitor (GMP) or the megakaryocyte-erythrocyte 
progenitor (MEP) (Akashi et al., 2000; Manz et al., 2002) as well as lineage restricted 
dendritic cell progenitors (Liu and Nussenzweig, 2010). Downstream of the GMP, the 
cells differentiate into lineage restricted progenitors and finally macrophages, 
monocytes and dendritic cells (Iwasaki and Akashi, 2007b). Similarly, the MEP 
differentiates into lineage-restricted progenitors that eventually develop into 
megakaryocytes and platelets, and erythrocytes respectively (Iwasaki and Akashi, 
2007b). A summary of the phenotypic expression of surface markers for the 
developing cells in the haematopoietic system and the differences between mouse and 
human cells are in Table 1.2. 
 
1.6 Haematopoietic stem cells 
    Till and McCulloch discovered (Till and McCulloch, 1961) that bone marrow cells 
transplanted into lethally irradiated hosts gave rise to colonies on their spleens. The 
cells were found to be differentiated and they speculated that these cells are clones of 
single cells. They later showed that cells from these colonies could form new colonies 
if serially transplanted (Siminovitch et al., 1963) and therefore had the capacity of 
self-renewal. However, later work found that the cells forming the colonies are not 
pluripotent HSCs (Jones et al., 1990) and should probably be seen as a form of early 
progenitor cells (Coulombel, 2004).  
  30 
    The phenotype for isolating HSCs has been defined using various surface marker 
combinations. Spangrude and colleagues isolated HSCs from mice that lacked surface 
markers of differentiated cells, lineage negative (Lin-) cells, and were positive for the 
surface markers stem cell antigen-1 (Sca-1), v-kit Hardy-Zuckerman 4 feline sarcoma 
viral oncogene homolog (c-Kit) and had a low expression of thymus cell antigen-1 
(Thy-1) (Spangrude et al., 1988). HSCs were later isolated from humans with the 
surface marker phenotype Lin- CD34+ Thy-1lo (Baum et al., 1992). Even though the 
Lin- Sca-1+ c-Kit+ (LSK) fraction in mouse bone marrow is enriched for HSCs 
(Okada et al., 1992) only about 10 % of the LSK fraction are HSCs, whereas the 
remaining cells are various progenitors (Challen et al., 2009). The LSK phenotype 
still forms the basis for the definition of many surface marker combinations. As 
described, Spangrude et al. 1988 isolated cell on the basis of the expression of Thy-1. 
If this surface marker is combined with the Flt3 receptor, three populations with 
different properties can be isolated, the LSK Thy-1lo Flt3- population of long-term 
reconstituting HSCs (LT-HSC), LSK Thy-1lo Flt3+ cells with short-term HSC 
reconstituting potential (ST-HSC) and the LSK Thy-1- Flt3+ MPP (Christensen and 
Weissman, 2001). Furthermore, the surface marker CD38 was found in mice to be a 
marker of LT-HSCs. The LSK CD38+ fraction gave reconstitution long-term, whereas 
the LSK CD38- fraction was enriched for cells with short-term reconstituting ability 
and progenitors (Randall et al., 1996). In contrast, CD38 is expressed on more 
committed cells in humans (Terstappen et al., 1991). Other surface marker 
combinations that have successfully used for isolating HSCs in mice are Endoglin 
(Endo)+ Sca-1+ Rhodamine (Rho) lo (Chen et al., 2003) and CD150+ CD244- CD48- 
(Kiel et al., 2005).  
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1.7 Early progenitor cells and myeloid development 
    Multipotent progenitors (MPP) have a limited ability to self-renew, but can still 
differentiate into multiple lineages (Christensen and Weissman, 2001). It is possible 
to further fractionate the LSK Thy-1- Flt3+ MPPs into cell populations that have 
different potential for the lymphoid and myeloid lineage. The fractionation is done by 
the expression of vascular cell adhesion molecule-1 (VCAM-1). Progenitors that are 
Flt3hi VCAM-1- are preferentially developing into common lymphoid progenitors 
(CLP), but can also develop into granulocyte-macrophages and not megakaryocytes. 
The Flt3lo VCAM-1+ population can develop in to common myeloid progenitors 
(CMP) and erythroid cells, whereas the Flt3hi VCAM-1+ population cannot develop 
into erythroid cells, but have a granulocyte-macrophage potential (Lai and Kondo, 
2006).    
    Myeloid progenitors in mice are not part of the LSK fraction and in contrast to the 
CLP do not express the interleukin-7 receptor α chain (IL-7Rα) (Table 1.2). Myeloid 
progenitors express c-Kit and can therefore be classified as IL-7Rα- c-Kit+ Lin- Sca-1-. 
There are three different subsets of myeloid progenitors that are further possible to 
fractionate according to their expression of FcγRIII/II apart from belonging to the IL-
7Rα- c-Kit+ Lin- Sca-1- fraction. The CMP that is FcγRIII/IIlo CD34+, the 
megakaryocyte-erythrocyte progenitor (MEP) that is FcγRIII/IIlo CD34- and the 
granulocyte-macrophage progenitor (GMP) that is FcγRIII/IIhi CD34+ (Akashi et al., 
2000). FcγRIII is also expressed on macrophages (Gordon and Taylor, 2005). 
    Other surface markers that are found on myeloid progenitor cells are CD31 and 
Ly6C. Ly6C is expressed at intermediate levels on granulocytes. The marker is also 
expressed on early myeloid progenitors. CD31 is expressed on myeloid progenitors, 
but not on mature granulocytes (van der Loo et al., 1995). A combination of the two 
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markers Ly6c and CD31 is also expressed on dendritic cells precursors (Nikolic et al., 
2003). Both Ly6C and CD31 are expressed in combinations with other surface 
markers on more mature monocytes (Gordon and Taylor, 2005). 
    Mature granulocytes express Gr-1 (Ly6G) (Fleming et al., 1993) whereas 
macrophages and monocytes express Cd11b/Mac-1 (Arnaout 1990). 
      
1.8 Transcription factors in myeloid development and leukaemia 
    Proteins called transcription factors bind to regulatory elements of DNA, enhancers 
and repressors, to regulate the expression of eukaryotic genes. In doing so, they can 
interact with the general transcription factors binding to the TATA-box and RNA 
polymerase II (Alberts et al., 2002). In the context of myeloid differentiation and 
maturation, the correct actions of transcription factors and interactions between them 
are vital. If these actions and interactions are disrupted by for example small point 
mutations in DNA sequences coding for transcription factors or translocations 
involving parts of chromosomes, the result could be the development of myeloid 
leukaemia through the dysregulation of differentiation and maturation of myeloid 
cells (Figure 1.2) (Rosenbauer and Tenen, 2007). 
    The transcription factor runt-related transcription factor 1 (RUNX1, also called 
AML 1) is involved in the development of all haematopoietic lineages. A knockout of 
the gene is embryonic lethal, whereas a conditional deletion of the gene in adult mice 
inhibits CLP production and also lead to blocked B-cell production, T-cell maturation 
and platelet formation. Conditional deletion of RUNX1 also leads to a mild  
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Figure 1.2. Transcription factors in myeloid development.  
The expression of certain transcription factors is essential for the development of 
some haematopoietic lineages. The interplay between transcription factors and the up- 
or down-regulation of them furthermore decides lineage commitment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  34 
myeloproliferative disorder. Furthermore, the fusion product of RUNX1 (AML1) 
ETO lead to AML through the down regulation of the transcription factors PU.1, 
C/EBPα and the expression of RUNX1 itself (Rosenbauer and Tenen, 2007; Cohen, 
2009).  
    C/EBPα is expressed in myeloid progenitors and granulocytes, but not in 
macrophages. The transcription factor regulates the expression of genes important for 
encoding myeloid differentiation and those of growth factor receptors (eg. 
granulocyte colony- stimulating factor receptor (G-CSFR), macrophage colony-
stimulating factor receptor (M-CSFR), granulocyte–macrophage colony-stimulating 
factor receptor (GM-CSFR)). C/EBPα is also involved in the regulation of HSCs, 
where a deficiency lead to increased self-renewal and reconstitution ability. The 
CEBPA gene has been found to be mutated in about 10 % of AML cases, resulting in 
constitutive activation of for example the Flt3 and c-kit receptors, both tyrosine kinase 
receptors (Reckzeh and Cammenga, 2010).  
    Interferon-regulatory factor 8 (IRF8) knockout mice are immunodeficient, 
presumably because of being deficient in macrophages. The mice also develop a 
chronic myeloid leukaemia (CML) like syndrome (Tamura and Ozato, 2002). The 
transcription factor is involved in the lineage decision at GMP level to decide on the 
differentiation along either the macrophage or granulocyte lineage (Rosenbauer and 
Tenen, 2007). Together with the transcription factor PU.1, IRF8 also regulates B-cell 
lineage specification (Wang and Morse, 2009). 
    The transcription factor growth-factor independent 1 (GFI1) restricts HSC and 
myeloid progenitor proliferation. It is also required for the differentiation of myeloid 
progenitors. Lack of function of GFI1 lead to neutropenia and it is also required for 
megakaryocyte maturation and erythrocyte formation. GFI1 also antagonises PU.1 in 
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monocyte/granulocyte lineage choice, where PU.1 lead to monocyte differentiation 
and GFI1 to granulocyte differentiation. Low levels of GFI1 have been found in some 
patients with myelodysplastic syndrome whereas higher than normal levels of 
expression has been linked to CML (van der Meer et al., 2010). 
    A knock out of the gene encoding the transcription factor GATA binding protein-1 
(GATA-1) is embryonic lethal. The gene is also required for terminal erythroid 
differentiation and essential for megakaryocyte differentiation. A mutation in the 
GATA-1 promoter leads to 15 % normal platelet levels in mice as well as blocked 
eosinophil development (Crispino, 2005). GATA-1 also physically interacts with 
PU.1. At the CMP level, this interaction specifies erythroid (GATA-1) or myeloid 
(PU.1) differentiation. Mutations in the Gata1 gene with a resulting truncated protein 
lead to a myeloproliferative disorder or megakaryocyte leukaemia in patients with 
Down’s syndrome. A knockdown of the gene to 5 % of normal expression levels lead 
to erythroleukaemia in mice (Burda et al., 2010). 
 
1.9 The gene Sfpi1 
    PU.1 is a transcription factor, encoded by the gene Sfpi1, expressed in 
haematopoietic cells belonging to the ETS family of transcription factors (Hromas et 
al., 1993). Sfpi1-/- mice die at day 18 and analysis at day 16.5 found that T- and B-
cells development in the thymus was absent as well as the absence of granulocytes 
and macrophages in the fetal liver (Scott et al., 1994) Mice engineered to have 
targeted disruption of the expression of the exon encoding the DNA binding domain 
of the PU.1 protein die soon after birth from septicaemia unless they are given 
antibiotics, in which case they survive up to two weeks of age. Normal 
haematopoietic development is furthermore disrupted with macrophage development 
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absent and abnormal granulocyte development. Furthermore, the B-cell differentiation 
aberrant with a differentiation block and T-cell differentiation is delayed (McKercher 
et al., 1996). Apart from Sfpi1 being needed for thymocyte development at the fetal 
stage, the gene is expressed in early T-cell development in adult mice (Nutt et al., 
2005). Recent work has found a role for Sfpi1 in the development of interleukin-9 
producing T cells in allergic response (Chang et al., 2010) and T-helper 2 effector cell 
development (Hadjur et al., 2009). 
    Using Sfpi1-/- embryonic stem cells it was found they could produce erythroid cells, 
but not cells of the lymphoid or myeloid lineage. The same results were found when 
fetal liver cells were transplanted into lethally irradiated hosts (Scott et al., 1997). 
However the Sfpi1-/- fetal liver cells differentiate into myeloid progenitors when 
cultured and express certain myeloid restricted genes. The cells could also develop 
into granulocyte precursors, but not fully differentiated granulocytes (DeKoter et al., 
1998). It was later found that a low expression level of PU.1 protein in 
haematopoietic progenitors resulted in B-cell development, whereas a high expression 
blocked B-cell development and led to macrophage development (DeKoter and Singh, 
2000). Sfpi1 has further been found to be essential for self-renewal in HSCs that are 
transplanted into lethally irradiated hosts. When cells deficient in Sfpi1 were 
transplanted haematopoiesis disappeared after 6 months. The CMPs, GMPs and CLPs 
were dependent on the expression of the gene, but in contrast to myelomonocytic 
maturation, B-cell maturation was independent of the expression of Sfpi1 (Iwasaki et 
al., 2005). Recent work has also found that Sfpi1 is essential for dendritic cell 
development. The action of Sfpi1 seems to be through the gene Flt3 that it directly 
regulates in a concentration dependent manner (Carotta et al., 2010).  
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     The expression of Sfpi1 is regulated by cell type specific promoters and can 
autoregulate itself in myeloid cells (Chen et al., 1996a; Chen et al., 1996b). Further 
regulation is by distal regulatory elements in myeloid cells (Li et al., 2001). The          
-14 kb upstream regulatory element (URE) was later shown in vivo to be 
autoregulated by PU.1 itself (Okuno et al., 2005) and knockdown of this URE result 
in a graded reduction of the expression of Sfpi1 and the development of leukaemia 
(Rosenbauer et al., 2004). The same URE also enhances B-cell development while 
repressing T-cell development (Rosenbauer et al., 2006). The promoter and -14 kb 
URE has also been shown to be regulated at the chromatin level by the transcription 
factors in B-cells, T-cells and macrophages (Hoogenkamp et al., 2007). Further 
regulatory elements have also been found for early T-cell regulation and a model was 
proposed for strong and weak silencers and enhancer URE (Zarnegar et al., 2010). 
Sfpi1 was also recently found to be regulated by the transcription factor nuclear 
factor-κB (NF-κB) at an upstream enhancer element (Bonadies et al., 2010). 
 
1.10 Myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML) 
    MDS is characterised by impaired peripheral blood cell production, leading to 
cytopenia. The bone marrow is hypercellular with blasts, but not to the same extent as 
seen in leukaemia. Analysing the peripheral blood, the morphology of the cells 
involves, for example, abnormal granules and abnormal shapes and sizes of cells. 
Some chromosomal aberrations seen are trisomy 8, deletions on chromosome 5 and 
aberrations on chromosome 20 and 7. The spleen and liver is infiltrated with cells in 
some cases, leading to splenomegaly or hepatomegaly. In about 40 % of cases of 
MDS, the disease can progress to AML (Silverman, 2003; Nimer, 2008).      
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    AML is a cancer of the white blood cells, more specifically cells of the myeloid 
lineage. It is characterized in humans by the accumulation of undifferentiated myeloid 
cells in the bone marrow, which outgrow the normal cell population and interfere with 
the normal production of haematopoietic cells (Lichtman and Liesveld, 2001). There 
are several subtypes of AML, which can be classified in different ways. The French-
American-British (FAB) classification (Table 1.3) separates the leukaemia on the 
basis of the stage where the leukaemic blasts have stopped differentiating (Bennett et 
al., 1976; Tenen, 2003), whereas the WHO classification (Table 1.4) of acute myeloid 
neoplasms and leukaemias also includes genetic abnormalities, immunophenotypes 
and clinical features in its classification (Brunning et al., 2001; Vardiman et al., 
2009). 
    The differentiation of haematopietic cells follows specific stages via defined 
subsets of progenitor cells to more lineage-restricted progenitors and finally to mature 
effector cells. Each subset and cell type has a defined surface marker phenotype, as 
was described above, making it possible to distinguish cell types from each other by 
antibody staining and flow cytometric analysis. In some cases, the activity of 
transcription factors lead to the expression of specific cell surface markers. Blast cells 
in MDS, AML and other types of leukaemia such as lymphoblastic leukaemia express 
surface markers in aberrant ways, which in some cases is connected to specific 
genetic abnormalities. For example, in acute promyelocytic leukaemia (APL), the 
immunophenotye of the blasts is close to promyelocytes when the translocation 
(15;17) is present in human APL (Orfao et al., 2004). In AML, the inversion of 
chromosome 16 is connected to the expression of CD34 and a strong expression of 
CD117 (c-kit). An aberrant expression of CD2 is often seen, although the expression 
is not specific for the genetic aberration (Ossenkoppele et al., 2011). 
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French-American-British (FAB) classification of AML 
Subtype Description 
M0 Undifferentiated 
M1 Myeloblastic without differentiation 
M2 Myeloblastic with differentiation 
M3 Promyelocytic 
M4 Myelomonocytic 
M4EO Myelomonocytic with bone marrow 
eosinophilia 
M5 Monocytic 
M6 Erythroleukemia 
M7 Megakaryoblastic 
 
Table 1.3. French-American-British (FAB) classification of AML. 
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Myeloproliferative neoplasms (MPN) 
 
Chronic myelogenous leukemia, BCR-ABL1–positive 
Chronic neutrophilic leukemia 
Polycythemia vera 
Primary myelofibrosis 
Essential thrombocythemia 
Chronic eosinophilic leukemia, not otherwise specified 
Mastocytosis 
Myeloproliferative neoplasms, unclassifiable 
 
Myeloid and lymphoid neoplasms associated with eosinophilia and 
abnormalities of PDGFRA, PDGFRB, or FGFR1 
 
Myeloid and lymphoid neoplasms associated with PDGFRA rearrangement 
Myeloid neoplasms associated with PDGFRB rearrangement 
Myeloid and lymphoid neoplasms associated with FGFR1 abnormalities 
 
Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) 
 
Chronic myelomonocytic leukemia 
Atypical chronic myeloid leukemia, BCR-ABL1–negative 
Juvenile myelomonocytic leukemia 
Myelodysplastic/myeloproliferative neoplasm, unclassifiable 
Provisional entity: refractory anemia with ring sideroblasts and thrombocytosis 
 
Myelodysplastic syndrome (MDS) 
 
Refractory cytopenia with unilineage dysplasia 
Refractory anemia 
Refractory neutropenia 
Refractory thrombocytopenia 
Refractory anemia with ring sideroblasts 
Refractory cytopenia with multilineage dysplasia 
Refractory anemia with excess blasts 
Myelodysplastic syndrome with isolated del(5q) 
Myelodysplastic syndrome, unclassifiable 
Childhood myelodysplastic syndrome 
Provisional entity: refractory cytopenia of childhood 
 
Acute myeloid leukemia and related neoplasms 
 
Acute myeloid leukemia with recurrent genetic abnormalities 
AML with t(8;21)(q22;q22); RUNX1-RUNX1T1 
AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 
APL with t(15;17)(q22;q12); PML-RARA 
AML with t(9;11)(p22;q23); MLLT3-MLL 
AML with t(6;9)(p23;q34); DEK-NUP214 
AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1 
AML (megakaryoblastic) with t(1;22)(p13;q13); RBM15-MKL1 
Provisional entity: AML with mutated NPM1 
Provisional entity: AML with mutated CEBPA 
Acute myeloid leukemia with myelodysplasia-related changes 
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Therapy-related myeloid neoplasms 
Acute myeloid leukemia, not otherwise specified 
AML with minimal differentiation 
AML without maturation 
AML with maturation 
Acute myelomonocytic leukemia 
Acute monoblastic/monocytic leukemia 
Acute erythroid leukemia 
Pure erythroid leukemia 
Erythroleukemia, erythroid/myeloid 
Acute megakaryoblastic leukemia 
Acute basophilic leukemia 
Acute panmyelosis with myelofibrosis 
Myeloid sarcoma 
Myeloid proliferations related to Down syndrome 
Transient abnormal myelopoiesis 
Myeloid leukemia associated with Down syndrome 
Blastic plasmacytoid dendritic cell neoplasm 
 
Acute leukemias of ambiguous lineage 
 
Acute undifferentiated leukemia 
Mixed phenotype acute leukemia with t(9;22)(q34;q11.2); BCR-ABL1 
Mixed phenotype acute leukemia with t(v;11q23); MLL rearranged 
Mixed phenotype acute leukemia, B-myeloid, NOS 
Mixed phenotype acute leukemia, T-myeloid, NOS 
Provisional entity: natural killer (NK) cell lymphoblastic leukemia/lymphoma 
 
B lymphoblastic leukemia/lymphoma 
 
B lymphoblastic leukemia/lymphoma, NOS 
B lymphoblastic leukemia/lymphoma with recurrent genetic abnormalities 
B lymphoblastic leukemia/lymphoma with t(9;22)(q34;q11.2);BCR-ABL 1 
B lymphoblastic leukemia/lymphoma with t(v;11q23);MLL rearranged 
B lymphoblastic leukemia/lymphoma with t(12;21)(p13;q22) TEL-AML1 
(ETV6-RUNX1) 
 
B lymphoblastic leukemia/lymphoma with hyperdiploidy 
B lymphoblastic leukemia/lymphoma with hypodiploidy 
B lymphoblastic leukemia/lymphoma with t(5;14)(q31;q32) IL3-IGH 
B lymphoblastic leukemia/lymphoma with t(1;19)(q23;p13.3);TCF3-PBX1 
 
T lymphoblastic leukemia/lymphoma 
 
 
Table  1.4 WHO classification of myeloid neoplasms and acute leukaemia 
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However, in general the surface marker expression in AML is quite heterogeneous in 
human AML and a particular surface marker is often difficult to link to a certain type 
of leukaemia and surface markers are therefore best used in combination with each 
other. In the case of biphenotypic leukaemia, both a lymphoid and myeloid 
phenotype, there is quite a clear characteristic surface marker expression since the 
markers are not usually coexpressed (Orfao et al., 2004) 
    Many animal models of leukaemia or other types of cancer are genetically modified 
to have particular fusion genes, deletions of genes or mutations by specific alterations 
of the genome (McCormack et al., 2008; Heyer et al., 2010).  This could potentially 
lead to a slightly more homogenous phenotype that is useful in describing the disease 
and in investigating how specific genetic defects has altered the normal differentiation 
and/or maturation of haematopoietic cells (Oravecz-Wilson et al., 2009; Zuber et al., 
2009). 
As a way of standardising the classification of haematopoietic neoplasms in mice, the 
Mouse Models of Human Cancers Consortium (MMHCC) at the National Institute of 
Health in the USA decided on a set of proposals to help diagnosis and standardise 
classification and descriptions between laboratories investigating similar 
abnormalities. They devised proposal for both non-lymphocytic and lymphocytic 
haematopoietic neoplasms (Kogan et al., 2002; Morse et al., 2002). The classification 
is similar to the WHO classification in that it takes into account several characteristics 
such as morphology, immunophenotype and genetic abnormalities. The proposals also 
contain suggestions for antibody panels that can be used. Results presented later in 
this thesis have made use of some of the proposals in the immunophenotyping work. 
    Apart from using immunophenotyping as a complement to aid diagnosis, the 
technique has been used to decide the phenotype of leukaemic cells capable of 
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initiating the disease when transplanted into myeloablated or immunoompromised 
hosts. The aim is to find the leukaemia initiating cell or leukaemic stem cell as 
described below. 
 
1.11 Leukaemic stem cells and the cell of origin 
    In human leukaemias, it was found that only a small fraction of leukaemic cells 
were able to proliferate and expand, which led to the concept of leukaemic stem cells 
(LSCs) or cancer stem cells (CSC) (Lapidot et al., 1994; Passegue et al., 2003). They 
were identified in patient samples as having the surface phenotype CD34+ CD38- 
Thy1- and could be transplanted into non-obese diabetic/severe immunodeficiency 
(NOD/SCID) mice and give rise to acute myeloid leukaemia (Lapidot et al., 1994). 
These mice lack most features of a functioning immune system and have therefore 
been used for the xenotransplantation of human AMLs (Blair et al., 1997; Bonnet and 
Dick, 1997). Since the LSCs have a stem cell-like phenotype, CD34+ CD38-, it is 
likely that the mutations causing the leukaemia originate in HSCs. The HSCs already 
have self-renewal capacity and would acquire mutations leading to a differentiation 
block and a proliferative advantage. Committed progenitors, which are still at an 
immature stage, could theoretically become LSCs by re-acquiring the ability to self 
renew and then accumulate mutations that lead to a leukaemic phenotype (Passegue et 
al., 2003; Clarke and Fuller, 2006). 
    The CSC model is not without some controversies and difficulties regarding the 
definition of a CSC. The fact that the original experiments with cell from human 
AML xenotransplanted into immunodeficient mice showed that the LSC was rare 
does not mean that it is a signifier for the CSC/LSC model. The number of tumour 
cells required for initiating the disease is not always dependent on the number of 
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transplanted cells. That is, disease can sometimes be initiated at a similar rate 
irrespective of whether a large or small number of cells are transplanted (Kelly et al., 
2007). Also, there is an argument for whether the phenotype of the cell initiating 
disease in xenotranplant models is reflecting a LSC or a cell type that is able to adapt 
to grow when transplanted into a specific xenotranplant model (Adams et al., 2007). 
In a transplant model of melanoma, a solid tumour, a large number of surface markers 
were tested to see whether a CSC would be found, but all subpopulations were able to 
initiate tumours when transplanted. Furthermore, 28 % of melanoma cell were 
tumour-initiating cells (Quintana et al., 2010) However, as a definition it can be said 
that the CSC or LSC does not necessarily refer to the cell of origin but “a cell type 
that sustains the growth of many cancers [and] possesses stem cell properties such as 
self-renewal and lies at the pinnacle of a neoplastic hierarchy, giving rise to 
‘differentiated’ progeny that lack the same properties” (Kennedy et al., 2007).  
    As previously mentioned in relation to immunophenotyping of AML, there can be 
considerable heterogeneity of the tumour cells. Two examples of models that could 
explain this are the genetic mutation model and the cell-of-origin model. In the first 
example, the heterogeneity is the result of separate genetic or epigenetic cancer 
inducing events that give rise to separate phenotypes. In the second model, the cell of 
origin, where the event initially occurred, shapes the phenotype of the tumour. 
Therefore, within the same disease, the tumour phenotype will look different if the 
initiating event was in a stem cell than if the event occurred in a progenitor cell, but 
both cell types can give rise to the same cancer. In both these models, tumour 
heterogeneity could also further be the result of additional mutations after the initial 
event (Visvader, 2011). To demonstrate the cell of origin in mouse models using 
fusion proteins for example, the cell of origin varies. The MLL-GAS7 fusion protein 
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that lead to a mixed-lineage leukaemia can only be initiated if the protein is 
transduced into HSC or MPPs, but not more committed haematopoietic progenitors 
(So et al., 2003). In contrast, the MLL-AF9 fusion protein can initiate leukaemia 
irrespective of whether it is transduced into HSCs or committed progenitors (Krivtsov 
et al., 2006).  
 
1.12 The effect of radiation on HSCs and pre-leukaemic cells 
    Apart from the direct damage to DNA and directly causing oncogenic mutations, 
ionising radiation has found to have effects on HSCs that have implications for the 
concept of the cell of origin and LSCs in the induction of leukaemia. Total body 
irradiation (TBI) results in long-lasting damage in LSK cells, a fraction that as 
previously discussed contains HSCs and progenitor cells. The number of LSK cells is 
notably lower in irradiated mice a long time after exposure and the cells have an 
increased senescence phenotype (Wang et al., 2006). The effect was found to be due 
increased oxidative stress in HSCs (Wang et al., 2010).  
    Phenotypic changes to HSCs have also been found with a transient increase in Sca-
1 expression and a reduction in c-Kit expression. Furthermore, the amount of LSK 
cells were reduced in a dose-dependent effect that was long-lasting and the HSCs 
were less competitive in reconstituting when transplanted into myeloablated hosts 
(Simonnet et al., 2009).  
    Marusyk et al (Marusyk et al., 2009) found that ionising radiation reduced the 
competitiveness of BMCs even when transplanted at a 9:1 ratio irradiated/unirradiated 
cells. The number of functional HSCs was found to be reduced about 10-fold. They 
suggested that the reduction of fitness was due to reactive oxygen species (ROS). 
Furthermore, they found that certain oncogenic mutations had a competitive 
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advantage after irradiation and could form expanding clones at a higher rate. This was 
also translated into a higher frequency of leukaemia compared to irradiated control 
cells without the same mutations. 
     Mutations connected to the oncogene p53 have also been found to give a 
competitive advantage to irradiated HSCs. Bondar et al (Bondar and Medzhitov, 
2010) found that p53 mediated a stress-induced competition after irradiation in HSCs 
and progenitor cells that was dependent on the levels of the gene. The outcompeted 
cells were furthermore found to have a senescence like phenotype. Similarly, 
Marusyk et al (Marusyk et al., 2010) found that p53 deficient irradiated progenitor 
cells were selected for. The selection was due to protection against ablation in p53 
deficient cells, which also led to an increased in lymphoma. 
    The concept of cellular fitness caused by exposure to irradiation, selection for 
certain mutations and changes in the microenvironment has therefore been discussed 
in a recent review article (Fleenor et al., 2010). The induction of senescence is 
probably partially responsible for some of the competitive changes. Why certain 
mutations are selected for by radiation exposure compared to others is however not 
known. In the case of p53 deficient cells, the selection seems to be due to the radio 
protective effect the mutated form of the gene has. Furthermore, changes in the bone 
marrow microenvironment could influence the selection of certain cells over others. 
The selection could either be due to cells carrying oncogeneic mutations receiving 
positive proliferation signals from the stromal cells that have a positive impact on 
cells with oncogenic mutations. Or, inhibitory signals from the stromal cells could 
have less impact on cells carrying the oncogeneic mutations.  
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    The complexities of how exposure to ionising radiation and oncogenic mutations, 
senescence and the microenvironment therefore has an as yet unresolved connection 
that needs to be further investigated. 
 
 
1.13 Radiation-induced acute myeloid leukaemia in the CBA/H mouse 
     Mouse models of radiation-induced AML (rAML) have been developed to study 
the development of the disease in vivo. For example in the RF strain which is 
susceptible to rAML and thymic lymphoma (Upton et al., 1958), the C3H/He strain 
(Hayata et al., 1983), and the SJL/J strain (Trakhtenbrot et al., 1988). The CBA/H 
mouse model was first developed almost 30 years ago and a brief, single whole-body 
exposure of x-rays at a dose of 3 Gray gave maximal yields. Approximately 12-18 
months after irradiation, up to 25% of mice develop AML (Major and Mole, 1978). In 
the mouse, rAML is characterised by undifferentiated cells in the bone marrow and 
splenomegaly is common through the infiltration of leukaemic blasts, which can 
furthermore occur in liver and kidneys (Major, 1979). 
    The spontaneous incidence of rAML in the CBA/H strain is low, quoted as being 
less than 1/1000 (Major, 1979), which makes it a good model for the disease since it 
can be assumed that the leukaemia is caused by ionising radiation and not by a 
spontaneous event. In contrast another strain, C57BL/6, is not susceptible to rAML, 
but does develop thymic lymphoma in response to radiation (Yokoro, 1986). Boulton 
et al. (Boulton et al., 2001) crossed the two strains and studied the rAML incidence in 
F1 crosses.  From this study, they suggest that the incidence of rAML is higher in F1 
progeny (average 7%) than in the C57BL/6 (0%) strain but lower than in the CBA/H 
strain.  
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    In the mice that develop rAML, it has been found that over 90% of the leukaemic 
blasts have a partial deletion of one copy of chromosome 2 (Azumi and Sachs, 1977; 
Hayata et al., 1983; Rithidech et al., 1995). Damage to chromosome 2 can be detected 
already 24 hours after irradiation at the individual cell level (Rithidech et al., 1995; 
Bouffler et al., 1997; Peng et al., 2009) and at 12 -15 months after irradiation, 50 % 
of mice carries an expanding chromosome-2-aberrant clone (Figure 1.3 and Bouffler 
et al. 1997). Molecular mapping of leukaemic cells in mice with rAML found a 
minimal deleted region on chromosome 2, where a potential tumour suppressor gene, 
Sfpi1 was identified (Silver et al., 1999; Finnon et al., 2002). The gene encodes the 
transcription factor PU.1. Further work found that from around 70-84 %, of the 
remaining copies of the Sfpi1 gene, there is a point mutation in the DNA sequence 
located in the DNA-binding domain of the protein (Cook et al., 2004; Suraweera et 
al., 2005; Hirouchi et al., 2008). It is currently not known at what point after 
irradiation this point mutation occurs. In human cases of AML, heterozygous point 
mutations have been found in just 7 % of cases. It was found that the mutation leads 
to a reduced or aberrant function of the transcription factor (Mueller et al., 2002). 
    In mice with a knock-out of a growth factor gene (Csf3), meaning the mice are 
deficient in the production of granulocyte colony-stimulating factor (G-CSF) lead to 
an increase in granulocytic cell when the gene Sfpi1 is expressed heterozygously. The 
phenotype can only be seen on the knockout genetic background and not when Csf3 is 
wild type and expressed as normal (Dahl et al., 2003). Further evidence that the mice 
with one copy of Sfpi1 lead to dysregulated haematopoiesis was seen in a mouse 
model where Sfpi1 heterozygote mice were bred onto a background expressing the 
fusion gene promyelocytic leukaemia-retinoic receptor alpha (PML-RARα). The 
Sfpi1 heterozygote mice, not expressing PML-RARα, developed splenomegaly and an  
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Figure 1.3. Timeline for the development of rAML after the exposure to a 
whole-body dose of ionising radiation.  
(Bouffler et al., 1997)  
  
One copy of Sfpi1  deleted 
X-ray irradiation 3Gy 
Day 1 
All mice have chromosome 2 aberrations 
12-15 months 
50 % of mice have a clonal expansion of 
chromosome 2 aberrations  
12-18 months 
25 % of the irradiated mice have 
developed AML with chromosome 2 
aberrations 
Early event 
Later event 
Point mutation 
1-9 months 
13 % of mice have a clonal expansion of 
chromosome 2 aberrations 
AML 
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expanded myeloid population, but not AML. However, Sfpi1 heterozygote mice on a 
PML-RARα background developed AML (Walter et al., 2005).  
    A graded reduction of Sfpi1 to 20% of normal levels, leads to AML after 3-8 
months (Rosenbauer et al., 2004). Metcalf et al. (Metcalf et al., 2006) induced the a 
conditional complete inactivation of the Sfpi1 gene by an injection of 
polyinosinepolycytosine in genetically primed adult mice, using the Interferon-
responsive MxCre transgene, which resulted in myeloid leukaemia after 13-34 weeks 
in 95% of the mice. The mice had normal characteristics of AML, including 
infiltration of the liver and spleen by immature granulocytic blast-like cells and 
leukopenia.  
    According to the two last examples, either reduction or complete loss of PU.1 
expression leads to the induction of AML. The results from Dahl et al and Walter et 
al suggests that a copy loss of Sfpi1 is not enough for the development of AML, but 
that a secondary mutation drives abnormal haematopoiesis or leukaemic development. 
The data clearly indicate that the transcription factor PU.1 acts as a tumour suppressor 
in rAML. However in the CBA/H mouse model, apart from copy loss of Sfpi1, a 
second event is needed. Most likely, this event is usually the point mutation on the 
remaining Sfpi1 allele. 
    Interestingly, Sfpi1 can also act as an oncogene, since over-expression of Spi1 (Spi1 
is a variant name for the murine gene) by a germinal mutation leads to murine 
erythroleukaemia similarly to Friend erythroleukaemia caused by the Friend virus 
(Moreau-Gachelin et al., 1996). Although the function in myeloid cells, HSCs and 
progenitors is more likely to be that of a tumour suppressor, Sfpi1 seems to have 
different functions in different cell types and at different stages in the development of 
haematopoietic cells. 
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1.14 Some methods to study early haematopoietic development 
    Several in vitro and in vivo assays have been developed and used over the years to 
study haematopoietic development. Each assay measures the proliferative capacity 
and differentiation potential of the particular cell type assayed.  
 
Colony forming cell (CFC) assay (Miller et al., 2008; Mohrin et al., 2010) 
    The CFC assay is an in vitro assay to detect haematopoietic progenitors that form 
colonies in semi-solid media. The media is based on a standard cell culture media (eg. 
Iscove's Modified Dulbecco's Medium) with methylcellulose added as a gelling agent. 
The test cells are added at a known number and incubated for 2-12 days depending on 
the colony type assayed. By adding different cytokine and growth factor 
combinations, it is possible to assay different haematopoietic progenitors. The 
colonies are counted under a normal inverted microscope and the colony morphology 
and type can be distinguished. The assay is used for example to detect differences in 
colony potential and formation of different lineages between the test cell populations, 
toxicology testing and radiation sensitivity. 
 
Ex vivo expansion of HSCs in suspension cultures  
(Brown et al., 1997; Miller and Eaves, 1997; Miller et al., 2002) 
    HSCs are a small proportion of the cells in the haematopoietic system and an 
expansion of the numbers could be useful, for example for cell transplants and for 
further characterisation of cells. The cultures usually contain no serum since it 
contains for example TGFβ that has been found to inhibit the growth of HSCs (Keller 
et al., 1990; Dybedal and Jacobsen, 1995). HSCs expanded ex vivo have been found 
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to give similar or increased levels of long-term reconstitution compared to freshly 
isolated HSCs for a period of up to 6 months.  
 
Colony unit forming-spleen (CFU-S) assay (McCulloch, 2002) 
    The CFU-S assay is an in vivo assay measuring mainly the short-term 
reconstituting potential of injected test cells. It was initially developed by Till and 
McCulloch (Till and McCulloch, 1961) when they found that BMCs formed discreet 
colonies on the spleens when injected into lethally irradiated hosts. The colonies 
formed on the spleen are descendants from single cells, and transient. Depending on 
the day the assay is analysed, different cell types will be found (Magli et al., 1982). 
Day 5-6 colonies consist mainly of erythroid cells, day 9-11 also contain cells from 
myeloid lineages and on day 12-14 the colonies contain cells from all lineages.  
 
Long-term reconstitution by transplanting HSCs  
(Purton and Scadden, 2007; Miller et al., 2008)   
    The assay is considered the “gold standard” for identifying HSCs as it is an in vivo 
assay where the ability to repopulate and reconstitute host animals after 
transplantation is assessed after an extended period of time. The test cells are injected 
into myeloablated hosts together with helper cells (a small number of total BMCs 
capable of sustaining the animals until the HSCs have produced effector cells). The 
test cells need to contain a sufficient number of cells with long-term reconstituting 
ability for a period of 16 weeks to 6 months since the reconstitution can fluctuate 4-6 
months post transplant. For assaying human HSCs, immunocompromised animals 
such as NOD/SCID mice are often used since human cells would elicit an immune 
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response and graft rejection if human cells were transplanted into myeloablated mice 
with an otherwise functioning immune system. 
    Detection of the reconstitution can be made by flow cytometry for either cell 
surface markers that are specific for the strain of the donor and hosts (eg. congenic 
markers CD45.1 and CD45.2) or fluorescent reporter genes. Flow cytometry can also 
be used to detect the surface markers of different cell types to determine the lineages 
that have been reconstituted. For long-term reconstitution, myeloid markers, such as 
Mac-1, from the donor cells is the best proof of long-tem reconstitution since they are 
short lived and must therefore have been produced within the last few days. 
Polymerase chain reaction (PCR)-based methods can also be used, for example to 
detect the Y chromosome from male donor cells in female host animals.  
 
1.15 Experimental system – the Sfpi1 GFP/GFP mouse  
    A transgenic mouse from the C57BL/6 strain was developed at the Walter and 
Eliza Hall Institute in Australia to study the expression of Sfpi1 in vivo (Nutt et al., 
2005). The mice are genetically engineered to express green fluorescent protein 
(GFP) as a reporter gene for Sfpi1 through the insertion of an internal ribosome entry-
site (IRES)-GFP cassette in the 3’ untranslated region of the gene under the control of 
the Sfpi1 promoter (Figure 1.3). The result was the transcription of a bicistronic 
mRNA that produced wild type PU.1 protein and GFP. The insertion does not affect 
the transcription of Sfpi1 and the Sfpi1 GFP/GFP mice are indistinguishable from non-
GFP controls (Nutt et al. 2005). It was shown that the half-life of GFP and Sfpi1 were  
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Figure 1.4. The Sfpi1 GFP locus after insertion of the targeting construct.  
Coding regions of exons are indicated as blue boxes, untranslated regions of exons as 
black boxes and introns as lines. The arrows show the direction of translation. 
Triangles are loxP sites. Circles are frt sites. Primer binding sites for genotyping a, b 
and c are indicated.  
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similar, giving the opportunity of studying Sfpi1 expression by monitoring GFP 
expression. They furthermore showed that the copy number of the GFP construct was 
easily identifiable by flow cytometry. By performing PCR using specific primers, it is 
possible to genotype the mice carrying the GFP construct and determine whether they 
carry one or two copies. Primer a and b identifies the 512 base pairs (bp) Sfpi1 GFP 
allele and primer b and c identifies 680 bp wild type Sfpi1 allele (see Figure 1.4 for 
the location of primer binding sites). 
    Due to the location of the GFP construct in relation to the gene Sfpi1 (Nutt et al., 
2005) and the size of the minimal deleted region in the mouse model of rAML (Silver 
et al., 1999; Finnon et al., 2002), a copy of Sfpi1 and copy of the GFP construct 
would be lost together at a loss event. A reduction in GFP copy number in cells from 
Sfpi1 GFP homozygote (Sfpi1 GFP/GFP) mice would therefore give half the 
fluorescence level compared to mice with intact alleles. In Sfpi1 GFP heterozygote 
(Sfpi1 GFP/+) mice the reduction would give cells with a loss on the allele carrying the 
GFP construct fluorescence levels comparable to animals not carrying the reporter 
construct. In both cases, the loss event should be detectable by flow cytometry. 
    The transgenic mice were on a C57BL/6 background. For the purpose of this 
project, in order to be able to study the Sfpi1 expression with the reporter gene on 
mice susceptible to rAML, the original mice were bred onto a CBA/H background 
and also a C57BL/6 background (Figure 2.1). Both Sfpi1 GFP/+ and Sfpi1 GFP/GFP mice 
were bred. The C57BL/6 strain will be used as controls since they do not develop 
AML in response to radiation.  
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1.16 Aim of the project 
    The current project is based on the hypothesis that chromosomal damage and point 
mutations due to exposure of radiation in haematopoietic stem cells (HSCs) or early 
progenitor cells result in AML. Previous research shows that the transcription factor 
PU.1 is involved in the leukaemic processes of rAML. The role of PU.1 in the 
induction of rAML is probably complex and more work needs to be performed to 
elucidate the molecular events that lead to leukaemia in the CBA/H model. 
Quantitative data on mechanisms of Sfpi1 loss and point mutation are required to 
support risk estimates based on biological models (Little et al., 2008; Dekkers et al., 
2011). There is also a lack of data regarding the target cell for the initial copy loss, 
which eventually lead to rAML through the further acquired point mutation. Point 
mutations in the DNA sequence of Sfpi1 are in human AMLs occurring spontaneously 
(Mueller et al., 2002). However, there are also a small number of cases in humans 
where point mutations in an URE have been found, leading to a down regulation of 
PU.1 mRNA expression (Bonadies et al., 2010). Notably, a down regulation of Sfpi1 
expression in a mouse model with a mutation in an URE led to AML (Rosenbauer et 
al., 2004). In a further mouse model, in this case of acute promyelocytic leukaemia, 
the loss of Sfpi1 is a secondary event that increases the leukaemic effect of the PML-
RARα fusion gene (Walter et al., 2005). Treatment of human acute promyelocytic 
leukaemia cells with all-trans retinoic acid restores PU.1 expression in the cells and 
therefore shows a way how targeting PU.1 for treatment might be a possible strategy 
(Mueller et al., 2006). Therefore, even though Sfpi1 is normally mutated only in few 
cases of human AML, the mouse model of rAML could potentially give new data on 
the function of Sfpi1 in both haematopoiesis and AML. 
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    The aim of the current work was to investigate the consequences of copy loss of the 
gene Sfpi1, leading to a lack of function or loss of function of PU.1, in relation to 
early post-irradiation events, to define a target cell population for the initial copy loss 
and relate these to the manifestation of rAML.   
 
To achieve the aim of the project, the following approaches were used: 
 
The use of flow cytometry to detect copy loss of Sfpi1 in live immature BMCs after 
exposure to ionising radiation, since this had not been done before. This was done 
using Sfpi1 GFP/GFP and Sfpi1 GFP/+ mice.   
 
Studying the difference in radiation sensitivity between C57BL/6 and CBA/H mice in 
immature BMCs using in vitro colony forming assays. 
 
Setting up a long-term reconstitution assay to transplant potentially pre-leukaemic 
HSCs and progenitor cells and the CFU-S assay to characterise early events in clones 
from early progenitor cells. The Sfpi1 GFP/GFP mice were used to try and select 
immature bone marrow progenitor and stem cells with copy loss of Sfpi1. 
 
Using the Sfpi1 GFP/GFP and Sfpi1 GFP/+ mice to study copy loss of Sfpi1 in cases of 
rAML and the expression of Sfpi1 through the expression of GFP by flow cytometry. 
The point mutation of the remaining Sfpi1 allele was also studied as well as the 
mRNA expression of the gene. 
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Chapter 2. Material and methods 
2.1 Mice 
C57BL/6 mice expressing GFP in the 3’ untranslated region of Sfpi1 were originally 
produced at the Walter and Eliza Hall Institute in Melbourne, Australia (Dakic et al., 
2005; Nutt et al., 2005). For the use at Health Protection Agency Centre for 
Radiation, Chemical and Environmental Hazards, sperm from this genetically 
modified strain was used to in vitro fertilise eggs from the radiation sensitive strain 
CBA/H (Figure 2.1). F1 progeny were either bred onto the rAML resistant strain 
C57BL/6 or were backcrossed to CBA/H mice. Staff at the animal facility at CRCE 
assessed animals carrying the GFP construct and selected them for further breeding. 
Mice were backcrossed to a CBA/H or C57BL/6 background for at least 6 generations 
before being used for experiments in chapter 3.1 and for at least 10 generations for all 
other experiments. 
    After the initial backcrossing, GFP homozygous animals were bred from animals 
homozygous for the GFP construct and heterozygous animals generated from a 
homozygous male and wild type female. All animals were bred and handled 
according to UK Home Office (Animals Scientific Procedures) Act 1986 regulations. 
 
2.2 Animal necropsy and tissue extraction 
    Animals were euthanised either by cervical dislocation or by CO2 asphyxiation and 
then laid down on their back and pinned out on a dissection board. The body was 
sprayed with 70 % ethanol before starting the dissection. 
    If heart blood was collected, this was done first. An incision was made in the skin 
using scissors to expose the thoracic cavity. Blood was collected through cardiac  
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Figure 2.1. Schematic representation of the initial mouse breeding.  
C57BL/6 mice, not susceptible to rAML, (black mouse) homozygous for Sfpi1GFP/GFP  
(one green shape is one allele) were crossed (by in vitro fertilisation) with a wild type 
the CBA/H female (brown mouse). The F1 progeny were Sfpi1 GFP/+ and were 
backcrossed for five generations to either C57BL/6 (left hand side) or CBA/H (right 
hand side) mice. F6 generation Sfpi1 GFP/+ mice were mated to obtain Sfpi1 GFP/GFP 
mice. Analysis by polymerase chain reaction (PCR) was performed until the 8th 
generation to identify the carriers of the GFP construct. 
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puncture using an insulin needle and syringe and then transferred to a heparinised 
blood collection tube (BD Biosciences, Oxford UK) that was stored on ice. Before 
counting of white blood cells or further processing, red blood cells were lysed by 
mixing blood and lysis buffer (20.5 g NH4 Cl, 2.5 g NaH CO3, 0.093 g Na2 Ethylene-
diamine-tetra-acetic acid (EDTA)) in a 1:20 dilution and incubating for approximately 
5 min at room temperature. 
    The spleen was excised by making an incision through the peritoneal muscle wall 
and the spleen was dissected out and placed on ice in a small dish with some 
phosphate buffered saline (PBS) (P4417-100TAB, 0.01M Phosphate buffer, 0.0027M 
Potassium Chloride and 0.137M Sodium Chloride, 5 tablets made up in 1L double 
distilled water (ddH20) Sigma, UK). To disaggregate the spleen, it was first divided 
into smaller pieces by holding it with forceps and using a pair of bow spring scissors. 
Each piece of the spleen was then further disaggregated to give a suspension that 
could be aspirated by a 19 G needle (BD Bioscience, Oxford) and a 5 mL syringe (BD 
Bioscience). After gently syringing the suspension a couple of times, the procedure 
was repeated with a 21 G needle (BD Bioscience). Finally, the suspension was passed 
through a 40 micron cell strainer (BD Bioscience).  
    Femora and tibias were dissected out by making an incision in the lower abdomen 
and cutting down along a hind leg to expose the bones. The bones were removed by 
cutting through the pelvis. Excess muscle tissue was removed by gently polishing the 
bones with tissue paper and then placed on ice. To flush out the bone marrow, the 
lower end of the femur was broken at the knee and a 25 G needle (BD Bioscience) 
was used to drill a hole at the hip joint at the top of the femur. The bone marrow was 
then flushed with PBS using a 1 mL syringe (BD Bioscence) into a suitable container. 
Bone marrow was flushed from the tibias in the same way after cutting off the ends of 
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the bones. The cell suspension was then syringed with a 25 G needle and 1 mL 
syringe before passed through a 40 micron cell strainer.  
 
2.3 Flow cytometry analysis of bone marrow from GFP mice 
 BMCs were isolated from femurs and tibias. Disaggregated cells were counted using 
a haemocytometer. Cell suspensions containing 105 cells/sample were transferred to 
round bottom FACS tubes (BD Bioscience) and washed twice in PBS supplemented 
with 1 % fetal bovine serum (FBS) (Invitrogen, Paisley UK) by centrifugation at 1200 
rpm for 5 minutes at 4 °C. The cells were then suspended in 100 μL PBS and 7-
Amino-Actinomycin D (7-AAD) (Sigma, UK), which binds to DNA and is excluded 
by live cells (Schmid et al., 1992), was added to samples (5 µL, about 0.25 
µg/sample). After 10 minutes incubation at 4 °C, 400 µL PBS was added and the 
samples analysed on a FACS Calibur flow cytometer (BD Bioscience). Cells in the 7-
AAD negative fraction (viable cells) were analysed for their GFP expression. 
 
2.4 GFP expression in Lin- cells from in vivo irradiated mice 
    3 Sfpi1 GFP/+ and 3 Sfpi1 GFP/GFP mice were exposed to a total body dose of 3 Gy 
using an x-ray source 250kVp, 11 Amp at a dose rate of 0.887 Gy/min at MRC 
Harwell using an x-ray source. Unirradiated and non-GFP mice were included as 
controls. 9 days after exposure, mice were euthanised and BMCs isolated from femurs 
and tibias. The bone marrow suspensions within each group were pooled and Lin- 
cells were selected by immunomagnetic cell separations as described. Purified cell 
suspensions were analysed on a FACS Calibur flow cytometer as described. 
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2.5 Immunomagnetic cell separation 
 Femora and tibias from mice were flushed into either Robosep buffer (Stem Cell 
Technologies, Grenoble France) or PBS/2% FBS/1mM 0.5 M EDTA, pH 8.0. Cell 
were disaggregated gently by pipetting and passed through a 40 µM cell strainer and 
washed by centrifugation, 1200rpm for 5 minutes at 4 °C. Washed cells were counted 
and resuspended at a concentration of 1x108 cells/mL in buffer with 5% rat serum in a 
FACS tube. Samples containing more than 2x108 cells were split for processing. 
 Lin- cell were selected using the Mouse Hematopoietic Progenitor Enrichment Kit 
(Stem Cell Technologies). A progenitor enrichment cocktail was added to cells at 50 
µL/mL, containing biotinylated monoclonal antibodies against lineage antigens (CD5, 
CD11b, CD19, CD45R, Ly-6G (GR1),TER-119, 7-4) and incubated for 15 minutes at 
4 °C. Cells were washed with 2 mL of buffer and resuspended at 1x108 cell/mL for 
either manual separation using the Easysep magnet (Stem Cell Technologies) or 
loading on to the Robosep (Stem Cell Technologies) for automated separation.  
    For manual separation using Easysep, a biotin selection cocktail was added at 100 
µL/mL and incubated for 15 minutes at 4 °C. 100 µL/mL magnetic microparticles 
were added, the suspension mixed and incubated for a further 10 minutes at 4 °C. The 
cell suspension was mixed gently and placed in a pre-chilled purple Eaysep magnet 
for 3 minutes. The non-labelled Lin- cells were poured into a new FACS tube, leaving 
the labelled Lin+ cells in the original tube. The Lin- cells were either antibody stained 
for fluorescence activated cell sorting (FACS) or purified further for c-Kit+ cells. 
    For c-Kit selection, the Lin- cells were counted and resuspended in 100 μL of 
buffer and 5 μL of c-Kit-Phycoerythrin (PE) labelling reagent was added and 
incubated for 15 minutes at 4 °C. To this suspension, 7 μL PE selection cocktail was 
added with a further incubation for 15 minutes at 4 °C. 5 μL of the nanoparticle 
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suspension was pipetted into the suspension and incubated for 10 minutes at 4 °C. 
The volume was made up to 2.5 mL with buffer and the tube placed in a pre-chilled 
purple Easysep magnet (Stem Cell Technologies) for 5 minutes. The supernatant was 
then poured off and the positively labelled cells remaining in the tube and 
resuspended by adding 2.5 mL of buffer and the process was repeated. A total of 4x5 
minutes separations were performed. Analysis of GFP expression of the Lin- and Lin- 
c-Kit+ cells was done by flow cytometry as described.  
    For analysis of c-Kit expression in total BMCs, c-Kit-PE monoclonal antibodies 
(Miltenyi Biotec, Bergisch Gladbach Germany) were added to a total volume of 110 
µL of PBS/3% bovine serum albumin (BSA), incubated for 10 minutes at 4 °C, 
washed twice with PBS/1% FBS and then analysed by flow cytometry using a FACS 
Calibur flow cytometer. In some cases the dye 7-AAD (Sigma, UK) was added to 
samples (5 µL, about 0.25 µg/sample). 
    For automated cell separations, the Robosep (Stem Cell technologies) and 4 “The 
Big easy” Easysep magnets (Stem Cell Technologies) were used. The magnets and 
the same reagents used for the manual separation were loaded on to the carousel 
according to the manufacturer’s instructions. Lineage depletion was performed using 
the protocol “Mouse Progenitor Negative Selection 19756 – high purity”. To keep 
cells and reagents as cold as possible, the magnets were stored overnight at -20 °C 
before use. 
 
2.6 Setting up methylcellulose cultures 
    Cells were plated in Methocult (M3534, Stem Cell Technologies), based on 
Iscove’s modified Dublecco’s media (IMDM) containing 1 % methylcellulose, 15% 
FBS, 1% BSA, 10 µL/mL Insulin, 200 µL/mL Transferrin, 2-mercaptoethanol, 50 
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ng/mL recombinant mouse stem cell factor (SCF), 10 ng/mL recombinant mouse 
interleukin-3 (rmIL-3) and 10 ng/mL recombinant human interleukin-6 (rhIL-6). 
Tubes containing 4 mL Methocult were vortexed to mix the contents and left to stand 
until bubbles had disappeared. 400 µL of cells in IMDM (Invitrogen) were added to 
the tubes at an appropriate concentration, vortexed and left to stand for 5 minutes. The 
media containing the cells was dispensed using a 2.5 mL syringe (BD Bioscience) and 
18 G needle (BD Bioscience) in triplicate (1.1 mL/culture). Cultures were set up in 
two different types of plates, 6-well plates (Nunc, Denmark), with one well containing 
sterile water or in 35 mm petri dishes (Corning, US) stored inside a larger petri dish 
containing an open petri dish with sterile water. Cultures were then incubated at 37 
°C, 5% CO2 until colonies were counted on day 10-12 using an inverted microscope 
(Nikon, Japan) at x20 magnification. The average colony count was calculated from 
the mean colony count of three wells.  
 
2.7 In vitro cell irradiations and cell survival curves  
Irradiations of methylcellulose cultures in vitro were performed using an x-ray source, 
250 kVp 11 Amp at a dose rate of 0.887 Gy/Min the day after plating at MRC 
Harwell. The cultures were incubated for 10-12 days before the colonies were 
counted. The surviving fraction (SF) was calculated by using the formula: 
𝑆𝐹 = 𝐶𝑜𝑙𝑜𝑛𝑖𝑒𝑠 𝑐𝑜𝑢𝑛𝑡𝑒𝑑
𝐶𝑒𝑙𝑙𝑠 𝑝𝑙𝑎𝑡𝑒𝑑 ×  (𝑃𝐸 ×  100) 
 
where  
𝑃𝑙𝑎𝑡𝑖𝑛𝑔 𝐸𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 (𝑃𝐸) = 𝐶𝑜𝑙𝑜𝑛𝑖𝑒𝑠 𝑐𝑜𝑢𝑛𝑡𝑒𝑑
𝐶𝑜𝑙𝑜𝑛𝑖𝑒𝑠 𝑝𝑙𝑎𝑡𝑒𝑑 ×  100 
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The radiation dose in Gy was plotted against the surviving fraction (average from 
three independent experiments). A curve was fitted with the linear-quadratic model 
(Kellerer and Rossi, 1974). The equation: 
𝑆 = 𝑒−𝛼𝐷−𝛽𝐷2 
 (where S is the surviving fraction, D is the dose and α and β are constants) of the 
curve gave the α and β coefficients for the cell type by using Graphpad Prism 4.0 
(GraphPad Software Inc, La Jolla USA). The f-test was used by Graphpad Prism to 
compare the curves.  
     
2.8 Colony formation in methylcellulose cultures of in vivo irradiated Lin- cells 
and antibody staining of isolated cultures 
   Methylcellulose cultures were set up from in vivo irradiated Lin- cells and 
unirradiated controls. The cultures were incubated for 10-12 days before colonies 
were counted. Cultures were isolated and cells in each culture were pooled. Each well 
or petri dish was rinsed three times with PBS/2%FBS/1mM EDTA. A cell scraper 
was used to remove adherent cells. Cells were washed twice with PBS/1% FBS and 
counted before being stained with antibodies for analysis by flow cytometry. 
    Antibodies used for cell staining: 10 μL c-Kit-PE (Miltenyi Biotec), 0.1 μg 
FcγRIII/II-PE (Abcam, Cambridge UK), 0.1 μg Mac-1-PE, 0.1 μg Gr-1-PE, 0.1 μg 
Immunoglobulin gamma (IgG)2a-PE isotype control and 0.1 μg IgG2b-PE isotype 
control (BD Bioscience).  
    All samples for antibody staining contained approximately 105 cells. For staining 
with c-Kit-PE, cells were resuspended in FACS tubes (BD Bioscience) in a volume of 
100 µL, the antibodies were added and samples incubated for 10 minutes at 4 °C. 
Antibodies from BD Bioscience were added to a volume of 25 µL PBS/3%BSA and 
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incubated for 45 minutes to 1 hour at 4 °C. All samples were washed twice with 
PBS/1% FBS and then analysed on a FACS Calibur flow cytometer. 
  
2.9 Cloning of individual colonies from methylcellulose cultures 
    50 μL of IMDM was aspirated using a 200 μL pipette tip and a standard air-
displacement pipettor set to a 100 μL volume. Individual colonies were aspirated and 
mixed in a total volume of 100 μL IMDM and added to 1 mL of Methocult M3534 
(Stem Cell Technologies). An 18 G needle and 2.5 mL syringe was used to dispense 
the media in a single labelled 35 mm petri dish. All aspirated colonies were given an 
individual number so that the growth of the colony could be followed. After a week, 
all colonies were monitored for growth. Colonies that were deemed to have formed 
new colonies were harvested, the cell number counted and the cells were replated as 
detailed above. Cell counts were done using an automated cell counter ADAM-MC 
(Digital Bio, South Korea) according to the manufacturer’s instruction. The procedure 
was repeated once a week for a total of number of three rounds of replating.  
 
2.10 Suspension cultures for expansion of haematopoietic progenitor cells 
    Cells were seeded at an appropriate number/culture for the individual experiment in 
Stemspan serum-free expansion medium (SFEM) (Stem Cell technologies) with the 
addition of recombinant murine stem cell factor 50 ng/mL (rmSCF), 100 ng/mL 
recombinant human interleukin-11 (rhIL-11) and 100 ng/mL recombinant human Flt3 
Ligand (rhFlt3L) (all cytokines from Stem Cell Technologies), 40 μg/mL low density 
lipoprotein (LDL) (Sigma), 100U/mL Penicillin (Fisher Scientific, UK) and 100 
μg/mL Streptomycin (Fisher Scientific). The culture volume was 2 mL in 35mm Petri 
dishes and up to five cultures were placed together in a larger dish at 37 °C, 5% CO2. 
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Growth was monitored by visually checking the cells under an EVOSXL microscope 
(AMG, USA). If the cell density were higher than 5x105 cells/mL, the culture was 
diluted in fresh media. After 7-9 days, cells were harvested and the culture dish rinsed 
with IMDM. A cell scraper was used to gently remove any cells that had adhered to 
the culture dish. 
 
2.11 Preparation of Lin- cells and cell sorting 
    Lin- cells were isolated as described from CBA and C57 Sfpi1 GFP/GFP mice exposed 
to a 3 Gy total body dose of x-rays 7 or 9 days before or unirradiated control animals. 
X-ray exposure was done at MRC Harwell using an x-ray source 250kVp, 11 Amp at 
a dose rate of 0.887 Gy/min. Lin- cells were also acquired from non-GFP control 
mice. Antibodies used for cell staining: 1 μg c-Kit-PE/ Allophycocyanin (APC) (BD 
Bioscience, Oxford) and 0.2 μg Sca-1-PE (Biolegend, CA, USA). Samples were 
resuspended and stained in 25 μL of PBS/3% FBS in FACS tubes and incubated for 
45-60 minutes on ice. Unstained samples and single stained samples were prepared as 
controls for fluorescence compensation. Samples were washed twice with 
PBS/1%FBS, resuspended in PBS, passed through a cell strainer into a new FACS 
tube. 7-AAD was added (5 µL, about 0.25 µg/sample) to the sort samples. All 
samples were kept on ice until sorting. Cell sorting was done at the Jenner Institute, 
Oxford on a MoFlo cell sorter (Dako Cytomation, Denmark) by Mr Andrew Worth. A 
region was set round the major population to exclude debris. Cells were gated on the 
7-AAD negative population and a further gate was set on the Sca-1+ c-Kit+ 
population. The cells in this gate were sorted as GFP-/lo or GFP+ using cells from non-
GFP mice as a control and collected in FACS tubes containing a small amount of 
Stemspan SFEM media. The tubes containing were kept on ice until further 
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processing. Cells were either injected on the same day or plated in suspension 
cultures. 
 
2.12 Long-term transplantation assay of sorted and cultured cells 
     All licensed procedures were performed by Dr Christophe Badie or Dr Rosemary 
Finnon. Cells were resuspended in a volume of 120-200 μL in IMDM and injected via 
the tail vein into myeloablated wild type (non-GFP) CBA/H or C57BL/6 mice. 
Myeloablation was achieved by exposing animals to a total body dose of ionising 
radiation (8.5 Gy, but in one case 9 Gy). X-ray exposure was done at MRC Harwell 
using an x-ray source 250kVp, 11 Amp at a dose rate of 0.887 Gy/min. After 
injection, mice were kept in a Scantainer (Scanbur, Denmark) for 21 days to keep 
them warm and filter the air. Animals were fed pelleted rodent food, dried and a small 
amount previously soaked in boiled water. Antibiotics (Terramycin) were added to 
the drinking water. Strawberry jelly containing antibiotics were given to maximise 
both the amount of antibiotics and the liquid that the animals consumed. Weights 
were monitored daily and general health was monitored twice a day. Animals that 
reached the humane endpoint were euthanized by asphyxiation with CO2 and a post 
mortem performed. After 21 days, all animals were housed under regular conditions. 
 
2.13 Analysis of reconstitution after transplantation  
    Licensed procedures were performed by Dr Christophe Badie or Dr Rosemary 
Finnon. The analysis of blood samples were made in collaboration with Dr Natalie 
Brown. For acquiring samples of heart blood, the mice were euthanized by CO2 
asphyxiation. The chest cavity was opened up and an insulin syringe was used to draw 
out blood from the heart. The blood was deposited in standard blood collection tubes 
  69 
(BD Biosciences) and kept on ice. For tail vein bleeding, anaesthetic cream was 
applied to the tail of the animal 30 minutes before the procedure. The animal was 
placed in a heat box at 27 °C for 5 minutes and then placed in a restraint tube. The tail 
vein was punctured with a 25G needle (BD bioscience) and blood collected using a 
heparinised capillary tube. The blood was then deposited in a 0.2 mL tube (Starlab, 
UK) on ice.  
Before antibody staining, the red blood cells were lysed as described. 105 cells were 
stained in a 25 μL volume in FACS tubes. Antibodies were added and samples 
incubated for 45-60 minutes at 4 °C using. Samples were washed twice with 
PBS/1%FBS at 1200 rpm, 5 minutes, at 4 °C. Antibodies used were: 0.1 μg CD3-PE 
(BD Bioscience), 0.04 μg B220-PE/Cyanine 5 (PE/Cy5) (Abcam, Cambridge, UK), 
0.1 μg Gr-1-PE (BD Bioscience) and 0.06 μg Mac-1-PE/Cy5 (Abcam). Samples from 
tail vein bleeding were not antibody stained. Samples were washed once after lysis 
with a small amount of PBS/1%FBS and then resuspended in PBS. All samples were 
analysed by flow cytometry using the FACS Calibur (BD Biosciences).  
 
2.14 Colony forming unit- spleen day 12 (CFU-S 12) assay 
    To acquire in vivo irradiated BMCs, cells were isolated from mice exposed 7 days 
earlier to a 3 Gy total body dose from an x-ray source at CRCE at a dose rate of 0.5 
Gy/minute, 250 kVp, 13 Amp (AGO, Reading UK). BMCs were acquired from 
unirradiated mice for in vitro x-ray exposure or for unirradiated control cells. In vitro 
exposure with 3 Gy was performed at the same x-ray source with cells suspended in 
IMDM in 1.5 mL tubes. Cells were injected into the tail vein of myeloablated mice 
(8.5 Gy) and the mice cared for as described before. On day 12 after injection, the 
mice were euthanised and the spleen was dissected out. The colonies on the spleen 
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were counted and individual colonies were dissected out using a scalpel under a 
dissecting microscope. Colonies were added to 1.5 mL microfuge tubes containing 
PBS, disaggregated using bow spring scissors and passing the suspension through 
first a 19G and then a 21G needle. Aliquots of cells were taken for flow cytometry 
analysis and DNA extraction for genotyping. Cells were prepared and analysed by 
flow cytometry as described before. 
 
2.15 Long-term rAML induction experiment 
The long-term rAML induction experiment was monitored by Dr Rosemary Finnon, 
who also performed most of the sample collection. 50 male CBA/H Sfpi1 GFP/+, 50 
male CBA/H Sfpi1 GFP/GFP and 15 female Sfpi1 GFP/GFP mice were given a single, 3 Gy 
total body dose of x-rays at 12 -15 weeks of age to induce rAML. Exposure was 
performed at MRC Harwell using an x-ray source   250kVp, 11 Amp at a dose rate of 
0.887 Gy/min. Autopsies were performed on mice that needed to be euthanised due to 
humane reasons if this occurred at least 6 months after irradiation.  A blood sample 
was collected from the heart and deposited in a blood collection tube for a blood 
count and later analysis. If the spleen was enlarged, the animal was treated as a 
potential AML case. The spleen was dissected out, weighed and divided into pieces. 
One piece was deposited in RNA later for nucleic acid extraction. The remaining 
spleen pieces were disaggregated and suspensions prepared for freezing down viable 
cells, setting up of spleen preps, cultures for production of cell lines and flow 
cytometry analysis. The femora and tibias were dissected out, the bone marrow 
flushed as previously described and cells used for setting up cell line cultures and 
flow cytometry. 
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2.16 Flow cytometry phenotyping of rAML cases 
    Samples from bone marrow, spleen and blood were stored at 4 °C and processed 
within 24 hours. Cells were prepared for flow cytometry by staining samples of 105 
cells in FACS tubes. Antibodies (Table 2.3) were added to a 25 μL volume of PBS/3 
% FBS and incubated for 45-60 minutes on ice. Samples were washed twice in PBS/1 
% FBS at 1200  rpm, 5 minutes at 4 °C.  
    Samples were analysed on a FACS Calibur (BD Bioscience) flow cytometer. 
Regions were drawn around major populations of cells on a forward scatter/side 
scatter (FSC/SSC) dot plot. Events with low FSC/SSC were assumed to be dead cells 
and debris and were excluded from analysis (Holmes et al., 2001). Due to the capacity 
of the FACS Calibur, that is only three available channels for detection, no 7-AAD 
was added to the samples since the PE/Cy5 fluorochrome is detected in the same 
channel as 7-AAD. In leukaemic samples the analysis was performed on the region 
with high FSC/SSC, which is not normally present in spleen. Leukamic samples were 
compared to the combined major regions in BMCs. The GFP expression was defined 
as mean fluorescence level, which is the geometric mean channel number on a log 
scale x-axis on the lower right quadrant on a dot plot.  
 
2.17 Chromosome preparations and fluorescent in situ hybridisation (FISH) of 
cells cultured in Stemspan SFEM 
    Cells were harvested and resuspended at a concentration of 1.5-2x106 cells/mL 
(minimum 1 mL) of complete Stemspan SFEM (Stem Cell technologies) with added 
cytokines as for normal culturing in 12 mL culture round bottom tubes (Sarstedt, 
Germany). 0.6 μL/mL Colcemid from a 100 ng/mL stock solution (Invitrogen, UK) 
was added and the suspension cultured a minimum of 1 hour to overnight  
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Antibody Fluorochrome Amount used Company 
Rat IgG2aκ isotype R-phycoerythrin 0.1 μg BD Bioscience, 
Oxford UK 
Rat IgG2bκ isotype R-phycoerythrin 0.1 μg BD Bioscience, 
Oxford UK 
Rat IgG2a isotype-
biotin 
N/A 0.1 μg Abcam, Cambridge 
UK 
Rat IgG2b isotype-
biotin 
N/A 0.1 μg Abcam, Cambridge 
UK 
Rat IgG2c isotype-
biotin 
N/A 0.1 μg Abcam, Cambridge 
UK 
Streptavidin  Phycoerythrin/Cyanine 5 0.0125μg Biolegend, CA USA 
Gr-1/Ly6G 
(clone 1A8) 
R-phycoerythrin 0.1 μg BD Bioscience, 
Oxford UK 
Mac-1  Phycoerythrin/Cyanine 5 0.06 μg Abcam, Cambridge 
UK 
CD31 R-phycoerythrin 0.1 μg BD Bioscience, 
Oxford UK 
Ly6C R-phycoerythrin 0.02 μg Abcam, Cambridge 
UK 
Sca-1 R-phycoerythrin 0.2 μg Biolegend, CA USA 
c-Kit R-phycoerythrin 0.01 μg Abcam, Cambridge 
UK 
c-Kit Phycoerythrin/Cyanine 5 0.2 μg Biolegend, CA USA 
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CD3 R-phycoerythrin 0.1 μg BD Bioscience, 
Oxford UK 
B220 (CD45R) Phycoerythrin/Cyanine 5 0.04 μg Abcam, Cambridge 
UK 
CD34 R-phycoerythrin 0.1 μg Abcam, Cambridge 
UK 
CD38 Phycoerythrin/Cyanine 5 0.02 μg Abcam, Cambridge 
UK 
Flt3 R-phycoerythrin 0.1 μg BD Bioscience, 
Oxford UK 
VCAM-1-biotin N/A 0.01 μg Abcam, Cambridge 
UK 
VCAM-1 R-phycoerythrin 0.02 μg Abcam, Cambridge 
UK 
Thy-1 Phycoerythrin/Cyanine 5 0.02 μg Abcam, Cambridge 
UK 
FcγRIII/II 
(CD16/32) 
R-phycoerythrin 0.1 μg Abcam, Cambridge 
UK 
Table 2.1. Antibodies used for phenotyping of AML cases. 
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at 37 °C/ 5% CO2. The cultures were then transferred to 15 mL conical tubes 
(Sarstedt) and spun down at 1200 rpm for 5 minutes at room temperature. The 
supernatant was aspirated and the cells resuspended in 2 mL of 0.075 M KCl (1M 
74.55g KCl in ddH2O) and incubated for 15 minutes in a water bath set at 37 °C. 
Afterwards, 10 drops of fixative (1:3 Acetic Acid/Methanol) was added dropwise 
without mixing before the cells were spun down. After aspirating the supernatant, the 
cells were resuspended in a total of 10 mL of fixative by first adding 1 mL of fixative 
dropwise while vortexing the tube. Further fixative was then added up to the total 
volume. The fixing was repeated for a total of three rounds and the prep was 
resuspended in 5 mL of fixative and stored at -20 °C until slide preparations. 
    Preparation of bacterial artificial chromosomes (BAC) and labelling of prob es 
were performed by Dr Rosemary Finnon. BAC clone 253H22 containing Sfpi1/PU.1, 
49N22 containing D2Mit31, which hybridizes to the centromeric region of 
chromosome 2, and a BAC clone containing D2Mit74, which hybridizes to the 
telomeric region of chromosome 2 were cultured in 500 mL cultures in Luria broth 
with 12.5 μg/mL Chloramphenicol and cultured overnight at 37 °C/ 5% CO2. Cultures 
were harvested and spun down at 2000 rpm at room temperature and the supernatant 
poured off. BAC DNA was prepared using Qiafilter Maxipreps (Qiagen). First, 8 mL 
buffer P1 was added to the pellet and resuspended. Then, 8 mL of freshly prepared 
buffer P2 (200 mM NaOH, 1% sodium dodecyl sulphate (SDS)) was added and the 
contents mixed by inverting 4-6 times. The tube was then incubated at room 
temperature for 5 minutes. Chilled buffer P3 (8 mL) was then added and the contents 
mixed by inverting 4-6 times and then poured onto the cartridge and then left for 10 
minutes at room temperature. A Qiatip 500 was equilibrated by applying 10 mL of 
buffer QBT and the liquid allowed to flow through. The lysate was then applied to the 
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cartridge and forced through by using a plunger. The cartridge was then washed twice 
with 30 mL of buffer QC. The DNA was eluted by applying 10 mL of buffer QF (pre-
warmed to 60 °C) to the cartridge. The filtrate was divided into eppendorff tubes with 
approximately 0.8 mL in each. 0.56 mL of chilled isopropanol was added and the 
tubes left on ice for 10 minutes before being spun down for 10 minutes in a 
microfuge. The supernatant was removed and the pellet washed with 70% ethanol by 
spinning another 10 minutes and after removing the supernatant the pellet was 
airdried and resuspended in 10 μL of 70% ethanol. 
   For labelling the probes using a Nick Translation kit (Abbott Molecular, Des 
Plaines IL, USA), Clone 253H22 containing Sfpi1/PU.1, was labelled with modified 
deoxiuridine triphosphate (dUTP) Spectrum Orange (Abbott Molecular), clone 49N22 
containing centromeric D2Mit31and telomeric D2Mit74 were labelled with modified 
dUTP Spectrum Green (Abbott Molecular). For each reaction 1 μg of BAC DNA, 2.5 
μL 0.2 mM modified dUTPs, 5 μL 0.1 mM deoxythymidinephosphate (dTTP), 10 μL 
deoxynucelotide triphosphate (dNTP) mix, 5 μL 10x nick translation buffer, 10 μL 
nick translation enzyme and nuclease-free water was mixed in pre-chilled 0.5 mL 
tubes in a total volume of 50 μL. The tubes were incubated for 2 hours at 15 °C using 
a hot block. The temperature was then increased to 70 °C for 10 minutes to stop the 
reaction. A sample was taken to check the labelling and analysed on a 2% agarose gel.  
The samples were precipitated by adding 10 μg of mouse Cot-1 DNA (Invitrogen, 
UK) and 20 μg of salmon sperm DNA (Invitrogen) to each reaction and the volume 
made up to 120 μL with double-distilled water. 12 μL of 3 M sodium acetate and 300 
μL ethanol was added and the samples spun for 30 minutes at 12000 rpm in a 
microfuge. The precipitate was then resuspended in 10 μL ddH20 and left at 37 °C for 
30 minutes with occasional tapping of the tubes to dissolve the pellet. The labelled 
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probes were then stored at -20 °C until they were used. 
    For preparing the slides, microscope slides previously stored in ethanol were held 
2-3 cm over a waterbath set at 75 °C for a few seconds. 20 μL of fixed cells were 
placed on the slide and the slide held over the steam until it became grainy in 
appearance and dried on a hot plate. Slides were then left to dry for a couple of hours 
before further treatment. Chemical aging was performed to preserve the chromosome 
morphology by passing the slide through a series of ethanol in three Coplin jars 
warmed in a water bath set to 50 °C, 75 °C and 94 °C respectively. The slides were 
kept for 20 seconds at each temperature and passed from lowest to highest 
temperature, then back down again and dried on a paper towel. The slides were air 
dried and ribonuclease (RNAse) treated by adding 100 μL of RNAse (100 ng/ μL in 
2xSaline sodium citrate (SSC)) and the droplet spread under a 22x50 mm coverslip. 
The slides were incubated for 1-2 hours in a moist chamber at 37 °C. To remove the 
coverslips, slides were washed for 5 minutes in PBS on a shaker, dehydrated through 
an ethanol series (70%, 90% and 100% ethanol, 2 minute at each concentration) and 
air dried.  
    Before slide hybridisation, the probe and the slides were denatured. For probe 
denaturation, 1 μL of each labelled probe was mixed in a total volume of 10 μL with 
hybridisation buffer (ratio: 1 ddH2O, 5 Formamide, 1 20xSSC and 2 50% dextran 
sulphate) in eppendorff tubes. The tubes were then incubated for 5 minutes in a water 
bath set at 75 °C. Afterwards, the tubes were placed in a hot block at 48 °C covered 
with tin foil until use. The slides were denatured for 5 minutes in a solution pre-
warmed to 75 °C containing 70% Formamide/2xSSC, where 20 μL of HCl had been 
added to adjust the pH. The slides were passed through an ethanol series and kept in 
100% ethanol until ready to apply the probe. When ready, a slide was removed from 
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the ethanol, the back wiped with a tissue and the slide placed on the 48 °C hot block 
until completely dried. The 10 μL probe solution was applied to the slide with a 
pipette and a 22x22 mm coverslip was placed over and sealed with rubber solution 
glue. The slides were incubated overnight in a humidified chamber at 37 °C. The 
slides were washed in 0.4xSSC for 2 minute in a coplin jar placed in a 75 °C water 
bath with occasional agitation and a further 2 minutes in 2xSSC/ 0.1% Tween 
(Sigma) at room temperature on a shaker. The slides were passed through an ethanol 
series as before and air dried. The slides were mounted by adding 20 μL of 125 
ng/mL 4’,6-diamidino-2phenylindole (DAPI) and placing a 22x50 mm No 0 coverslip 
on the slide and sealing it with clear nail varnish. The slides were scored using a 
microscope Labphol-2 (Nikon), images captured using a Zeiss AxioCam Mrm and the 
images analysed using the Isis Fish Imaging System v 5.2 (Metasystems GmbH, 
Altluissheim, Germany).  
 
2.18 Spleen cultures for chromosome preparations of rAML samples 
    Disaggregated spleen cells were cultured at a concentration of 1.5-2x106 cells/mL 
in 5 mL IMDM/20% FBS, 100 U/mL Penicillin and 100 μg/mL Streptomycin (Fisher 
Scientific) with addition of 25 μg/mL Lipopolysaccharide (Sigma) and 4 μg/mL 
ConcavalinA (Amersham Biosciences, UK) for 48 hours at a 15° angle in 12 mL 
round bottom tubes (Sarstedt). Afterwards, Colcemid was added at 0.6 μg/mL and 
further incubated for one hour. Chromosome preparations were prepared as described. 
 
2.19 G-banding analysis of host bone marrow 
    Mice were euthanised and the femurs dissected out and kept on ice. The bone 
marrow was flushed into a pre-warmed tube containing 10 mL of 0.075M KCl, 0.01 
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μg/mL Colcemid and 100 μL 10x Trypsin/EDTA, using 1 mL of the solution. One 
tube was used per femur. The tubes were then incubated for 30 minutes at 37 °C. 2-3 
drops of fixative was added to each tube and then centrifuged at 1200 rpm, 5 minutes 
at room temperature. All but 2 mL of the supernatant was removed, the pellet 
resuspended, and a total volume of 10 mL fixative was added while vortexing. The 
suspension was spun down again and all but 1 mL of the supernatant removed, two 
tubes from the same animal pooled and fixative added as before up to a total volume 
of 10 mL. After a final spin, the supernatant was removed but for 0.5 mL and fixative 
added as before and the preps stored at -20 °C until slide preparation. 
    Before slide preparation, the preps were spun down and resuspended in a small 
volume of fixative. The splashing of the slides was done by breathing on an ethanol 
cleaned slide and a drop of the prep was placed on the slide using a Pasteur pipette. A 
couple of drops of 70% acetic acid was added to the slide and spread by gently 
blowing on the slide. The slide was then left to dry under a heat lamp. The slide was 
then first placed in Xylene (Fisher Scientific) for 5 minutes and then mounted using 
Shandon synthetic mountant (Thermo Electron Corporation, UK). Slides were scored 
by Mr Paul Finnon using a microscope and analysing the metaphases with the Metafer 
Slide scanning system v 3.6.7 (MetaSystems). 
 
2.20 DNA and RNA extraction from spleen cells and BMCs 
    BMCs were isolated from femurs and tibias from mice by flushing using a 25G 
needle and a 1mL syringe with a 1 mL of PBS. Spleens were excised as described. All 
cells samples were stored in RNA later (Ambion, Warrington UK) until processing of 
samples. Cells in suspension were pelleted by centrifugation in a microfuge at 12000 
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rpm for 10 minutes before start of protocol. A small spleen sample was used for 
nucleic acid extraction.  
    Samples for DNA extraction were homogenised using the MagnaLyser (Roche, 
UK), 2 cycles, 3000rpm for 30 seconds (Roche, UK) using the MagNA Pure DNA 
tissue lysis buffer in a 200 μL volume. Dioxyribonucleic acid (DNA) was extracted 
using the MagNa Pure Compact system (Roche) according to the manufacturer’s 
instruction.  
     Samples for RNA exraction were homogenised using the MagnaLyser (Roche, 
UK) as described in 350 µL lysis buffer provided in the RNA extraction kit used, 
RNAqueous 4PCR kit (Ambion). Nucleic acid was extracted according to the 
manufacturer’s recommendations with some modifications. An equal volume of 64 % 
ethanol was added and the lysate mixed. The lysate was applied to the supplied filter 
cartridge attached to a collection tube and the columns were centrifuged 12000 rpm in 
a bench top microfuge, 15 seconds at room temperature. The column was washed 
three times (first wash 500 μL, second and third wash 700 μL) by adding wash 
solutions and centrifuging the columns, 12000 rpm, 30 seconds at room temperature. 
A final centrifugation was performed to remove the last traces of wash solution, 
12000 rpm, 60 seconds at room temperature. The RNA was eluted into a new tube by 
adding 40 µL of elution buffer (pre-warmed to 75 °C) and centrifuging, 12000rpm, 30 
seconds at room temperature. A further 20 µL of elution buffer was added and the 
centrifugation was repeated for 60 seconds. Deoxyribonuclease I (DNaseI) treatment 
was performed by adding a buffer/DNaseI/water mix and the tube incubated for 20 
minutes at 37 °C in a heating block. DNAse inactivation reagent (6 µL) was added 
and the tube incubated at room temperature for 2 minutes, with the tube being flicked 
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occasionally to mix the contents. The supernatant was then transferred into a new tube 
and stored on ice until final storage at -80 °C.  
 
2.21 Agarose gel electrophoresis 
    The DNA and RNA concentration was determined using Nanodrop ND1000 
(Thermo Scientific) and the integrity of the nucleic acid was assessed by running a 
2% agarose gel for DNA and 1.3 % gel for RNA. The gel was prepared by mixing the 
required amount of agarose (BioRad, Hemel Hempsted UK) in Tris/Borate (TBE) 
buffer (5x stock: 54g Tris base, 27.5g boric acid, 20 mL 0.5 M EDTA pH 8.0 diluted 
to 1x for use) and heating the solution in a microwave until the agarose was dissolved. 
After the gel solution had cooled to approximately 55 °C, 10 μg/mL Ethidium 
bromide (BDH, Poole UK) or 10 μL GelRed (Biotium, Hayward California) was 
added and the solution gently swirled to mix. The gel solution was poured into a gel 
platform sealed with tape and left to set with a gel comb inserted. When ready for use, 
the tape and the comb were removed and the gel platform was submerged in a gel 
tank containing TBE buffer. Samples were mixed 1:6 with loading buffer (0.25 % 
bromophenol blue, 40 % (v/w) sucrose in H2O) and added to the wells. A 1 kB ladder 
was used at 0.0625 μg/mL to estimate the sizes of products. 1.3 % gels were run for 
approximately an hour at 100 V and 2 % gels were run at 80 V for 1 hour. The gel 
was visualised using the Gel Doc 2000 system (BioRad). 
 
2.22 PCR for identifying carriers of the GFP construct 
    PCR genotyping of cells from spleen colonies or spleen samples from animals with 
rAML was performed using Qiagen Taq polymerase kit by preparing a mastermix 
containing buffer, Qsolution and Taq polymerase (Qiagen, UK) primers  (Sigma) and  
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Table 2.2 Primers used for genotyping of spleen cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Primer Sequence 
Forward A 5’ TGGCGCCTACCGGTGGATGTGG 3’ 
Reverse B 5’ CTGTGTGCCACCACCTGCCTACATT 3’ 
Forward C 5’ GTGCTTCTTTGGGAGTCTGGCGCT 3’ 
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dNTPs (Invitrogen). Primers were used at 6.6 μM and dNTPs at 200 μM 
concentration. The DNA concentration used was 25 ng/ μL. For a standard to estimate 
the amount of splenocyte DNA to DNA from leukaemic cells, a mix of known 
concentrations of WT and Sfpi1 GFP/GFP DNA was used to estimate potential 
contamination of spleen tissue.  The ratio WT/ Sfpi1 GFP/GFP DNA was: 1:0, 9:1, 
7:3, 1:1, 3:7, 1:9 and 0:1. 
    Primer a and b identifies the 512 base pairs (bp) Sfpi1 GFP allele and primer b and 
c identifies 680 bp wild type Sfpi1 allele. The samples were run on a Hybaid PCR 
express thermocycler on the following cycling conditions: 4 min at 95 °C followed by 
45 cycles of 15 s each at 95 °C, 55 °C and 72 °C and a final 10 min at 72 °C. The 
final product was analysed using a 2% agarose gel as described. 
 
2.23 Reverse transcription (RT) 
     Reverse transcription reactions were performed using High Capacity 
complementary DNA (cDNA) Reverse Transcription kit, (Applied Biosystems, Foster 
City, CA, USA) according to manufacturer’s protocol using 700 ng of RNA in a 50µl 
reaction volume. A master mix was made up containing ddH20, RT buffer, dNTP mix, 
random primers and the RT enzyme. RT reactions were set up in 0.2 mL strip tubes 
using the iQ5 Real-Time PCR detection system (Bio-Rad). 
 
 
 
 
  83 
2.24 Primer design validation protocol for quantitative polymerase chain 
reaction 
All primer design and validation was performed by Sylwia Kabcik and Grainne 
Manning. Primers (Table 2.3) were tested by a SYBRGreen assay using iQ5 
thermocyclers (Bio-Rad). All reactions were run in triplicate using PerfeCTa® 
SYBR® Green SuperMix for iQ™ (Quanta Biosciences, Inc. Gaithersburg, MD, 
USA), with primers at a 300 nM concentration each (Eurogentec Ltd., Fawley, 
Hampshire, UK) and 1µl of cDNA in 25µl reaction volume. Cycling parameters were: 
2 minutes at 95 °C, then 35 cycles of 10 seconds at 95 °C and 60 seconds at 60 °C 
followed by a melting curve analysis. Data was collected and analysed by iQ5 
Detection System software. Primers were considered as specific if only one peak was 
present on melt curve graph and PCR product was of the appropriate size on a 1.3 % 
agarose gel. 
    Probes were tested by serial dilution of PCR-amplified DNA fragments of each 
gene produced by covering primers. PCR-amplified DNA fragments were prepared 
using Taq DNA Polymerase (Qiagen Ltd., Crawley, UK) according to the 
manufacturer’s protocol with gene specific primers at 500 nM concentration and 10 µl 
of cDNA in 100 µl reactions. Cycling parameters were: 4 minutes at 95 °C, then 35 
cycles of 30 seconds at 95 °C, 30 seconds at 57 °C and 30 seconds at 72 °C, followed 
by a final extension step, 10 minutes at 72 °C. Amplified PCR products were purified 
on 1.3% agarose gel and extracted using MinElute Gel Extraction Kit (Qiagen) 
according to manufacturer’s instruction. Purified products were quantified by using 
the Nanodrop ND1000 (Nanodrop, Wilmington, USA). A standard curve covering six 
logs was prepared by series of nine 5-fold dilutions starting from 640 ng/µl for each 
gene. The design was considered to be validated only if the PCR efficiency in four- 
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Primer Sequence  Probe sequence Dye 
Sfpi1 
(forward) 
5’ 
AGAAGCTGATGGCTTGGAGC 
3’ 
 
5’ TGGGCCAGGTCTTCTGCACGG 3’ 
 
HEX 
Sfpi1 
(reverse) 
5’ 
GCGAATCTTTTTCTTGCTGCC 
3’ 
 
  
GFP 
(forward) 
5’ 
AGCCGCTACCCCGACCACAT 
3’ 
 
5’ 
GCCCGAAGGCTACGTCCAGGAGCGC 
3’ 
 
Texas 
Red 
GFP 
(reverse) 
5’ 
CGGTTCACCAGGGTGTCGCC 
3’ 
 
  
HPRT1 
(forward) 
5’ 
GGACAGGACTGAAAGACTTG 
3’ 
 
5’ 
CCCTTGAGCACACAGAGGGCCACA 
3’ 
FAM 
HPRT1 
(reverse) 
5’ 
TAATCCAGCAGGTCAGCAAA 
3’ 
 
  
Table 2.3 Primers and probes for analysis of Sfpi1 and GFP gene expression.
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plex PCR was between 93 % and 105 % and R2>0.998. Reaction and cycling 
conditions were as described for the Multiplex quantitative Real-Time-PCR (MQ-RT-
PCR) only instead of 2.5 µl of cDNA, 2.5 µl of standard was used. 
 
2.25 Multiplex quantitative real-time polymerase chain reaction 
    All reactions were run in triplicate using PerfeCTa® MultiPlex qPCR SuperMix 
(Quanta Biosciences, Inc. Gaithersburg, MD, USA), primer and probe sets (Table 2.3) 
at 300 nM concentration and 2.5 µl of cDNA in a 30 µl reaction volume. 3’ 6-
Carboxyfluorescein (FAM), 6-Hexachlorofluorescein (HEX), and Texas Red 
(Eurogentec Ltd., Fawley, Hampshire, UK) were used as fluorochrome reporters for 
the hydrolysis probes analysed in multiplexed reactions. Cycling parameters were 2 
minutes at 95 °C, then 45 cycles of 10 seconds at 95 °C and 60 seconds at 60 °C on 
the Rotor Gene Q real-time PCR cycler (Qiagen, Crawley, UK). Data were collected 
and analysed by Rotor Gene Q Series software. Gene target cycle threshold (Ct) 
values were normalised to a Hypoxanthine–Guanine phosphoribosyltransferase 1 
(HPRT1) internal control and were converted to transcript quantity (SQ) using  
standard curves run with each MQ-RT-PCR plate. This value was then graphed using 
Excel. The linear dynamic range of the standard curves covering six orders of 
magnitude (serial dilution from 3.2x10-4 to 8.2x10-10) gave PCR efficiencies between 
93 % and 105 % for each gene with R2>0.998.  
 
2.26 DNA sequencing and analysis of point mutations 
    A PCR reaction was set up to amplify exon 5 of the Sfpi1 gene from rAML samples 
using primers specific for the locus (F-5’CGACATGAAGGACAGCATCT3’ and R-
5’TTTCTTCACCTCGCCTGTCT3’). The Qiagen Taq polymerase kit was used by 
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preparing a mastermix containing buffer, Qsolution and Taq polymerase (Qiagen, 
UK) primers  (Sigma) and dNTPs (Invitrogen). Primers were used at 6.6 μM and 
dNTPs at 200 μM concentration. The DNA concentration used was 25 ng/ μL. A 
small aliquot was analysed on an agarose gel as previously described.  
    The product was cleaned-up using the PCR Kleen spin columns (BioRad). The 
resin in the columns was resuspended by vortexing and the tip snapped off and the 
column placed in a 2 mL wash tube. The column was pre-spun at 735 x g in a 
microfuge and then placed in a 1.5 mL collection tube. The PCR sample was added to 
the centre of the column and the spun for 2 minutes at 735 x g. The purified sample 
was then transferred to a 0.5 mL tube and sent for sequencing at Source BioScience, 
University of Oxford, UK.  
    The sequencing files were analysed for point mutations using 4 peaks 
(Mekentosj.com).  
 
2.27 Analysis of FLT3-ITD mutation status of rAML cases 
    A PCR reaction was set up as described above, using primers specific for the ITD 
in exon 14 (F-5’GCAATTTAGGTACGAGAGTCAG3’ and  
R- 5’CTTTTAGCATCTTCACCGCCAC3’). The products were analysed on an 
agarose gel as described. 
 
 
2.28 PCR for microsatellite analysis 
    The microsatellite analysis was performed by Dr Rosemary Finnon. A mastermix 
was made by adding buffer, Magnesium Chloride and di-nucleotide triphosphates 
(Thermo Fisher Scientific, Loughborough UK) to distilled water and Taq polymerase 
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(Thermo Fisher Scientific).  Primer pairs for D2MITs were from Sigma-Aaldrich UK 
and the sequences are available at http://mp.invitrogen.com/mappairs_mouse.php3.   
The samples were run on a Hybaid PCR express thermocycler on the following 
cycling conditions: 4 min at 95 °C followed by 45 cycles of 15 s each at 95 °C, 55 °C 
and 72 °C and a final 10 min at 72 °C. The final product was analysed using a 3% 
agarose gel for 60 min at 80 V and the gel visualised as described. 
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Chapter 3. Results 
3.1 Investigation of early events after in vitro and in vivo exposure to 
ionising radiation 
 
3.1.1 Introduction 
    Previous work has been performed on mice presenting symptoms and being 
diagnosed with rAML in the CBA/H strain. A significant amount of work has also 
been done on studying chromosomal aberrations, specifically deletions of 
chromosome 2. These deletions are seen in up to 90% of the cases diagnosed with 
rAML in CBA/H mice and other strains susceptible to the disease (Azumi and Sachs, 
1977; Hayata et al. 1983; Rithidech et al. 1995; Hirouchi et al. 2008). This event is 
therefore of significant interest for understanding the first molecular events that lead 
to rAML. Of note is that chromosome 2 internal deletions can be seen in bone marrow 
from all CBA/H mice irradiated with a whole body dose of 3 Gy 24 hours after 
exposure (Bouffler et al. 1997; Peng, 2009). This early chromosome deletion does not 
lead to rAML in all mice. Cells carrying the chromosome deletion start to expand 
clonally in 50% of the animals around 12 months after radiation exposure (Bouffler et 
al., 1997), probably due to a proliferative or selective advantage, but ultimately up to 
only 25% of mice are diagnosed with rAML (Major and Mole, 1978). The gene that 
has been identified as being a key gene in the deleted region and most likely acting as 
a tumour suppressor is Sfpi1 and its product the transcription factor PU.1 (Cook et al. 
2004; Suraweera et al. 2005), a gene that is of essential for haematopoietic 
development (Hromas et al. 1993; Silver et al. 1999; Kastner and Chan, 2008).  
    Since most previous work has either been done on cell lines derived from 
leukaemic mice or fixed cells from leukaemic samples, the project aims to study the 
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early events in live bone marrow cells (BMCs). Transgenic mouse models expressing 
GFP as a reporter gene for Sfpi1 expression has been created by two separate research 
groups making it possible to monitor the expression of Sfpi1 during hematopoiesis 
and the development of subpopulations of BMC (Nutt et al. 2005; Back et al. 2005). 
Using the model created by Nutt et al, it was predicted that we would be able to 
identify live cells that have lost a copy of Sfpi1 through their expression levels of the 
reporter gene and isolate them for further analysis.  
 
3.1.2 Genotyping using microsatellite markers 
    The mice carrying the GFP construct were created using the C57BL/6 strain (Nutt 
et al. 2005). Since we wanted the GFP reporter gene on the rAML-susceptible CBA/H 
strain, the two strains CBA/H and C57BL/6 had to be bred to create F1 progeny. The 
F1 progeny were then backcrossed to the CBA/H strain for a minimum of 6 
generations to produce mice that were as far as possible genetically homozygous for 
the CBA/H alleles. Mice that were heterozygous and homozygous for the reporter 
gene GFP was produced on both the CBA/H and C57BL/6 background. By using 
primers for microsatellite markers specific for one mouse strain it is possible in F1 
crosses to determine from which parent strain a specific allele or loci is inherited from 
(Clark et al., 1996). The assay is here used to test for homozygosity of strain specific 
microsatellite markers, in this case on F5 and F6 backcrosses, but does not assess the 
overall genetic purity of the whole genome of the mice. When the product of 
amplification is analysed on an agarose gel, the band will be of a size specific for the 
parental strain, C57BL/6 or CBA/H. 
    This work was performed by Dr. Rosemary Finnon. DNA was extracted from 
BMCs of F5 and F6 CBA/H mice carrying the GFP construct and PCR using primers 
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for microsatellite markers on chromosome 2 was used to establishing whether mice 
were heterozygous or homozygous for the CBA/H allele at a particular loci (Clark et 
al., 1996, Silver et al., 1999).  
    The results from two CBA/H GFP mice can be seen in Figure 3.1.1. Out of 15 
tested markers, mouse A was found to be homozygous for the CBA/H variant at 10/15 
(66%) of the markers and mouse B at 8/15 (53%) of the markers. The markers chosen 
were previously used to determine loss of heterozygosity in F1 mice for previous 
mapping work (Clark et al. 1996). It is generally assumed that after 6 generations of 
back crossing, the genome of the mice would be 96% homozygous for CBA/H strain 
markers (Silver, 1995). However, since the mice are selected for carrying the GFP 
construct, some level of heterozygosity would likely remain on chromosome 2 
specifically around the loci where the construct is located, which is what the results 
show. This is due to the fact that the further away to loci are on a chromosome, the 
more likely they are to cross over (Silver, 1995). For the purpose of this work it is 
important to note that rAML in F1 (C57BL/6 x CBA/H) mice have a similar 
frequency of loss of Sfpi1 alleles, irrespective whether the allele is acquired from the 
C57BL/6 strain or the CBA/H strain (Silver et al., 1999). Therefore the mixed CBA/H 
and C57BL/6 background in the present strains is unlikely to affect AML yields. 
These results show that it is unlikely that a small contamination to the genetic 
background from the C57BL/6 strain would affect the frequency of loss of one allele 
of Sfpi1 for these studies. Ultimately, if the animals used in this work present with 
rAML with a comparable frequency to that found in previous work, this question will  
be answered.
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Figure 3.1.1. Microsatellite analysis of chromosome 2.  
The spleens were dissected out from 2 CBA/H mice (F5 and F6). The DNA was 
extracted and a PCR reaction was set up using primers specific for microsatellite 
markers on mouse chromosome 2. The markers are polymorphic between CBA/H and 
C57Bl/6 DNA and give products of different sizes. These can be distinguished on an 
agarose gel. White circles designate a locus that shows heterozygosity (both CBA/H 
and C57BL/6 marker variants present) and black circles designates a homozygous 
locus (only the CBA/H marker variant present). The approximate location of the 
microsatellite marker is indicated on the left of the table on a schematic of mouse 
chromosome 2. The distance from the centromere in centiMorgans (cM) is indicated 
to the left of the chromosome. The approximate location of the gene Sfpi1 is shown. 
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3.1.3 Characterisation of GFP expression levels in mice by flow cytometry 
     
    GFP expression in the bone marrow cells from the genetically modified mice were 
analysed by flow cytometry. Bone marrow was taken from C57BL/6 and CBA/H GFP 
heterozygote (Sfpi1 GFP/+) and homozygote (Sfpi1 GFP/GFP) mice and the GFP 
expression analysed by flow cytometry (Figure 3.1.2). Control non-GFP mice on a 
C57BL/6 background were used to estimate the level of autofluorescence. The 
expression of GFP can be divided into three levels: GFP negative, GFP low and GFP 
high. The GFP expression levels have previously been shown to correspond to T-cells 
and erythrocytes (GFP negative expression fraction), B-cells (GFP negative/low 
expression fraction) and myeloid cells such as monocytes and macrophages (GFP 
high expressing fraction) (Dakic et al., 2007). The percentage of GFP expressing cells 
in bone marrow is similar between the Sfpi1 GFP/+ and Sfpi1 GFP/GFP mice in each 
level. Overlaying the histograms for the Sfpi1 GFP/+ and Sfpi1 GFP/GFP mice shows that 
GFP expression in the heterozygote is approximately half that of the homozygote 
mice as expected. Furthermore, the GFP expression is comparable in the C57BL/6 
and CBA/H strains corresponding to similar levels of PU.1 expression in both strains. 
The expression level of GFP protein in the GFP-mouse model has been shown by 
others to be comparable to the level of PU.1 protein and also to have a similar half-
life, as assessed by western blotting (Nutt et al., 2005).  
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Figure 3.1.2. GFP expression in bone marrow of Sfpi1 GFP/+ and Sfpi1 GFP/GFP 
C57BL/6 and CBA/H mice.  
The data are representative of 2-3 individual mice. A. BMCs were extracted from 
bone marrow of three mice from each group and analysed by flow cytometry. Cells 
were gated on the 7AAD negative population (left panel) and bone marrow from non-
GFP mice were used as an autofluorescence control (right panel). B. The GFP 
expression (in %) in the bone marrow (upper and middle panels) and an overlay of 
Sfpi1 GFP/+ (red lines) and Sfpi1 GFP/GFP (blue lines) histograms (lower panels). 
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3.1.4 Characterisation of the Sfpi1 and GFP expression in spleen and bone 
marrow cells by MQ-RT-PCR 
    To further examine GFP expression in the mouse model, MQ-RT-PCR was 
performed on RNA extracted from spleen cells and bone marrow from CBA/H wild-
type (WT), Sfpi1 GFP/+ and Sfpi1 GFP/GFP mice. As one would expect, CBA/H WT mice 
did not express GFP, whereas both Sfpi1 GFP/+ and Sfpi1 GFP/GFP mice do (Figure 
3.1.3.A and B). In both tissues there is good agreement between the GFP levels and 
the copy number of the GFP construct. In spleen (Figure 3.1.3.A), the mRNA 
transcript level relative to HPRT1 was 0.54 in the Sfpi1 GFP/+ sample and 1.0 in the 
GFP+/+ sample. In bone marrow, the expression of GFP was close to 3 times higher in 
Sfpi1 GFP/GFP (3.05) mice compared to Sfpi1 GFP/+ mice (0.96) (Figure 3.1.3B). The 
Sfpi1 expression in spleen was similar between all the genotypes showing that the 
difference in GFP expression was due to copy number, ie. one compared to two 
copies of the GFP construct (Figure 3.1.3C). In the bone marrow samples, the WT 
and Sfpi1 GFP/+ mice in this experiment had similar levels (0.65 and 0.61 respectively) 
of Sfpi1 mRNA expression relative to HPRT1, whereas the Sfpi1 GFP/GFP samples 
showed 1.6 times higher expression (0.98) (Figure 3.1.3D). The GFP expression 
correlates with this trend for a higher Sfpi1 expression in the Sfpi1 GFP/GFP sample. The 
variation in the results is most likely due to the sample size (1 animal per genotype), 
further animals would need to be assessed to confirm the expression levels observed.  
 Together with previous published data on this mouse model (Nutt et al. 2005), this 
confirms that GFP should be possible to use to detect a copy loss of Sfpi1. Also, the 
minimal deleted region characterised in rAML in the CBA/H mouse always contains 
Sfpi1 (Silver et al., 1999). Sfpi1 and the GFP construct would be expected to be lost 
together in the GFP strains, suggesting that loss (Sfpi1 GFP/+ mice) or 
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Figure 3.1.3. The Sfpi1 expression and GFP expression in spleen and bone 
marrow cells analysed by MQ-RT-PCR.  
RNA was extracted from spleen material or BMCs of CBA/H WT, Sfpi1 GFP/+ or Sfpi1 
GFP/GFP mice (data are from 1 experiment,1 mouse/genotype). cDNA was obtained by 
performing an RT step followed by MQ-RT-PCR to quantitate transcript levels of the 
relevant genes. A. mRNA transcript levels of the GFP construct in spleen from 
CBA/H mice relative to HPRT1. B. mRNA transcript levels of the GFP construct in 
BMCs from CBA/H mice relative to HPRT1. C. mRNA transcript levels of the gene 
Sfpi1 in CBA/H spleen relative to HPRT1. D. mRNA transcript levels of the gene 
Sfpi1 in CBA/H BMCs relative to HPRT1. 
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reduction (Sfpi1 GFP/GFP mice) of GFP expression in cells is likely to be associated 
with Sfpi1 loss. However, in Sfpi1 GFP/+ mice, the loss of Sfpi1 would only be 
detectable by flow cytometry if the loss occurs on the allele carrying the GFP 
construct. 
   
3.1.5 Selection of Lineage-negative (Lin-) or Lin- c-Kit+ cells for in vitro 
irradiation 
 
    HSC and myeloid progenitors are a small proportion (0.01-0.05 %) of the total 
bone marrow cell population (Spangrude et al., 1988; Iwasaki and Akashi, 2007a). In 
order to follow up specific sub-populations of cells exposed to ionising radiation, they 
need to be separated from the total bone marrow. We opted to use immunomagnetic 
cell separation where cells are labelled with antibodies against cell surface markers 
and selected by adding (magnetic) ferrous micro- or nano particles binding to the 
antibodies. The cells can then be separated into labelled and unlabelled fractions using 
a magnet. Whole bone marrow was depleted of mature, differentiated cells (eg. 
granulocytes, macrophages, B-cell and T-cells) by the use of immunomagnetic cell 
separation resulting in a fraction of cells that are Lin- (Spangrude et al., 1988) through 
negative selection. Further enrichment of Lin- cells was used to positively select Lin- 
c-Kit+ cells. Figure 3.1.4 describes the process in more detail. The Lin- fraction is 
expected to contain a mixture of various immature progenitors and HSC whereas the 
Lin- c-Kit+ fraction is expected to contain mostly myeloid progenitor cells (Iwasaki et 
al., 2007b).  
Lin- and Lin- c-Kit+ cells were isolated from BMCs of non-GFP control mice and 
Sfpi1 GFP/+ C57BL/6 and CBA/H mice by immunomagnetic cell separation. The GFP 
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 Figure 3.1.4. Immunomagnetic cell separation of subpopulations of BMC 
and in vitro irradiation.  
BMCs were extracted from femora of mice and labelled with antibodies against 
lineage markers and magnetic beads. Cells were separated into a Lin- and a Lin+ 
fraction using a magnet. A. Lin- cell were plated in semi-solid medium and exposed to 
ionising radiation. After 10-12 days, the colonies were counted. B. Lin- cell were 
further enriched and selected for c-Kit+ cells. The cell were plated in semi-solid 
medium and exposed to ionising radiation. After 10 -12 days, the colonies were 
counted. 
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Figure 3.1.5. GFP expression in Lin- cells after immunomagnetic cell 
separation.  
Lin- cells were selected from bone marrow of non-GFP control mice and GFP+/- 
C57BL/6 and CBA/H mice using immunomagnetic separation. The GFP expression 
of the Lin- cells were analysed by flow cytometry. Data is representative of 3 
individual experiments where BMCs have been pooled from a minimum of 4 CBA/H 
or C57BL/6 Sfpi1 GFP/+ mice. A. R1 contains a high proportion of dead cells, as 
defined by the uptake of 7-AAD. Cells in the R2 region contains mostly live cells (7-
AAD negative). B. GFP expression of gated Lin- cells in control and Sfpi1 GFP/+ mice. 
A gate was set round the population where most live cells are found and then plots 
were based on a combined gate with 7AAD negative cells. Lin- cell from non-GFP 
mice were used as negative controls for GFP expression (top right).
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expression was analysed by flow cytometry. Forward and side scatter were plotted 
against each other and two regions, R1 and R2 were defined (Figure 3.1.5A). R1, as is 
seen in Figure 3.1.5A, was found to contain a substantial amount of dead cells, as 
defined by the uptake of the dye (7-Amino-Actinomycin D) 7-AAD. Therefore, in 
further plots the main region was set round the population of mostly live cells. The 
GFP expression in both the C57BL/6 and CBA/H strain were comparable after Lin 
depletion at approximately 37% in the C57BL/6 strain and 38 % in the CBA/H strain 
(Figure 3.1.5B). Around 10 % of the c-Kit+ cells in whole bone marrow (as gated in 
Figure 3.1.6A) were positive for GFP. After Lin- cells have been enriched for c-Kit, 
this increased to 32 % in CBA/H mice (30-34%) and to 38 % (30-46 %) in C57BL/6 
mice (Figure 3.1.6B). The purity for the c-Kit selection in both strains was uniformly 
high at around 96 %. Again, both plots were gated on 7-AAD negative, live cells. 
 Since the purity of the c-Kit selection was very good, the subpopulation was as 
homogenous as possible for the expression of c-Kit. The plating efficiency in 
methylcellulose media was also increased by up to 38-fold compared to total BMCs 
(Table 3.1.1). For the negative selection of Lin- cells, biotin conjugated antibodies 
with no fluorescent marker was used to directly label the cells. This meant that the 
exact purity of the cells could not be defined. On average, the plating efficiency was 
increased by 16- to 20-fold compared to plated unselected BMCs (Table 3.1.1). This 
indicates that the negative selections had worked, although precise percentage purity 
at the time of plating cannot be given due to the negative selection process. 
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Figure 3.1.6. GFP expression in Lin- c-Kit+ cells after immunomagnetic cell 
selection. 
Data are representative of 3 individual experiments where BMCs have been pooled 
from a minimum of 4 CBA/H or C57BL/6 Sfpi1 GFP/+ mice. A. BMCs from CBA/H 
Sfpi1 GFP/+ mouse were extracted from bone marrow, stained with mAb against c-Kit 
and analysed by flow cytometry. A region was set around the major cell populations 
on a FSC vs SSC plot and then cells in the 7-AAD negative population was analysed. 
B. Lin- Ckit+ cells were selected by immunomagnetic cell separation as described 
before from BMC of C57BL/6 and CBA/H Sfpi1 GFP/+ mice and a sample was 
analysed by flow cytometry. Cells were gated on a combined gate of the major 
population and 7-AAD negative cells. 
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    Lin- cells  Lin- c-Kit+ cells 
         
  BMC  CBA/H C57BL/6  CBA/H C57BL/6 
 
Average 
PE (%) 0.1  2.1 2.7  4.4 5.0 
Table 3.1.1 Average plating efficiency for BMC, Lin- and Lin- c-kit+ cells plated 
in methylcellulose media. 
 
 
 
 
 
 
       
 Lin- cells  Lin- c-Kit+ cells  
  CBA/H C57BL/6 p CBA/H C57BL/6 p 
              
alpha -0.02 0.33   0.12 0.19  
              
beta 0.13 0.04   0.10 0.08  
              
 F-test   0.009     0.94 
       
Table 3.1.2. Parameters given by the linear-quadratic model of cell survival for 
in vitro irradiated Lin- and Lin- c-Kit+ cells. 
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3.1.6 The effect of ionising radiation on the colony formation of Lin- or Lin- c-Kit+ cells 
in CBA/H and C57BL/6 mice 
    To study cell survival after exposure to ionising radiation, we used a colony forming assay 
in methylcullulose medium (Charbord, 1994; Coulombel, 2004). In this culture system, early 
progenitors will give rise to discrete colonies that can be analysed further. Sensitivities of 
different populations of immature BMCs to ionising radiation were investigated by plating 
the selected cells in semi-solid medium and irradiating them in vitro the next day 
(approximately 16 hours later) with doses ranging between 0.25 and 3 Gy of x-rays. After 10-
12 days, colony formation was assessed and the radiation dose (in Gy) was plotted against the 
surviving fraction according to the linear-quadratic model of cell survival (Kellerer and 
Rossi, 1974). 
   The survival curves for the in vitro irradiated cell populations from both CBA/H Sfpi1 GFP/+ 
and C57BL/6 Sfpi1 GFP/+ mice can be seen in Figure 3.1.7 and a mean plating efficiency for 
unirradiated Lin- and Lin- c-Kit+ cell can be seen in Table 3.1.1 The values for the linear-
quadratic model cell survival constants α and β can be seen in Table 3.1.2. In the CBA/H 
strain, Lin- cells have a negative value for α. This is probably due to the level of cell killing 
being low at lower doses (0.25 and 0.5 Gy), leading to the surviving fraction being close to 1 
in some cases. The value for β is higher in the CBA/H than in the C57BL/6 strain, suggesting 
that the misrepair in the CBA/H strain may be slightly higher. For Lin- c-Kit+ cells, the α and 
β values in CBA/H and C57/BL6 are relatively similar. If the shapes of the survival curves 
are compared to each other, there seems to be a trend for the Lin- cells from the C57BL/6 
strain to be more sensitive than the CBA/H strain (Figure 3.1.7A). The curves were compared 
statistically using the f-test in Graphpad Prism 4.0. According to this comparison, the shapes 
of the curves are significantly different (p= 0.009), indicating a difference in sensitivity 
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between the two strains, when Lin- cells are irradiated. Notably, the shapes of the survival 
curves for the Lin- c-Kit+ subpopulation are very similar in both the CBA/H and C57BL/6 
strains in comparison to the cell survival curves for the Lin population (Figure 3.1.7B). An f-
test shows that the curves are not significantly different (p = 0.94) and the survival of the Lin- 
c-Kit+ population was similar in the CBA/H and the C57BL/6 strains.   
    These results suggests there is a difference in sensitivity to ionising radiation in a 
subpopulation of immature haematopoietic cells in the two strains CBA/H, which can 
develop rAML, and the C57BL/6 strain, which does not. The Lin- population contains all the 
bone marrow cells that have not committed to differentiating into a specific cell type and 
include HSCs, myeloid progenitors and lymphoid progenitors (Bryder et al. 2006). In the 
contrast, the Lin- c-Kit+ population should theoretically contain more myeloid progenitors 
(Iwasaki and Akashi, 2007b). It has been suggested that cells of the C57BL/6 strain undergo 
apoptosis at a higher rate than cells from CBA/H mice in response to radiation (Lindsay et 
al., 2007). The implication of this would be that BMCs from the CBA/H strain might survive 
exposure to radiation to a higher degree even though they have acquired DNA damage. 
Potentially leukaemogenic mutations giving a proliferative advantage would make these cells 
survive, further accumulate mutations and eventually become leukaemic and outgrow the 
normal bone marrow population. In the C57BL/6 strain, such damaged cells would more 
readily undergo apoptosis and therefore not contribute to leukaemogenesis. It is noteworthy 
that a clonal expansion of cells with chromosome 2 aberrations has been noted in irradiated 
CBA/H mice (Bouffler et al., 1997). However, the presence of clonal expansion is not
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Figure 3.1.7. Survival curve for in vitro irradiated cell populations.  
 Subpopulations of pooled BMC from C57BL/6 and CBA/H Sfpi1 GFP/+ mice were selected through immunomagnetic cell separations, 
triplicates for each dose was plated in semi-solid cultures and irradiated the next day with a dose ranging between 0.25 Gy to 3 Gy. After 
10-12 days, the colonies were counted and a survival curve was plotted, radiation dose against surviving fraction, on a semi-log scale. 
Each data point is derived from 2-4 individual experiments. A. CBA/H and C57BL/6 Sfpi1 GFP/+ Lin- cells B. CBA/H and C57BL/6 Sfpi1 
GFP/+ Lin- c-Kit+ cells. 
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necessarily an indication of rAML since not all mice with such expanded clones go on 
to develop the disease.It is important to note that progenitor cells and HSCs have 
substantially more complicated phenotypes than those used in the current 
experiments, but separation for further markers would not be technically feasible with 
the technique used. The experiments should rather be seen as a base for further work, 
which could for example make use of fluorescent activated cell sorting (FACS). 
 
3.1.7 GFP expression in Lin- cells from in vivo irradiated mice 
    To assess the effect of ionising radiation on immature BMCs after in vivo radiation 
exposure, Sfpi1 GFP/+ and Sfpi1 GFP/GFP mice from both strains (C57BL/6 and CBA/H) 
were given a whole body dose of ionising radiation (x-rays, 3 Gy). After 9 days, the 
BMCs were extracted as before and Lin- cells were obtained as previously described 
(see Figure 3.1.8 for protocol outline). The GFP expression of Lin- cells were 
analysed by flow cytometry. 
    Interestingly, GFP expression was lowered in Lin- cells by between a 1.6 to a 2-
fold change in all four groups, compared to non-irradiated controls (Figure 3.1.9).  
    The GFP expression in Lin- cells isolated from mice that had been exposed to a 
whole body dose of 3 Gy of ionising radiation suggests that the PU.1 expression in 
the cell population has been affected (Figure 3.1.9 B). The decrease in GFP 
expression, up to 50% compared to unirradiated controls, can potentially be attributed 
to a Sfpi1 copy loss. Nevertheless, the proportion of cells with Sfpi1 loss would in that 
case be significantly higher than reported before using fluorescent in situ  
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Figure 3.1.8. In vivo radiation and analysis of Lin- cells.  
Sfpi1 GFP/+ and Sfpi1 GFP/GFP mice from both the CBA/H and the C57BL/6 
 strains were irradiated with a whole body dose of ionising radiation (3 Gy). After 9 
days, the BMCs were extracted, Lin- cells obtained by immunomagnetic cell 
separation and the selected cells were plated in semi-solid media. After 7 days, the 
cells were isolated and analysed by flow cytometry.   
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 Figure 3.1.9. GFP expression in Lin- cells from in vivo irradiated mice.  
BMC were extracted from femora of mice (non-GFP mice, C57BL/6 or CBA/H Sfpi1 
GFP/+ and Sfpi1 GFP/GFP mice), which were non-irradiated or exposed to a whole body 
dose of 3 Gy of ionising radiation. 9 days after irradiation, Lin- cells were selected as 
described previously before being analysed by flow cytometry. A. Cells were gated 
combined on the main region and the 7-AAD negative cells. Non-GFP mouse were 
used as autofluorescence control. B. GFP expression in Lin- cells of non-irradiated 
C57BL/6 or CBA/H Sfpi1 GFP/+ and Sfpi1 GFP/GFP mice compared to mice irradiated 
with a whole body dose of 3 Gy. 
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hybridisation (FISH) (Peng et al. 2009). Peng et al reported just under 16 % cells with 
Sfpi1 loss in CBA/Ca mice and just under 6% for C57BL/6 mice 7 days after 
irradiation under same conditions and at the same X-ray facility. However, Peng et al. 
2009 reported loss in total bone marrow cells whereas the current experiment 
analysed loss in Lin- cells. It is therefore possible that the Lin- population is more 
sensitive to radiation-induced Sfpi1 copy loss than the total bone marrow in general. 
From these experiments, it is not possible to deduce which specific cells in the Lin- 
fraction the GFP reduction occur in. As mentioned, the Lin- fraction contains HSCs, 
myeloid and lymphoid progenitors. By staining Lin- cells with antibodies against 
surface markers that define different cell types within the Lin- fraction, further 
characterisation of GFP loss and reduction in immature BMCs could be investigated.  
 
3.1.8 The effect of exposure to 3 Gy ionising radiation on colony formation in 
Lin- cells from CBA/H and C57BL/6 mice 
    BMCs or Lin- cells from the mice analysed by flow cytometry in Figure 3.19 were 
plated in methylcellulose media as described before. Colonies were counted after 7 
days of incubation. Colony counts from the same condition and strain were averaged, 
eg. CBA/H Sfpi1 GFP/+ and Sfpi1 GFP/GFP.  
    BMC control cultures gave comparable plating efficiencies between strains, 0.2% 
(Figure 3.1.10). The plating efficiency for Lin- cells from C57BL/6 mice (4.5 %) was 
slightly higher than for CBA/H mice (3.2 %). The plating efficiency from in vivo 
irradiated cells was much reduced in both strains as expected. However, the reduction 
in the Lin- C57BL/6 cultures was 5-fold compared to 3-fold in the Lin- CBA/H 
cultures. This was a single experiment, however the trend was the same as. 
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Figure 3.1.10. Plating efficiencies of Lin- cells from mice irradiated in vivo 
(3 Gy). . 
 Samples of cells analysed in Figure 3.1.9 were plated in triplicate in methylcellulose 
media and colonies counted after 7 days. Mean plating efficiencies of triplicate 
cultures were calculated and results from Sfpi1 GFP/+ and Sfpi1 GFP/GFP cultures were 
averaged for each strain. Numbers above each bar is the plating efficiency. The chart 
shows the results from one experiment. 
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seen for in vitro irradiated Lin- cells (Figure 3.1.7). That is, the Lin- cells from the 
C57BL/6 mice showed a similar trend to be more sensitive to ionising radiation than 
the same cell population in CBA/H mice. This further strengthened the conclusion 
that C57BL/6 Lin- cells are more sensitive to radiation than those of CBA/H. To 
substantiate these results, more repeats of this experiment and also the equivalent with 
Lin- c-Kit+ cells should be performed. 
 
3.1.9 Characterisation of colonies from in vivo irradiated mice 
To assess whether it was possible to characterise any potential difference in GFP 
expression in the cultured cells resulting from loss of a copy of the Sfpi1 gene and 
potential variations between cell types, cells isolated from the cultures were plated in 
semi-solid cultures 9 days after irradiation and cultured for 7 days before being 
analysed by flow cytometry. Cells were recovered from the semi solid cultures and 
stained for cell surface markers or washed and analysed without antibody staining.  
    To minimise autofluorescence, the region analysed was the core of the main 
population (Figure 3.1.11A). Cells with low forward and side scatter were mainly 
dead or apoptotic cells as can be seen from the staining with 7AAD in Figure 3.1.11 
A, upper panels. The pooled cells from the colonies arising from Lin- c-Kit+ selected 
cells were furthermore stained for surface markers (c-Kit, FcγRIII/II, Mac-1 and Gr-
1) to see if it was possible to analyse the GFP expression in more defined cell 
populations. The surface marker c-Kit is expressed on HSCs and myeloid progenitors 
Spangrude et al. 1988; Okada et al. 1991), whereas FcγRIII/II is expressed on 
myeloid progenitors and more mature myeloid cells (Akashi et al. 2000; Daëron, 
1997). Mac-1 and Gr-1 are expressed on monocytes and granulocytes respectively 
(Arnaout, 1990; Hestdal et al. 1991). Cultured cells from non-GFP C57BL/6 mice 
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Figure 3.1.11. Gating strategy and isotype controls for flow cytometry 
analysis of cells isolated from methocult cultures of cells derived from in 
vivo irradiated CBA/H and C57BL/6 Sfpi1 GFP/GFP mice.  
Lin- cells from non-irradiated mice or mice exposed to a whole body dose of 3 Gy of 
ionising radiation were selected as described previously and plated in methocult. 
After 7 days, the cultures were isolated as before and stained with monoclonal 
antibodies. GFP expression and surface marker expression were analysed by flow 
cytometry. A. Cells with low forward and side scatter were left out from the analysis 
since they were mostly dead cells. A region was made around the major population to 
minimise autofluorescence. B. Non-GFP control mice were used for autofluorescence 
and isotype controls. Cells are gated on 7-AAD negative cells in the major population. 
FL1 is the same channel as GFP can be detected in. The dot plots show (left to right) 
unstained cells, IgG2a-PE isotype control and IgG2b-PE isotype control.  
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Figure 3.1.12. Antibody staining (c-Kit) of cells isolated from methocult 
cultures of Lin- BMCs from in vivo irradiated mice.  
The results are from one experiment. A. C57BL/6 Sfpi1 GFP/GFP cells stained with c-
Kit antibodies. B. CBA/H Sfpi1 GFP/GFP cells stained with c-Kit antibodies. 
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stained with isotype control antibodies (anti-Rat IgG2aκ and anti-Rat IgG2bκ) were 
used to set the quadrants (Figure 3.1.11B).  
    The expression of c-Kit was 14 % (1+13) in the C57BL/6 and 34 % (7+27) in the 
CBA/H (Figure 3.1.12 A and B). In cultures from irradiated animals, the c-Kit 
expression was slightly lowered at 10.5 % (0.5+10) in C57BL/6 and 21.5 % (0.5+21) 
in CBA/H. GFP expression was generally around 90% or over in all cultures. There 
were no major differences between cultures from non-irradiated and irradiated mice in 
terms of the GFP expression.  
    FcγRIII/II was expressed in almost all cells (Figure3.1.13 A and B) with little 
difference between the strains or whether the cultures originated from non-irradiated 
or irradiated mice. Almost all cells expressed GFP in the C57BL/6 GFP cultures with 
no difference between cultures from non-irradiated and irradiated mice. In the CBA/H 
cultures there was a slight increase in the GFP expression from 84 %  (83+1) to 96% 
(95+1) after irradiation.  
    The expression of Mac-1 was high in all cells (Figure 3.1.14 A and B) although 
with slight variations. In the culture from C57BL/6 mice there was no change 
between non-irradiated and irradiated mice, whereas in the CBA/H cultures a small 
increase in the Mac-1 expression could be seen. The GFP expression was above 90 % 
in all the cultures.  
    The proportion of Gr-1 expressing cells was similarly quite high in all the cultures 
(Figure 3.1.15 A and B) at above 70%. There was no difference in the expression 
after irradiation. The GFP expression was stable in cultures from both non-irradiated 
and irradiated C57BL/6 mice. The CBA/H cultures had an increase from 72 % to 89 
% after irradiation (Figure 3.1.15 B).  
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Figure 3.1.13. Antibody staining (FcγR III/II) of cells isolated from 
methocult cultures of Lin- BMCs from in vivo irradiated mice. 
 The results are from one experiment. A. C57BL/6 Sfpi1 GFP/GFP cells stained with 
FcγR III/II antibodies. B. CBA/H Sfpi1 GFP/GFP cells stained with FcγR III/II 
antibodies. 
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Figure 3.1.14. Antibody staining (Mac-1) of cells isolated from methocult 
cultures of Lin- BMCs from in vivo irradiated mice.  
The results are from one experiment. A. C57BL/6 Sfpi1 GFP/GFP cells stained with 
Mac-1 antibodies. B. CBA/H Sfpi1 GFP/GFP cells stained with Mac-1 antibodies. 
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Figure 3.1.15 Antibody staining (Gr-1) of cells isolated from methocult 
cultures of Lin- BMCs from  in vivo irradiated mice.  
The results are from one experiment. A. C57BL/6 Sfpi1 GFP/GFP cells stained with Gr-
1 antibodies. B. CBA/H Sfpi1 GFP/GFP cells stained with Gr-1 antibodies. 
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    The relatively low expression of c-Kit (Figure 3.1.12) indicated that the cells have a 
more mature phenotype. This is consistent with the observations that the expression of 
FcγRIII/II, Mac-1 and Gr-1 is high (Figure 3.1.13-15). However, since FcγRIII/II are 
also expressed on committed myeloid progenitors (Iwasaki and Akashi, 2007b) the 
exact state of maturation cannot be determined unless additional surface markers are 
included in the analysis. The proportion of cell with c-Kit expression is furthermore 
different between the C57BL/6 (10.5%) and CBA/H strain (21.5%), which indicated 
there is approximately double the number of progenitor cells in the CBA/H cultures. 
The variation in the frequency of c-Kit expression between CBA/H and C57BL/6 
cultures may also contribute to the difference seen in overall cell survival in in vitro 
irradiated Lin- cells (Figure 3.1.7 A). Both experiments show a difference in survival 
or growth of a sub-population of progenitor cells.  
 
3.1.10 Cloning of individual colonies from methylcellulose assays 
    Since one individual colony does not contain enough cells to analyse by both flow 
cytometry and other assays, such as qPCR for gene expression or FISH for 
confirmation of Sfpi1 copy loss on chromosome 2, it was necessary to try and expand 
the cell numbers. To achieve this, Lin- cells were plated in methylcellulose media and 
incubated for 10 days. Single colonies were picked and replated in methylcellulose, 
new colonies were allowed to form and these colonies were replated for a total of four 
rounds of replating. Cell numbers were counted each time cells were isolated from the 
cultures (Figure 3.1.16). It was hoped that after a couple of replatings, enough cells 
would be acquired for further analysis of clonal descendants of single cells. 
    Intitially, 25 colonies were picked and replated. After 7 days of incubation, 11 (41 
%) colonies had produced new colonies (Figure 3.1.17). After another round, 10 
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Figure 3.1.16. Replating of methylcellulose colonies.  
BMCs were isolated from CBA/H Sfpi1GFP/+ mice and Lin- cells were selected as 
previously described. Lin- cells were plated in methylcellulose media and incubated 
for 10 days. Single colonies were picked and disaggregated (1), replated in new 
methylcellulose cultures and incubated for 7 days. Each plate was individually 
checked and if colonies had formed (2), the entire plate was isolated, cell number 
counted and replated in new methylcellulose for a total of four times (3 and 4). After 
the 4th round of replating, the entire plate was isolated and the final number of cells 
was recorded (5).  
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Figure 3.1.17. Cell counts of cloned colonies at each round of replating. 
25 colonies were picked and replated in new methylcellulose (see Figure 3.1.16). 
Every 7 days the plates were scored positive or negative for colony growth. After the 
first 7 days, 11 colonies were still growing. The completed culture of positive plates 
was isolated individually, cells were counted and the individual cultures replated in 
new methylcellulose. After 4 rounds of replating the final cell number was recorded. 
The graph shows the cell numbers at each round of replating. The results are from one 
experiment. 
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colonies remained and it was possible to sustain growth for a total of 4 rounds of 
replating. However, when the total cell numbers in the cultures were plated, it was 
evident that the efficiency of the approach did not meet the requirements needed for 
further analysis. Out of 25 colonies that were picked, only 10 (40 %) grew through all 
the rounds of replating. Furthermore, the maximum total number of cells in any one 
culture grew to only 8x105 cells with most cultures producing significantly fewer 
cells. It was therefore decided that this approach to acquire material for analysis was 
not adequate and another approach was needed. 
    However, some interesting observations can be made from the replating 
experiment. Whereas the total number of progeny from an initial colony was rarely 
more than 1x105 cells after 4 rounds of replating, 4 colonies gave a total number of 
progeny between 2x105 to 8x105 cells. The increase in cell number was particularly 
noticeable between the 3rd and 4th round of replating. The behaviour could be 
explained by the colonies in question being blast colony-forming cells as has 
previously been described (Metcalf et al., 2008; Metcalf et al., 2009, Metcalf et al., 
2010). These colonies are formed after culturing total bone marrow cells or 
fractionated cells in semisolid media with the addition of either SCF and IL-6 or Flt3 
ligand and IL-6. The colonies are then picked and replated and cultured with additions 
of various cytokines depending on the aim of the experiment. The cytokines added to 
the cultures in Figure 3.1.16 included IL-6 and SCF. These cytokines have been found 
to stimulate the formation of blast colonies with c-Kit expression similar to Lin- cells 
in the bone marrow (Metcalf et al., 2009). When pooled samples of the replated 
colonies (Figure 3.1.17) were analysed by flow cytometry, c-Kit expression was 
increased compared to the initially plated Lin- cells (Table 3.1.3). The selected Lin- 
cell fraction contained around 30% of mature Lin+ cells when plated, whereas the  
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Lin- cells plated Pooled replated colonies 
Lin+ cells c-Kit+ cells c-Kit+ cells FcγRIII/II+ Mac-1+ Gr-1+ 
30 53 88 68 0.2 1.2 
 
Table 3.1.3. Flow cytometry analysis of pooled colonies.  
Cells were isolated from individual methylcellulose cultures as previously described. 
Cells from all cultures in Figure 3.1.17 were pooled to obtain a sufficient number of 
cells for antibody staining and analysis by flow cytometry. The percentage Lin+ and 
c-kit+ cells in the Lin- fraction of cells originally used for establishing the cultures are 
shown as a comparison. 
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colonies had a very low expression of Mac-1 and Gr-1 after 4 rounds of replating. It is 
therefore possible that by changing the cytokines that are added to the initial 
methylcellulose cultures a higher percentage of blast colonies could be obtained. 
Overall though, the total cell numbers at the end of the replating is still not sufficient 
to perform the intended full range of analysis. 
 
3.1.11 Conclusions 
    In this chapter it has been established that the mice are backcrossed sufficiently for 
use in radiation-induced leukaemogenesis studies since they will be used at a 
minimum backcross generation F6. The residual C57BL/6 genetic material is unlikely 
to reduce rAML induction as even F1 crosses between C57BL/6 x CBA/H show 
partial loss of chromosome 2 and have an rAML induction rate around 7.5 %. The 
results shows that loss of one GFP allele together with Sfpi1 would be detectable by 
flow cytometry as in vivo irradiation of both strains show a reduction of PU.1 protein 
expression, which confirms the ability to detect differences by using flow cytometric 
analysis.  
    After having established the protocol for immunomagnetic cell selection, in vitro 
irradiation of different sub-populations of immature BMCs point to a difference in the 
sensitivity in one population of immature cells in the CBA/H strain compared to the 
C57BL/6 strain. The cell survival and colony forming potential of Lin- cells after in 
vivo irradiation shows a similar trend. The expression of the surface marker c-Kit, 
expressed on immature haematopoietic progenitors, is also double in cultured Lin- 
cells from CBA/H mice compared to C57BL/6 mice after in vitro irradiation. This 
further emphasises the inter strain differences in an immature bone marrow 
population. Furthermore as was seen after in vitro exposure, Lin- cells from in vivo 
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irradiated C57BL/6 mice showed a similar trend to be more sensitive to ionising 
radiation compared to the same cell type from CBA/H mice. 
    Cloning of individual colonies did not result in a sufficient cell numbers to be able 
to perform further analysis and another strategy to investigate early events needs to be 
developed to isolate immature cells that have loss of one allele of Sfpi1 in immature 
haematopietic bone marrow cells.  
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3.2 Transplantation assays 
 
3.2.1 Introduction 
Flow cytometry analyses single cells and can be used to sort cells according to cell 
surface markers and reporter genes such as GFP (Sharrow, 1991; Kim et al., 2008) 
This approach to acquire live cells provided a good alternative approach to the colony 
forming assays in methylcellulose, since the previous experiment indicated that using 
Sfpi1 GFP/GFP mice, GFP copy number can shift the fluorescence in a detectable way 
(Figure 3.1.2) and that the gene expression of GFP reflects the copy number (Figure 
3.1.3).  Furthermore, Lin- cells from in vivo irradiated mice show a noticeable shift in 
the GFP expression 9 days after irradiation (Figure 3.1.9). 
    The leukaemic stem cell hypothesis assumes that the initial damage and subsequent 
leukaemic events leading to AML occur is HSCs or myeloid progenitors (Passague et 
al., 2003; Clarke and Fuller, 2006). HSCs and myeloid progenitors express various 
surface marker combinations (Iwasaki and Akashi, 2007b; Purton et al., 2007). The 
majority of stem cells are found in the Lin- Sca-1+ c-Kit+ fraction (Spangrude et al., 
1988; Okada et al., 1991) and by sorting this population it was expected a target cell 
population could be acquired for further experiments and analysis. One way of 
investigating the potential target cells and determine their leukaemic potential is to 
transplant the sorted cells from irradiated animals (donors) into animals that have 
been exposed to a high dose of radiation (recipients), leading to their own innate 
haematopoietic system being compromised and allowing the donor cells to repopulate 
the host animal and reconstitute the haematopietic system (Miller et al., 2008) The 
ultimate aim is to successfully reconstitute the recipient animals with potential 
leukaemic stem cells from the donors, with the end result being the presentation of 
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rAML in the recipient animals. This approach addresses two aims. Firstly, a 
leukaemic stem cell population has not yet been defined or indeed demonstrated in the 
CBA/H model of rAML. Secondly, as has been previously mentioned, the deleted 
region on chromosome 2, where the gene Sfpi1 is located, is observed in 90 % of the 
cases of rAML in this model (Rithidech et al., 1995; Silver et al., 1999). By giving 
the host animals cells that have been specifically selected to carry the chromosome 2 
deletion it is was possible to investigate the impact of the deletion on the latency of 
the disease, which is usually 18 months following whole body irradiation (Mole et al., 
1983). Reduction of Sfpi1 gene expression to approximately 20 % of normal levels 
led to the presentation of AML with a latency of 3-8 months (Rosenbauer et al., 2004) 
and complete inactivation in adult animals has a similar latency (Metcalf et al., 2006). 
It was hoped that by selecting cells with a reduced Sfpi1 copy number and theoretical 
50 % of normal expression the mice would present with rAML with a shortened 
latency compared to normal rAML. HSCs are a small percentage (0.01-0.05%) of the 
total bone marrow (Spangrude et al., 1988; Kiel et al., 2005; Challen et al., 2009) and 
all HSCs probably do not survive after exposure to ionising radiation. Therefore a 
way of producing more cells to inject would be to expand the sorted cells in vitro. 
This approach has been tried and found successful by other groups (Miller et al., 
1997; Audet et al., 2001) and was consequently used in this project. Also, an 
expansion of cells might be expected to allow for cytogenetic studies of chromosome 
2 deletion events. Some experiments indicate that inflammatory effects could be 
responsible for some indirect effects of ionising radiation (Lorimore et al., 2001; 
Wright and Coates, 2006). By using cells that were irradiated either in vivo or in vitro, 
it may be possible to study the influence of the microenvironment on cells carrying 
chromosome 2 deletions. A further transplantation assay, which is based on clonal 
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expansion from single cells, is the colony forming unit-spleen (CFU-S) assay (Till 
and McCulloch, 1961; McCulloch, 2002). Till and McCulloch found that 
transplanting bone marrow cells into irradiated hosts gave rise to discreet nodules on 
the spleens at 10 to 11 days after injection (Till and McCulloch, 1961). Later 
experiments have suggested that colonies on day 12 after injection (Magli et al., 
1982) contain all lineages and are derived from a more immature cell type than 
colonies found on day 10 and 11. This assay is analysed at an early time point and 
would complement the results of the long-term assay with injected sorted cells. The 
latter assay is not completely clonal since it is based on the transplantation of multiple 
cells, albeit with theoretically the same or similar characteristics. 
 
3.2.2 Transplanting total BMCs successfully reconstitutes recipients irradiated 
with 8.5 Gy 
    As initial trial of the technique, myeloablated WT CBA mice were transplanted 
with total BMCs from Sfpi1 GFP/GFP (Figure 3.2.1). Since theoretically approximately 
1 per 10000-20000 cells in total bone marrow is able to repopulate and reconstitute a 
recipient animal (Szilvassy et al., 1990; Miller et al., 2008) a large number of cells 
(5x106) were injected to give a high probablility of success. Approximately 500 HSCs 
would be expected from that cell number (Miller et al., 2008). The dose chosen to 
irradiate the host animals to ablate them was 8.5 Gy. The dose was chosen after 
consulting the literature and comparing the sensitivity of different strains of mice and 
the doses commonly used. A standard dose in HSC transplants in C57BL/6 mice is 9 
to 12 Gy (Miller et al., 2008) and the strain has an LD50 of 6.9 to 7.3 Gy (Grahn and 
Hamilton, 1957; Storer, 1968). In comparison, the BALB/c strain is more sensitive 
and has an LD50 of approximately 5 to 5.7 Gy (Grahn and Hamilton, 1957; Storer, 
  127 
1968) and a lower dose or split dose is usually used (Schimmelpfennig et al., 2005; 
Marusyk et al., 2009) to ablate them. It is noteworthy that doses between 7 Gy to 13 
Gy are considered myeloablative and that the higher the dose given, the more likely 
the mice are to die from secondary effects such as the inflammatory response to 
radiation (Down et al., 1991; Duran-Struuck and Dysko, 2009) and gastrointenstinal 
syndrome (Potten 1990). Since the CBA/H strain has a similar LD50 to the BALB/c 
strain (Storer, 1968), a single dose of 8.5 Gy seemed an appropriate dose to use. As a 
pilot experiment, two recipient mice were injected with donor cells as soon as 
possible after irradiation (in general no more than after a couple of hours) by tail vein 
injection. After the procedure, the mice were kept in an environment that reduced the 
exposure to microbial infections for 21 days and given antibiotic supplements. After 
10 weeks, the mice were euthanised, samples of heart blood were taken and the cells 
stained with antibodies before flow cytometric analysis. Antibodies used were against 
surface markers for T-cells (CD3), B-cells (B220) (Hardy and Hayakawa, 2001; 
Dave, 2009), monocytes and granulocytes (Mac-1 and Gr1) (Arnaout 1990; Hestdal et 
al. 1991). Both mice showed a high level of reconstitution of donor cells (Table 3.2.1) 
with levels of GFP and surface marker expression in T-cells and B-cells comparable 
to Sfpi1 GFP/GFP control animals (Figure 3.2.2). The expression of Mac-1 was higher in 
one animal (52%) compared to the control (29%) whereas the other mouse had 
comparable levels (22%).  The Gr-1 expression was lower in both test animals (10% 
and 3 %) compared to cells from the control mice (42%). The test mice still showed 
some level of reconstitution from test cells, which showed that injected cells had 
differentiated to all lineages (Table 3.2.1). It was therefore concluded that the level of 
irradiation chosen to myeloablate the recipients (8.5 Gy, single dose) should be  
sufficient for the experimental purposes.
  128 
 
 
 
Figure 3.2.1.  Transplantation scheme GFP BMC. 
 Two CBA/H WT mice that had been irradiated with 8.5 Gy were transplanted with 
total BMC from CBA Sfpi1 GFP/GFP mice. After 4 months, blood and bone marrow  
were analysed by flow cytometry. 
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Figure 3.2.2. Staining example from peripheral blood of a CBA/H Sfpi1 
GFP/GFP control mouse.  
Peripheral blood was taken from euthanized mice, the red blood cells lysed and the 
cells stained with antibodies against CD3, B220, Gr-1 and Mac-1. Samples were 
analysed by flow cytometry. An example of analysis plots from a control mouse is 
seen in the figure. In the forward/side scatter (FSC/SSC) plot, the green region (R2) 
contains mostly lymphocytes whereas the pink region (R3) consists of myeloid cells. 
R1 (lower left) is not analysed since this region consists of red blood cells and debris. 
The results are from one experiment. 
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Table 3.2.1. Analysis of peripheral blood from mice transplanted with  
Sfpi1 GFP/GFP BMCs. 
 Total GFP + (%) R2 region R3 region 
 R2 
region 
R3 region CD3+ 
(%) 
B220+ 
(%) 
Gr-1+ 
(%) 
Mac-1+ 
(%) 
Sfpi1 GFP/GFP 
control 
39 87 44 50 42 29 
Mouse 1 43 85 44 55 10 52 
Mouse 2 43 80 53 45 3 22 
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3.2.3 Expanded immature bone marrow cells cultured in suspension cultures fail 
to reconstitute host animals 
    After having established that the dose used to compromise the host haematopietic 
system was sufficient, the next experiment was performed injecting expanded 
immature bone marrow cells instead of total BMCs. BMCs from Sfpi1 GFP/+ mice 
were lineage depleted using the Robosep system and cells were plated in Stemspan 
serum free expansion media (SFEM) with the addition of rhIL-11, rmSCF, rhFlt3L, 
LDL and Penicillin/Streptomycin for a total of 9 days (Figure 3.2.3). The cell number 
was either 500 cells/well or 100 cells/well to investigate if there was a difference in 
the total expansion. Some cultures had the media changed about every 3rd day while 
others were kept in the initial culture media, also to investigate differences in the total 
expansion. After 9 days, the cultures were harvested, cultures from similar conditions 
pooled and the cell numbers counted. The cells plated initially at 500 cells/well with 
media changes had a significantly higher fold expansion than both the cells cultured 
without media changes and those starting with a lower cell number (Figure 3.2.4). 
Cells from cultures started with 500 cells/well were divided equally (approximately 
2.5x104 cells/mouse) and injected through the tail vein into two myeloablated mice as 
before (Figure 3.2.3). After 10 weeks, the mice were euthanised and white blood cells 
from heart blood analysed by flow cytometry to determine whether the injected cells 
had reconstituted the host animals. From the analysis it was concluded that GFP 
positive cells could not be found at a level distinguishable from background levels 
(Figure 3.2.5) in either lymphocytes or monocytes/granulocytes and therefore no 
transplanted cells had reconstituted the host animals. The number of cells injected 
(approximately 2.5x104) was within the range where reconstitution has been 
previously shown to be possible (Miller et al., 2001 and Audet et al., 2001), so the 
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Figure 3.2.3.  Transplantation with cultured cells.  
BMCs were isolated from CBA/H Sfpi1 GFP/+ mice and mature cell types were 
removed by immunomagnetic cell sorting (Lin depletion). The immature cells were 
expanded in Stemspan (500 cells/well or 100 cells/well) for 9 days with the addition 
of IL-11, IL-6, Flt3L, LDL and Penicillin/Streptomycin. In some of the cultures, the 
media was changed every 3rd day, whereas in some cultures no media changes were 
made. After 9 days, the cultures based on 500 cells were isolated, pooled, the cell 
number counted and an equal number of cells (approximately 2.5x104 cells) were 
injected into non-GFP CBA/H WT mice that had been ablated with 8.5 Gy of x-rays. 
After 10 weeks, the mice were euthanised and the GFP expression was analysed by 
flow cytometry. 
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Figure 3.2.4.Fold expansion in Stemspan SFEM cultures.  
Three wells from each culturing condition was isolated, the cells were pooled and 
counted. The fold expansion was calculated by dividing the number of total cells after 
expansion with the total number of input cells. The results are from one experiment. 
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Figure 3.2.5. GFP expression in mice transplanted with cultured cells.  
CBA/H WT mice that had been irradiated with 8.5 Gy were injected with Lin- 
cultured cells (Figure 3.2.4). After 10 weeks, the mice were euthanised and white 
blood cells were stained as described. The plots were gated as described in Figure 
3.2.2 with green coloured plots gated on lymphocytes and pink coloured plots gated 
on granulocytes and monocytes. The do plot show GFP expression on the x-axis with 
the FL2 channel on the flow cytometer chosen for the y-axis. The results are from one 
experiment. 
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cell number injected should not have been too low to achieve reconstitution. One 
reason for the lack of reconstitution could be that the cultured cells injected had lost 
the ability to differentiate to more mature cells or only had the potential for very 
short-term reconstitution. Partially this could be because the Lin- fraction contains a 
very small amount of HSCs and mostly progenitors of varying levels of lineage 
restriction (Spangrude et al., 1988). However, published results (Kértesz et al., 2006) 
showed that injecting as few as 4000 cultured Lin- cells give at least a chimeric 
reconstitution after 10 months in 40% of the recipients.  
 
3.2.4 LSK sorted cells injected on the same day is partially successful for the 
transplantation of HSCs from Sfpi1 GFP/GFP mice 
     To address these issues, changes were made to the culturing of cells. The cells 
were cultured in 2 mL suspensions in culture plates where the bottom surfaces were 
not treated to allow cell adherence. Previously 1 mL cultures were grown on tissue 
culture treated plates. Media were changed as necessary as before, with the cell 
number kept below 5x105 cells/mL. It was also decided that some experiments would 
use sorted cells that would be injected on the same day to see if freshly sorted and 
injected cells would have a better reconstitution potential. The experimental approach 
is described in Figure 3.2.6.  
    Lin- cells were acquired from Sfpi1 GFP/GFP mice that had either been irradiated with 
a whole body dose (3Gy) of ionising radiation or from unirradiated mice as described 
before and the cells were stained with antibodies against the cell surface markers c-
Kit and Sca-1. The cells were sorted on a flow cytometer to acquire cell populations 
that were positive for both cell surface markers and either sorted as GFP + or GFP –/lo 
(Figure 3.2.7). The cells were injected into myeloablated hosts as previously 
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Figure 3.2.6. Transplantation of same-day sorted and cultured cells.  
A. BMCs were isolated from unirradiated CBA/H Sfpi1 GFP/GFP mice. After lin 
depletion, the cells were stained with antibodies for FACS sorting. The lin- cells were 
then gated on the c-Kit+ Sca1+ fraction and cells were sorted as GFP + or GFP -/lo. The 
sorted cells were either injected via the tail vein on the same day into CBA/H WT 
mice ablated with a 8.5 Gy dose or expanded for a total of 9 days in Stemspan SFEM 
cultures and the sorted as GFP+ or GFP-/lo before injected via the tail vein. Some 
cultures were irradiated with a 3 Gy dose in vitro after overnight incubation. B. BMCs 
were isolated from CBA/H Sfpi1 GFP/GFP mice that had been given a 3 Gy total body 
dose of x-rays. After 7 or 9 days (depending on the experiment), the cells were 
isolated and processed as above, with the exception that the Stemspan SFEM cultures 
were not irradiated. C. Characterisation. Mice were monitored for signs of AML and 
blood samples were taken at time points after tail vein injection for analysis of 
reconstitution by flow cytometric analysis. Cultured cells were also analysed by flow 
cytometry to determine the GFP expression and plated in methylcellulose cultures to 
determine colony forming potential. Cells were further characterised by FISH as 
described in material and methods for detection of partial chromosome 2 deletions 
with Sfpi1 copy loss. Aliquots of the cultures were stored in liquid nitrogen for future 
injections and/or characterisation. 
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Figure 3.2.7. Sorting gates for transplantation experiments.  
BMCs were isolated from 8 male CBA Sfpi1 GFP/GFP mice that had been exposed to a 
total body dose of 3 Gy x-rays 9 days previously (in one experiment the mice were 
exposed 7 days prior to BMC isolation). The cells were pooled, lin- cells were 
selected as described before and stained with antibodies for Sca-1 and c-Kit. The cells 
were sorted using a MoFlow cell sorter. A region was set around the major population 
to exclude debris and dead cells were excluded by gating on the 7-AAD negative 
population. Another gate was set on the Sca-1+ c-kit+ cells and from this population 
the cells were sorted as GFP + or GFP –/lo. The regions for GFP expression were set 
using Lin- WT cells gated on the Sca-1+ c-Kit+ cells. The figure shows the plots from 
experiment 1. 
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described, either on the same day or cultured for 9 days to achieve an expansion of 
cell numbers before injection. Some cultures from unirradiated mice were irradiated 
in vitro with a 3 Gy dose of ionising radiation.  
    Since LSK cells are very immature (Osawa et al., 1996) it is common practice in 
bone marrow transplant experiments to mix the immature cells with total BMC, 
referred to as helper cells (Kiel et al., 2005; Ema et al., 2006 and Miller et al., 2008). 
Normal BMCs contain cell capable of long-term reconstitution at a proportion of 
approximately 1/10000-20000 (Szilvassy et al., 1990; Lawrence et al., 2005; Miller et 
al., 2008). If 2x105 cells were injected, this would mean that an aliquot would contain 
at the most 20 cells able to reconstitute the host animal.  
    A small study was performed with animals injected with either 2x105 or 2x106 
BMCs from WT donor animals. The results from G-banding analysis of chromosomes 
from host animal bone marrow indicated that 2x105 BMCs would not significantly 
contribute to the reconstitution of the host animals, whereas 2x106 BMCs would give 
an almost complete reconstitution (Table 3.2.2). 
    Since the LSK fraction contains about 1/ 15-30 or 1 /50 cells able to reconstitute 
(Osawa et al., 1996; Bryder et al., 2006) the amount of cells injected on the same day 
(Table 3.2.3) would give a theoretical minimum of 3 and a maximum of 20 cells 
capable to long-term reconstitution of hosts. In principle, this should give a chance of 
at least a partial donor cell reconstitution by the injected cells from the Sfpi1 GFP/GFP 
animals.  
    The number of cells acquired from the different experiments is seen in Table 3.2.4. 
Each of the 6 experiments was performed separately, but experiment 1 and 3 were 
repeats of each other, as were experiments 2 and 6. 
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Recipient sex Injected cell 
number 
Injected 
cell sex 
Euthanized 
after 
Karyotype 
Male 2x105  Female 6 weeks Male 
Male 2x106  Female 9 weeks Female 
Male 2x106  Female 9 weeks Female 
 
Table 3.2.2. Injection with total BMCs to investigate reconstitution with helper 
cells.  
Male CBA WT mice that had been irradiated with either 8.5 Gy or 9 Gy were injected 
with female CBA WT BMCs as described before. The mice were later euthanized and 
karyotyping of BMCs performed as described in material and methods. 
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Experiment Number 
of mice 
Recipient 
(Male/Female) 
Cell 
type 
Donor 
mice 
irradiated 
Cell 
number 
21 day 
survival 
1 3 0/3 LSK 
GFP + 
Y 200-300 3 
 2 0/2 LSK 
GFP -/lo 
Y 200-300 2 
2 3 0/3 LSK 
GFP + 
N 200 3 
 2 0/2 LSK 
GFP -/lo 
N 200 1 
3 4 0/4 LSK 
GFP + 
Y 200-300 2 
 4 0/4 LSK 
GFP -/lo 
Y 200-300 4 
4 3 2/1 LSK 
GFP + 
Y 200 3 
 2 2/0 LSK 
GFP -/lo 
Y 150 1 
5 3 1/2 LSK 
GFP + 
N 200-300 3 
 2 1/1 LSK 
GFP -/lo 
N 200-300 1 
6 2 0/2 LSK 
GFP + 
N 200-300 2 
 3 0/3 LSK 
GFP -/lo 
N 200-300 3 
 
Table 3.2.3. Mice injected with LSK GFP + or GFP -/lo cells on the same day of 
sorting. 
  141 
 
Experiment Condition Mouse 
strain 
Total 
cells 
sorted 
LSK 
GFP + 
% of 
sorted 
LSK 
GFP -/lo 
% of 
sorted 
% LSK 
cellsa 
%         
c-Kit+ a 
%  
Sca-1+ a 
 
1 3 Gy in vivo 
(7days post-
irradiation) 
CBA/H 1.5x106 1.1x104 0.7 2.2x104 1.5 1.4 16 5.1 
2 Unirradiated CBA/H 1.2x106 4.7x103 0.4 1.2x104 0.9 0.6 25 2.9 
3 3 Gy in vivo 
(9 days post-
irradiation) 
CBA/H 5.1x105 1.5x104 2.9 2.2x104 4.4 7.2 19 5.8 
4 3 Gy in vivo 
(9 days post-
irradiation) 
C57BL/6 6.4x105 1.2x103 0.2 3.5x102 0.1 0.3 11 3.4 
5 Unirradiated C57BL/6 1.4x106 2.8x104 2.0 9.2x103 0.7 2.8 18 7.7 
6 Unirradiated CBA/H 9.2x105 1.5x103 0.2 1.7x103 0.2 0.4 26 3.3 
Table 3.2.4. The cell numbers and amount of cells in each fraction acquired from cell sorting.  
a: Based on number of gated cells
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There is a difference in the time between in vivo irradiation and the time of cell 
sorting in experiments 1 and 3 (7 and 9 days respectively) due to the availability of 
the radiation facility. The difference between the two sorts were mainly seen in the 
percentage of cells double-positive for c-Kit and Sca-1, which in experiment 3 (7.2 
%) were approximately 5 times more than in experiment 1 (1.4 %), while the number 
of GFP + and GFP -/lo cells were similar (1.1x104 and 1.5x104). The difference was 
therefore an increase in the total percentage of HSCs in experiment 3. This tendency 
for LSK cells to recover over time is confirmed by results published by Wang et al. 
(Wang et al., 2006), however in their experiments a much higher dose of 6.5 Gy was 
used and the recovery took place over a longer period of time. The total percentage of 
LSK cells increased in the irradiated CBA/H mice compared to in the unirradiated 
control experiments (Table 3.2.4, experiment 1: 1.4 %, experiment 3: 7.2 % compared 
to experiment 2: 0.6 % and experiment 6: 0.4 %), which is probably due to a 
mobilization of previously quiescent HSCs due to the radiation exposure. However, 
this pattern was reversed in the C57BL/6 mice (Table 3.2.4, Unirradiated experiment 
5: 2.8 % and irradiated experiment 4: 0.3 %). When cells from unirradiated CBA/H 
Sfpi1 GFP/GFP mice were sorted, a variation was seen between the two experiments. 
Experiments 2 and 6 had a relatively similar number of total LSK cells sorted (Table 
3.2.4, 1.2x106 in experiment 2 and 9.2x105 in experiment 6) but especially the 
percentage of GFP -/lo cells differed (Table 3.2.4 experiment 2: 0.9 % and experiment 
6: 0.2 %). If the experiments using unirradiated CBA/H and C57BL/6 mice were 
compared, the percentage of LSK cells was approximately 5 to 7 times higher in the 
C57BL/6 mice (Table 3.2.4 experiment 5: 2.8 %, experiment 2: 0.6 % and experiment 
6: 0.4 %). This is a known difference between the two strains, where the CBA/H 
strain has lower expression of Sca-1 than the C57BL/6 strain (Spangrude and Brooks, 
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1993). Furthermore, there are differences in the percentage of c-Kit and Sca-1 single 
positive cells found in the sort samples from experiments 1-3 and 6. In line with 
published data, the c-Kit expression is slightly reduced in irradiated mice (Table 3.2.4 
unirradiated: 25 %, 26 % and 18 % compared to irradiated: 16 %, 19 % and 11 %), 
whereas the Sca-1 expression is variable (unirradiated: 2.9 %, 7.7 % and 3.3 %; 
irradiated: 5.1 %, 5.8 % and 3.4 %) (Simonnet et al., 2009). The injections of sorted 
cells that were done on the same day are summarised in Table 3.2.3.    
    Approximately 9-12 months after transplantation, blood samples were acquired 
from some of the host animals either by a sample taken from the tail vein or from 
heart blood if an animal needed to be euthanized. The red blood cells were lysed and 
the samples were analysed by flow cytometry to determine if reconstitution had taken 
place. The results of the mice that have been analysed to date indicate that there is a 
stable reconstitution in the mice injected with unirradiated LSK GFP + cells from 
experiment 2 (3 out of 3 mice) (Table 3.2.5). In comparison, the LSK GFP -/lo cells 
from the unirradiated donors failed to reconstitute the hosts. The cells derived from 
irradiated donors seem to have a lower rate of reconstitution, with one animal 
reconstituted with LSK GFP + cells from irradiated hosts in experiment 1. It might be 
of significance that the animals injected with cells from experiments 1 (acquired 7 
days after irradiation) seemed to perform marginally better than those injected with 
cells from experiment 3 (acquired 9 days after irradiation). However, the results are 
based on a small number of mice, which means the reason for the difference is not 
completely clear and further repeats would be needed to clarify these results.  
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Experiment Number of 
mice 
Cell type Donor mice 
irradiated 
Reconstitution 
1 3 LSK GFP + Y 1/3 
1 2 LSK GFP -/lo Y 0/2 
2 3 LSK GFP + N 3/3 
2 1 LSK GFP -/lo N 0/1 
3 2 LSK GFP + Y 0/2 
3 4 LSK GFP -/lo Y 0/4 
6 1 LSK GFP -/lo N 0/1 
 
Table 3.2.5.  Analysis of repopulation of GFP cells by flow cytometry in mice 
transplanted with cells injected the same day. 
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3.2.5 Characterisation of sorted LSK cells cultured in Stemspan SFEM 
    Cells that were sorted from in vivo irradiated mice were cultured in suspension 
cultures for 9 days to expand them for further characterization and to see whether 
these cells were able to reconstitute mice when transplanted. Cells from irradiated 
mice in experiment 1 had a larger fold expansion than cells in experiment 3 (Figure 
3.2.8). Irradiated GFP + cells achieved about a 4500-fold expansion in experiment 1 
compared to a 1000-fold expansion in experiment 3. Similarly, the irradiated GFP -/lo 
cells had a 10-fold higher expansion in experiment 1, compared to experiment 2. 
Interestingly, when the cells were assayed in methylcellulose cultures, the reverse was 
found. Irradiated GFP + cells from experiment 3 had about a 6 times higher plating 
efficiency (20 %) than GFP + irradiated cells from experiment 1 (3.5 %), although in 
the irradiated GFP -/lo cells the plating efficiency was relatively similar between the 
experiments (Table 3.2.6). It seems that the higher expansion in experiment 1 led to a 
diminished short-term colony forming potential. However, the control GFP + culture 
had a an almost 3-fold higher expansion in experiment 3 (Figure 3.2.8 B, 7500-fold 
expansion), compared to experiment 1 (Figure 3.2.8 A, 2700-fold expansion)), and 
the plating efficiency was still doubled in experiment 3 (33 %) compared to 
experiment 1 (16 %) (Table 3.2.6). Therefore, the loss of colony forming potential in 
experiment 1 could be due to the fact that the input cells came from mice that had 2 
days less recovery before the cells were isolated, sorted and placed in culture. As 
previously mentioned regarding the recovery of LSK cells after exposure to ionising 
radiation in vivo, the same is the case for colony forming potential (Wang et al., 
2006), which means the difference in recovery time could be a likely cause for the 
difference. 
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Figure 3.2.8. Fold expansion for Stemspan cultures with cells derived from 
in vivo irradiated mice.  
LSK cells from mice that had been irradiated in vivo (Table 3.2.3) were cultured as 
described before. After 9 days, the cells were isolated and cell numbers counted. A. 
Fold expansion in cultures from experiment 1. B. Fold expansions on cultures from 
experiment 3. 
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 Experiment 1 
Plating efficiency (%) 
Experiment 3 
Plating efficiency (%) 
GFP + control 
 
16 33 
GFP + 3 Gy in vivo 
 
3.5 20 
GFP -/lo 3 Gy in vivo 
 
21 17 
 
Table 3.2.6. Colony forming units of cultured cells from experiment 1 and 3. 
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    Aliquots of the cultures were stained with antibodies against c-Kit and Sca-1 to 
assess the amount of HSCs and progenitors in the cultures. The analysis of the 
suspension cultures found no significant differences between the cultures from 
experiment 1 and the cultures from experiment 3 (Figure 3.2.9 and 3.2.10). Similar 
GFP expression and c-Kit+ Sca-1+ cells was found in the cultures, although there were 
a significantly higher amount percentage of c-kit+ cells (myeloid progenitors) in 
experiment 3 (Figure 3.2.10). Since the cells forming colonies are the early 
progenitors rather than stem cells (Purton and Scadden, 2007), this further explains 
the difference in the plating efficiencies between the methylcellulose cultures from 
GFP + irradiated cells (Table 3.2.6). The difference between the GFP + control 
cultures from experiment 1 and 3 is however still not completely explained. However, 
there was a marked increase in the amount of c-Kit+ Sca-1+ cells in the cultures 
originating from irradiated GFP -/lo LSK cells compared to those from GFP + LSK 
cells (Figure 3.2.9 and 3.2.10). Another interesting observation is that the cultured 
cells expressed GFP irrespective of whether they were sorted as GFP + or GFP -/lo. 
The lack of difference in GFP expression between the two sorted fractions were not 
expected. An explanation could be the sorting gates need to be further separated so 
any possible cross-contamination between the GFP + and GFP -/lo fractions is avoided.  
    The aim of these experiments was to select HSCs that were carrying chromosome 2 
deletions and the specific deletion of Sfpi1 found in the CBA/H model of rAML. 
Fluorescent in situ hybridization (FISH) was used to detect the level of Sfpi1 deletions 
in the different fractions of sorted cells that had been expanded for 9 days. Previous 
experiments have analysed the amount of deletions in total BMCs. This is, to our 
knowledge, the first time cells from the LSK fraction has specifically been analysed 
for Sfpi1 copy loss in the CBA/H mouse. The results showed that the level of Sfpi1 
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Figure 3.2.9. GFP expression and surface marker expression in cultured 
cells (Experiment 1) irradiated in vivo after expansion.  
Cultured cells were harvested, washed in PBS/1% FBS and stained with antibodies 
against surface markers for Gr-1, Mac-1, Sca-1 and c-Kit. Samples were analysed by 
flow cytometry. A. Cultures from experiement 1. A region was drawn around the 
major population and a gate created for the analysis. The GFP expression in the 
different samples was analysed. B. Cultures from experiment 1 gated on the major 
population. The expression of Gr-1, Mac-1, Sca-1 and c-Kit were analysed in the 
different samples. The numbers on the plots indicate percentage positivity in 
respective quadrant. 
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Figure 3.2.10. GFP expression and surface marker expression in cultured 
cells (Experiment 3) irradiated in vivo after expansion.  
Cultured cells were harvested, washed in PBS/1% FBS and stained with antibodies 
against surface markers for Gr1, Mac1, Sca1 and c-kit. Samples were analysed by 
flow cytometry. The GFP expression and surface markers was analysed as described 
above. The numbers on the plots indicate percentage positivity in respective quadrant. 
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deletions in the cultures is somewhat similar to previous results (Peng et al.,. 2009) 
where the level of deletions in CBA/Ca mice was 15 % (± 3%) 7 days post-irradiation 
(Table 3.2.7). However, since those experiments were done on unfractionated bone 
marrow, it is not possible to determine in which cell types the deletions occurred and 
any potential variation between cell types. In the current experiments, there were a 
higher proportion of Sfpi1 deletions in the fraction of LSK cells sorted as GFP+ than 
in the cells sorted as GFP -/lo from the in vivo irradiated mice in experiment 1. 
Cultured, unirradiated GFP + cells had a low level of background levels of deletions, 
which has been seen in previous research (Peng et al., 2009). The results were not 
expected and show that the correlation between GFP expression and deletion of one 
allele of Sfpi1 might not be simple. As was seen in Figure 3.1.1, under normal 
conditions, where there has been no exposure to ionising radiation, there is a clear 
difference between cells carrying one copy of the GFP construct compared to two 
copies. An explanation would therefore be that the activity of the Sfpi1 after exposure 
to ionising radiation masks the small number of cells that would express GFP at a 
lower level so that the difference is not as clear as in steady-state haematopoiesis. The 
gene Sfpi1 and its product, the transcription factor PU.1, are intrinsically important to 
haematopoiesis (Scott et al., 1994). The transcription factor is expressed in different 
cell types during various stages of haematopoiesis, not least in HSCs (Dakic et al., 
2007; Nutt et al., 2005; Dakic et al., 2005). After exposure to ionising radiation, the 
haematopoietic system needs to replace the cells that have been damaged and killed 
(Dainiak, 2002). Therefore, at the time points of 7 and 9 days post exposure to a 
moderate dose of ionising radiation, a significant proportion of LSK cells will be 
activated and in the process of reconstituting the haematopoietic system. Therefore, 
later time points post-irradiation could be tried for isolation and sorting of LSK cells 
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Experimenta Cells Irradiated Metaphases 
counted 
Two 
retained 
copies 
of Sfpi1 
Number of 
metaphases 
with Sfpi1 
deletions 
% 
deleted 
1 GFP+ In vivo 50 44 6 12 
1 GFP-/lo In vivo 50 50 0 0 
3 GFP+ No 67 66 1 1.5 
 
Table 3.2.7. Sfpi1 deletion status in cultured cells. 
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to see whether this would lead to a clearer distinction between GFP+ and GFP -/lo 
cells. Even though the incidence of Sfpi1 deletions are reported to be reduced at 30 
days post irradiation exposure compared to 7 days post irradiation exposure (Peng et 
al., 2009), this might be the minimum time point after radiation exposure to use for 
isolating LSK cells since the most acute effects of radiation exposure would have 
passed and some normalisation of the haematopoietic system can be seen (Dainiak, 
2002), although the recovery time is dependent on the severity of the damage 
(Fliedner et al., 2001). In conclusion, the sorted populations of LSK cells that were 
injected into host animals seem to contain cells carrying the Sfpi1 deletions even 
though the GFP expression was not, using this protocol, specifically an indicator of 
the Sfpi1 copy loss. Therefore, sorting LSK cells without fractionating them into 
GFP+ and GFP -/lo cells would be an option and also to compare the level of deletions 
in Lin- c-Kit+ Sca-1- cells (myeloid progenitors). Further work needs to be doe to 
establish what the GFP + and GFP -/lo levels of GFP represent in cells from irradiated 
animals a short time after radiation exposure. 
 
3.2.6 Mice injected with cultured cells show no reconstitution in host animals 
    Sorted LSK cells from in vivo irradiated mice that had been expanded in Stemspan 
cultures were injected into myeloablated hosts as described above (Figure 3.2.6) with 
the injected mice and the cell types and cell numbers as indicated in Table 3.2.8. 
Different numbers of cells were injected to see whether this would give varying levels 
of reconstitution of the host animals. 
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Experiment
a 
Number 
of mice 
Recipient 
(Male/Female) 
Cells 
type 
Donor 
mice 
irradiated 
Cell 
number 
21 day 
survival 
1 2 0/3 GFP+ Y 1x105 3 
1 2 2/0 GFP+ Y 2x104 1 
1 1 1/0 GFP+ Y 2x104 b 0 
3 1 0/1 GFP+ Y 1x105 1 
3 1 0/1 GFP-/lo Y 1x105 1 
3 2 2/0 GFP+ Y 1x105 b 2 
3 3 3/0 GFP+ Y 5x105 3 
3 1 1/0 GFP+ Y 5x105 b 0 
3 2 2/0 GFP+ N 1x105 2 
 
Table 3.2.8. Mice injected with cells from Stemspan SFEM cultures derived from 
mice irradiated in vivo. 
 a: Experiment number correlates with cells sorted in table 3.2.3. b: Mice were 
injected with the stated number of cells, but without helper cells. 
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Some cultures were also set up from unirradiated donor animals, which were 
irradiated in vitro to establish if there was any distinguishable difference due to the 
microenvironment when the cells are recovering after exposure to ionizing radiation 
(Figure 3.2.6 A). In general, the in vitro irradiated cells seemed to have a lower fold 
expansion (Figure 3.2.11) than cells exposed in vivo (Figure 3.2.8). The control GFP + 
had an expansion (2600-fold) reasonably comparable to the equivalent cells in 
experiment 1 (2700-fold). The GFP -/lo control cells in experiment 2 showed a 740-
fold expansion, whereas previously in experiment 3 they failed to expand. In 
experiment 2, cells originally sorted as GFP + and then irradiated in vitro had only a 
30-fold expansion. The results suggest cells that recover in vivo seem to have a 
growth advantage, which could be attributed to the bone marrow niche providing a 
more protective environment after exposure to ionising radiation. However, the actual 
time after the exposure to 3 Gy is different. Cells from in vivo irradiated donors were 
irradiated 7 or 9 days before being isolated and then cultured for 9 days, making the 
analysis at day 16 to 18, whereas cells that were irradiated in vitro are analysed on 
day 9 post-irradiation. Therefore, the difference could be due to a longer recovery 
time rather than the difference between in vivo and in vitro environment after 
exposure to ionising radiation.  
    The GFP+ cells that had been irradiated in vitro and cultured were again sorted as 
GFP+ or GFP-/lo on day 9 (Figure 3.2.12) to try and isolate cells with Sfpi1 copy loss 
from the cultures. The majority of the cells were sorted as GFP+ with only just over 
200 cells being GFP- (Table 3.2.9). The cultured cells that had been sorted as GFP+ 
were then injected into myeloablated as described before (Table 3.2.10). Due to the 
small number of cells acquired, all the GFP+ sorted cells were injected whereas the 
GFP-/lo cells were expanded for a further 12 days to increase the cell numbers before 
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Figure 3.2.11. Fold expansion for in vitro irradiated Stemspan SFEM 
cultures. 
  LSK cells from unirradiated mice that had been sorted as GFP + or GFP -/lo were 
cultured in Stemspan under the same conditions as before. The day after the initial 
sorting, cultures were irradiated with a dose of 3 Gy and then cultured as before for a 
total of 9 days. 
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Experiment Condition Mouse 
strain 
Total 
cells 
sorted 
LSK 
GFP+ 
% of 
sorted 
cells 
LSK 
GFP-/lo 
% of 
sorted 
cells 
2 3 Gy in 
vitro 
CBA/H 8.1x104 2.7x103 3.4 225 0.3 
 
Table 3.2.9. Cells sorted from in vitro irradiated cultures.  
Cultures that had been irradiated in vitro were harvested after 9 days in culture and 
sorted for their GFP expression on a MoFlo cell sorter.  
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Experiment
a 
Number 
of mice 
Recipient 
(Male/Female) 
Cell 
type 
Irradiated Cell 
number 
21 day 
survival 
2b 1 1/0 GFP+ Y 1x105 1 
2b 1 1/0 GFP-/lo Y 1x105 1 
2 1 1/0 GFP+ N 1x105 1 
2 1 1/0 GFP+ N 2x104 1 
 
Table 3.2.10. Mice injected with in vitro irradiated cells from Stemspan SFEM 
cultures. 
 a: experiment number is referring to table 3.2.3. b: These cells were injected at a 
later date as the cells needed to be expanded to obtain sufficient numbers to inject. 
 
 
 
 
 
 
Experimenta Cells Irradiated Metaphases 
counted 
Two 
retained 
copies of 
Sfpi1 
Number of 
metaphases 
with Sfpi1 
deletions 
% 
deleted 
2 GFP-/lo In vitro 32 30 2 7 
Table 3.2.11. Sfpi1 deletions in cultures irradiated in vitro. a: The experiment 
number refers to Table 3.2.3. 
 
 
 
Experimenta Number of 
mice 
Cell type Cell 
number 
Irradiated Reconstitution 
1 1 GFP+ 1x105 In vivo 0/1 
1 1 GFP+ 1x105 In vivo 0/1 
2 1 GFP-/lo 1x105 In vitro 0/1 
3 1 GFP+ 1x105 In vivo 0/1 
 
Table 3.2.12. Analysis of repopulation of GFP cells by flow cytometry in mice 
transplanted with cultured cells. a: The experiment number refers to Table 3.2.3. 
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Figure 3.2.12. Sorting gates for in vitro irradiated cultured cells.  
On day 9, the cultures were isolated, cells counted and the cells sorted as GFP+ or 
GFP-/lo on a MoFlow cell sorter. Cells from WT mice were used as a control to set the 
regions for GFP expression. 
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injection and setting up a chromosome prep for FISH to analyse Sfpi1 deletions in the 
fraction. The frequency of Sfpi1 deletions in the in vitro irradiated GFP-/lo fraction 
(Table 3.2.11) was then found to be 2 out of 30 cells (7%). Since the number of 
metaphases counted is quite low and in control cultures in a previous experiment 
(Table 3.2.7) the deletion frequency was 1 in 67 metaphases, more experiments on in 
vitro cells need to be done to confirm the results. In conclusion, the microenvironment 
of the bone marrow did not seem to change the amount of cells that carry Sfpi1 copy 
deletions. Further experiments need to be carried out to see if the differences in the 
microenvironment affect the recovery and the future expansion of the cells. 
    Approximately 9-12 months after transplantation, some of the mice that had been 
injected with cultured cells were tail vein bled or heart blood was taken if the animals 
needed to be euthanized. WBCs were analysed for reconstitution with GFP cells by 
flow cytometry (Table 3.2.12). From this small sample of mice, the irradiated cultured 
cells did not seem able to repopulate in the hosts.  
    The culture conditions had already been slightly modified to increase the likelihood 
of cells to reconstitute hosts long-term, but the results indicate culture conditions need 
to be further optimised for the cells to provide successful repopulation of 
myeloablated hosts. The cells clearly have an ability to form colonies in 
methylcellulose in the short-term (Table 3.2.6), but under the conditions used here 
lack the ability to survive and proliferate long-term. An explanation for this could lie 
in HSC senescence (Chen, 2004). Since the cells are forced through the culture 
process to expand at a high rate, this could lead to the HSCs losing their ability to 
proliferate before long-term reconstitution is achieved. Therefore, a modification of 
the concentrations of cytokines added could lead to a slightly reduced fold expansion, 
but a better ability to reconstitute. However, the cytokine concentrations were the 
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Figure 3.2.13. Chromosome aberration on unidentified chromosomes in 
cultured control cells from cells sorted as LSK GFP+ from experiment 3. 
 
 
 
 
 
Experimenta Cell type Irradiated Frequency of 
chromosome 
aberration (%) 
1 GFP-/lo In vivo 8 
4 GFP+ No 9 
Table 3.2.13. Frequency of chromosome aberration found in cultured cells. 
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same as in previous publications in which repopulation was reported to be successful 
(Miller and Eaves, 1997; Audet et al., 2001; Miller et al., 2002). Another potential 
contributing factor could be the approximately 8-9 % of cells in some cultures that 
carry chromosome aberrations (Table 3.2.13). The chromosomes affected have not 
been identified (Figure 3.2.13). Furthermore, since the exposure to radiation further 
compromise the cells (Marusyk et al., 2010; Otsuka et al., 2010;) and make them less 
competitive, this will also likely lead to reduced engraftment both for the cultured 
cells and the same day injected LSK cells. These results are also compatible with the 
theory of cellular fitness regarding ionising radiation and haematopoietic 
malignancies (Fleenor et al., 2010) that has recently been proposed. 
 
3.2.7 The CFU-S 12 assay 
    The CFU-S assay was originally developed by Till and McCulloch to measure the 
radiation sensitivity of BMCs (Till and McCulloch, 1961). It is based on the 
observation that injected BMCs form colonies, seen as nodules on the spleen, at day 
10 to 11 after injection into myeloablated hosts. If the mice are instead left until day 
12, it was noticed that the spleen colonies consisted of cells from all lineages (Magli 
et al., 1982). By using the CFU-S assay in the present set of experiments, the 
intention was to acquire progeny of irradiated HSCs by dissecting out individual 
colonies from the spleens of host animals. It would then possible to analyse the cells 
by flow cytometry to find colonies carrying Sfpi1 copy deletions as detected by 
reduced GFP fluorescence levels when analysed by flow cytometry. In the long-term 
this assay could then be used to study early events after exposure to ionising radiation 
in the same way that was intended with the in vitro colony formation assays in 
methylcellulose.  
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    The CFU-S 12 assay was performed as described in Figure 3.2.14 with both in vivo 
and in vitro irradiated test cells. Briefly, to acquire in vivo irradiated test cells, CBA/H 
Sfpi1 GFP/GFP mice were exposed to a whole body dose (3 Gy) of ionising radiation. 7 
days post-irradiation, the mice were euthanised, bone marrow isolated from femurs 
and tibias, and total BMCs were then injected into the tail vein of myeloablated hosts 
as before. On day 12 after the transplant, the animals were sacrificed and the spleens 
were dissected out. The number of spleen colonies was counted and individual 
colonies were dissected out. The cells from the colonies were analysed by flow 
cytometry to determine the GFP expression level and surface marker expression. 
Some colonies were analysed by PCR to determine if it was possible to detect the 
GFP construct. To acquire in vitro irradiated test cells, BMCs were isolated from 
unirradiated CBA/H Sfpi1 GFP/GFP mice and the cells were exposed in vitro to a 3 Gy 
dose of ionising radiation before being injected into myeloablated hosts. Since 
previous experiments (see Figure 3.1.7 and 3.1.10) showed that in vitro exposure of 
cells involves a high level of cell killing, it was decided to inject 10 times the number 
of cells when they had been exposed to ionising radiation in vitro. Both approaches 
also had animals that were injected with unirradiated CBA/H WT and CBA/H Sfpi1 
GFP/GFP cells.  
    Tables 3.2.14- 3.2.16 show the number of colonies counted on each spleen from 
each mouse and the total number of colonies dissected out from each of the 
experiments (one experiment with in vivo irradiated cells and two experiments with in 
vitro irradiated cells). When the colony forming potential was determined a clear 
difference was observed dependent on the irradiation status of the test cells (in vivo or 
in vitro). The test cells that had been acquired from in vivo irradiated donor mice were  
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Figure 3.2.14.  CFU-S 12 assay.  
A. CBA/H Sfpi1 GFP/GFP mice were given a whole body dose of ionising radiation (3 Gy). 
After 7 days, the femora and tibias were dissected out and total BMCs isolated. 3x106 cells 
were injected in to CBA WT mice that had been irradiated with 8.5 Gy. After 12 days the 
mice were euthanised and the whole spleen was dissected out from each recipient mouse. The 
spleen colonies were counted and individual colonies were dissected out. Syringing the tissue 
several times produced a cell suspension and samples were taken for flow cytometry analysis 
and DNA extraction for PCR. The same procedure was followed for unirradiated CBA/H 
Sfpi1 GFP/GFP or CBA/H WT control mice with the exception of the number of cell injected, 
which was 2x106. B. BMCs were isolated from CBA/H Sfpi1 GFP/GFP mice and samples of 
2x107 cells were irradiated in vitro with a 3 Gy dose of ionising radiation. Control samples as 
above with 2x106 cells were also prepared. Cells were then injected in to the tail vein of 
CBA/H WT mice that had been irradiated with 8.5 Gy. After 12 days, the mice were 
euthanised and spleen and the same procedure followed as above. 
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able to form colonies at a similar level to control cells (Table 3.2.17). However, in 
vitro irradiated test cells had a 10 times reduced number of colonies/106 injected cells. 
As with the long-term experiment, there is a difference in the actual analysis point and 
a different protocol would be needed to confirm whether the lower colony forming 
potential is due to the longer recovery time as such. A 24-hour time-point after in vivo 
exposure could be used to extract cells from the in vivo irradiated donors or cells 
could be extracted immediately after exposure. Then, similar post exposure recovery 
between the in vivo and in vitro irradiations would be maintained. 
    Cell samples from the isolated colonies were analysed by flow cytometry to 
determine the level of GFP expression. As shown earlier (Figure 3.1.1), cells with one 
copy, instead of two copies, had a GFP reduction in geometric mean fluorescence. 
Colonies with Sfpi1 deletions would therefore be distinguished from colonies where 
both alleles had been retained. A region was drawn around the events that had 
sufficient size and/or granularity to be lymphocytes, monocytes and granulocytes and 
the GFP expression was analysed in this gate. Figure 3.2.15 A shows a representative 
analysis plot where WT control (red line) has been overlayed with the GFP sample 
(green line). Colonies derived from CBA/H Sfpi1 GFP/GFP donors showed a clear 
bimodal distribution where the geometric mean of the more intense GFP peak could 
be determined. The analysis of GFP expression levels was done on colonies from 
CFU-S 12 experiment 1, 2 and 3. In experiment 3, a more detailed analysis of the 
surface marker expression of the cells was carried out to determine whether the 
colonies consisted of cells from all the major lineages, T- and B- cells, monocytes and 
granulocytes as previously observed for the WBC analysis. Figure 3.2.15 B shows a 
representative sample. No significant reduction in the GFP geometric mean of
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Mouse Cells 
injected 
Irradiated Total number of 
spleen colonies 
Spleen colonies 
dissected out 
  In vivo In 
vitro 
  
1 WT 
control 
  4 3 
2 GFP 
control 
  3 3 
3 GFP 3 Gy X  6 2 
4 “ X  7 3 
5 “ X  4 4 
6 “ X  6 3 
    Total dissected 18 
Table 3.2.14. Colony count from CFU-S 12 assay 1. 
 
 
Mouse Cells 
injected 
Irradiated Total number of 
spleen colonies 
Spleen colonies 
dissected out 
  In vivo In 
vitro 
  
1 WT control  X 9 4 
2 WT control  X 5 4 
3 GFP control  X 0* 0* 
4 GFP 3 Gy  X 3 2 
5 “  X 4 3 
    Total dissected 13 
Table 3.2.15. Colony count from CFU-S 12 assay 2. 
* Remnants of a colony was dissected out and analysed, but no proper colony was 
present. 
 
 
 
Mouse Cells 
injected 
Irradiated Total number of 
spleen colonies 
Spleen colonies 
dissected out 
  In vivo In 
vitro 
  
1 WT 
control 
  6 4 
2 “   0 N/A 
3 GFP 
control 
  4 3 
4 GFP 3 Gy  X 10 4 
5   X 6 3 
6   X 7 3 
7   X 7 4 
8   X 6 4 
9   X 6 3 
    Total dissected 28 
Table 3.2.16. Colony count from CFU-S 12 assay 3 
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CFU-S 12 experiment Mean colony 
number 
Number of cells 
injected 
Colonies/106 cells 
injected 
1 (controls) 3.5 2x106 1.8 
1 (irradiated in vivo) 5.8 3x106 1.9 
2 (controls) 4.7 2x106 2.4 
2 (irradiated in vitro) 3.5 2x107 0.2 
3 (controls) 3.3 2x106 1.7 
3 (irradiated in vitro) 7 2x107 0.4 
Table 3.2.17.  Comparison in colony forming potential in the CFU-S 12 
experiments. 
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Figure 3.2.15. Flow cytometry analysis of GFP and surface marker 
expression in spleen colonies (CFU-S 12 assay 3).  
Cell samples were from individual spleen colonies were stained with antibodies as 
previously described and analysed by flow cytometry. A. A region was drawn around 
events that were of a sufficient size and granularity to be cells (according to forward 
and side scatter). A gate was created and the GFP geometric mean expression level 
and percentage GFP positive cells was analysed. An overlay plot shows a 
representative WT sample in red and a GFP sample in green. B. Some samples were 
stained with antibodies to analyse the lineage characteristics of the colonies. CD3 was 
used as a T-cell marker, B220 for B-cells, Gr-1 and Mac-1 for granulocytes and 
macrophages. The plots are gated in the same way as for GFP expression analysis and 
show representative samples. 
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Colony Cells GFP expression 
(%) GFP geo mean 
1-3 WT control 0   
4 GFP control 5.7 70 
5 “ 6.7 70 
6 “ 4.0 76 
7 GFP 3 Gy 30 66 
8 “ 45 71 
9 “ 16 66 
10 “ 11 78 
11 “ 5.0 70 
12 “ 5.5 70 
13 “ 8.9 69 
14 “ 5.7 67 
15 “ 7.0 61 
16 “ 5.2 64 
17 “ 6.5 61 
18 “ 7.1 67 
 
Table 3.2.18. GFP expression in analysed colonies from CFU-S 12 experiment 1 
(In vivo irradiated cells). 
 
 
Colony Cells GFP expression 
(%) GFP geo mean 
1-8 WT control 0  
9 GFP control 27 77 
10 GFP 3 Gy 4.4 75 
11 “ 5.5 81 
12 “ 2.1 83 
13 “ 5.4 83 
14 “ 3.5 90 
Table 3.2.19. GFP expression in analysed colonies from CFU-S 12 experiment 2 
(In vitro irradiated cells)
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Colony Cells 
GFP 
expression 
(%) 
CD3+ 
expression 
(%) 
B220+ 
expression 
(%) 
GFP geo mean B220+ 
Gr-1+ 
expression 
(%) 
Mac-1+ 
expression 
(%) 
GFP geo mean Mac-1+ 
 WT control 0.0 2.0 4.0   10.0 5.0   
 GFP control 6.2 1.9 8.6 39.0 11.3 4.4 48.0 
1 GFP 3 Gy 12.1 2.8 4.4 43.0 15.0 2.1 51.0 
2 " 4.4 2.8 4.2 46.0 11.8 2.6 47.0 
3 " 2.9 9.3 6.7 37.0 10.0 3.1 43.0 
4 " 4.6 3.2 6.0 37.0 6.8 3.2 55.0 
5 " 8.8 1.3 4.3 52.0 10.6 1.8 47.0 
6 " 2.0 1.6 2.4 40.0 9.1 0.9 49.0 
7 " 0.6 1.3 2.1 39.0 4.7 0.2 49.0 
8 " 1.8 3.8 5.1 36.0 7.9 1.1 51.0 
9 " 1.1 0.01 2.0 4.0 3.7 0.1 56.0 
10 " 3.3 1.1 2.5 46.0 10.0 1.0 50.0 
11 " 7.3 5.6 7.7 44.0 16.6 1.9 57.0 
12 " 12.8 0.7 2.8 50.0 13.9 0.9 48.0 
13 " 0.6 1.2 2.9 43.0 5.4 0.1 45.0 
14 " 0.2 0.6 1.5 44.0 3.8 0.5 47.0 
15 " 1.6 4.4 4.8 45.0 5.4 0.8 55.0 
16 " 65.3 6.3 9.5 47.0 41.3 6.2 58.0 
17 " 4.1 1.5 2.7 48.0 5.8 0.1 52.0 
18 " 9.6 13.3 16.0 45.0 23.4 6.7 48.0 
19 " 6.3 1.0 2.5 41.0 11.0 0.3 51.0 
20* "         31.2 3.7 48.0 
Table 3.2.20. GFP expression in analysed colonies from CFU-S12 experiment 3 (In vitro irradiated cells).  
* This sample contained only enough cells to analyse one set of surface markers. 
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irradiated samples compared to the unirradiated Sfpi1 GFP/GFP control could be seen in 
either experiment 1 or 2 (Table 3.2.18 and 3.2.19). The percentage of GFP positive 
cells varied in the irradiated samples, but this could be due to the cell types present in 
the colonies. Macrophages for example have higher fluorescence intensity than B-
cells due to that their expression of Sfpi1 is higher. The amount of samples in 
experiment 2 was quite small (8), however in experiment 1 no difference in the 
geometric mean was seen in the 12 samples. In experiment 3 an analysis of the 
geometric mean was combined with surface marker expression in 20 in vitro 
irradiated samples. B-cells and monocytes both express PU.1 (Nutt et al., 2005) and 
these cell types were used to analyse the GFP levels. All the samples had a geometric 
mean comparable to the unirradiated Sfpi1 GFP/GFP control (Table 3.2.20). The 
individual colonies had a varying percentage of GFP positive cells but, as the surface 
markers show, the cell types were varied between colonies. In general, all colonies 
showed some expression of all lineage markers, with some exceptions. This confirms 
that the day 12 time-point is suitable for analysis of the CFU-S assay (Magli et al., 
1982). 
    As a further proof that the cells in the spleen colonies were derived from the 
transplanted cells a PCR based assay was performed. DNA was extracted from a 
selection of cells from colonies derived from CFU-S 12 experiment 2. Primers to 
detect the GFP construct were used to genotype samples isolated from the colonies 
(Dakic et al. 2005; Nutt et al., 2005). Colonies from WT animals had one band at 680 
bp, whereas colonies from Sfpi1 GFP/GFP animals had one band at 512 bp (Figure 
3.2.16). The size of the products depends on which primer combination is able to 
amplify the DNA as described in material and methods. Some contaminating spleen 
tissue from the CBA/H WT recipients occasionally produces WT bands in the GFP  
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Figure 3.2.16. Genotyping PCR of spleen colonies.  
DNA was extracted from cell samples of individual spleen colonies from experiment 
2. Genotyping PCR was performed to determine whether the colonies that formed 
originated from recipient cells or from injected Sfpi1 GFP/GFP cells. A representative 
gel is shown where DNA products from the CBA/H WT control were of 680 bp and 
those from GFP samples were 512 bp in length.  
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samples as can be detected by faint double bands. The results from the genotyping 
PCR therefore further confirm that the colonies in the samples are derived from  
Sfpi1 GFP/GFP donor cells and not from the host.  
 
3.2.8 Conclusions 
    The use of transplantation assays to investigate Sfpi1 deletions and clonal 
proliferation in the CBA/H model of rAML is a new approach to study the early 
molecular and cytogenetic events after exposure to ionising radiation and 
appropriated for leukaemogenesis. The assays need further work to achieve the aim of 
transplanting HSCs into host animals that then eventually will survive sufficiently to 
present with rAML.  
   The long-term reconstitution experiments to transfer HSCs with Sfpi1 deletions had 
mixed results. Overall, it is promising that some host mice seemed to be reconstituted 
with the same day injected LSK cells, including one mouse with cells that carry Sfpi1 
deletions. However, the cells need to be made more competitive so that the irradiated 
cells also can reconstitute hosts at a reasonable frequency. One way would to increase 
competitiveness would be to inject a larger number of LSK cells. Also, as previously 
mentioned, if the cells were isolated at a later time point post-irradiation, the cells 
would have had a longer time to recover and therefore potentially be more viable. 
From the results described, it seems difficult to use GFP as a specific marker for loss 
of one allele of Sfpi1 on chromosome 2 as used in cell sorting, especially since Sfpi1 
deletions can be found in both the GFP+ and GFP-/lo fractions. However, the reporter 
gene is still useful as a marker to determine reconstitution and to assess the overall 
expression of Sfpi1 in the sorted populations in these initial experiments. As further 
results will show in chapter 3.3, under different circumstances the GFP expression 
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can be used for the intended purpose. Refinement of the conditions could still be 
made to make this long-term transplantation assay an interesting and novel way to 
study radiation-induced leukaemogenesis.  
 In all three CFU-S 12 experiments there seems to be little detectable change in GFP 
levels between colonies derived from unirradiated and irradiated cells. To further 
analyse whether CFU-S 12 colonies contain cells with these deletions, which might 
not have been detected by flow cytometry, FISH could be used as was done with the 
cultured cells from the long-term transplantation experiments. 
    In conclusion, the transplantation assays need optimisation to get consistent results. 
Long-term reconstitution by irradiated cells up to at least 12 months is needed for 
rAML to develop and at them moment this is difficult to achieve. Potentially the 
difficulties are linked to HSCs exposed to ionising radiation not being competitive 
enough to repopulate recipient animals and they might also lose their proliferative 
capacity earlier than normal HSCs. The protocol for culturing of the cells need to be 
further optimised and variables such as culturing time, how often the cells are split 
and incubation conditions need to be investigated to establish whether there is a 
possibility of using cultured cells for the long-term reconstitution assay. 
    While 37 colonies were screened for their GFP expression, there is a possibility the 
copy loss of Sfpi1 is a rare event in the cells forming the CFU-S. Furthermore, the 
copy loss might actually make the colony forming cell less competitive compared to 
non-damaged cells, making the likelihood of finding a CFU-S with Sfpi1 copy loss   
even lower.
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3.3 Characterisation of surface markers on leukaemic blasts, Sfpi1 
copy loss and PU.1 transcription factor mutations in rAMLs  
 
3.3.1 Introduction 
The CBA/H model of radiation-induced AML (rAML) along with the closely related 
CBA/Ca, has been used for over 30 years (Major and Mole, 1978). Combining the 
CBA/H model with the transgenic reporter gene model that was acquired was 
hypothesised to give an opportunity to study the expression of PU.1 protein 
expression and Sfpi1 copy deletions in live leukaemic cells. Previous research 
performed in the group has used flow cytometry to phenotype leukaemic blasts 
(Finnon R, unpublished data). Immunophenotyping of suspected leukaemia cases aids 
classification of the leukaemia type in clinical settings and also monitoring relapse 
after treatment (Bain, 2010). To get a complete diagnosis, further methods such as 
histopathology, cytogenetics, and immunohistochemistry are used, however these 
latter analyses are not part of this work. Immunophenotyping is used in the present 
study in conjunction with analyses of Sfpi1 expression, PU.1 transcription factor 
mutations and copy loss of the gene Sfpi1 on chromosome 2 using flow cytometry. 
    As previously mentioned, a partial deletion of one copy of chromosome 2 leading 
to loss of one allele of the Sfpi1 gene is found in a high proportion of cases of rAML 
in the CBA/H model. In 67-74% of CBA/H rAML cases with chromosome 2 
deletions, the remaining copy of the gene carries a point mutation in the DNA binding 
domain encoded by exon 5 (Suraweera et al., 2005; Hirouchi et al., 2008), in other 
strains the point mutation can be found in 87% of cases (Cook et al., 2004). The level 
of Sfpi1 expression, and the expression of the PU.1 protein, has been shown in several 
cases to be important for the maturation and differentiation of haematopoietic cells 
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(DeKoter and Singh, 2000; Dahl et al., 2003). Furthermore, a reduction to about 20 % 
of normal levels of the gene was found to lead to the development of AML 
(Rosenbauer et al., 2004). Therefore, the point mutation reduces the function of the 
PU.1 as a transcription factor, leading to a hypomorphic protein that cannot regulate 
downstream target genes and may lead to the development of AML (Cook et al., 
2005, Suraweera et al., 2005). The upregulation of the oncogene c-myc (Hirouchi et 
al, 2008) and the downregulation of JunB (Steidl et al, 2006) have previously been 
found in cases of AML where PU.1 expression is deficient. Furthermore, a complete 
deletion of Sfpi1 expression in adult mouse bone marrow also leads to AML (Metcalf 
et al., 2006). 
    Experiments on cell lines have shown the point mutations affect the Sfpi1 mRNA 
abundancy and the amount of protein in leukaemic blast cells (Brown et al., 2011). 
The expression of downstream target genes was also found to be changed. However 
the surface marker expression on blast cells seemed to be independent of the point 
mutation (Brown et al., 2011). By using the current transgenic model, it should be 
possible to assess any potential link between surface marker expression, Sfpi1 mRNA 
expression, PU.1 protein, point mutation status and Sfpi1 copy loss in live leukaemic 
blasts from primary AMLs. The aim is to investigate if the surface marker phenotype 
is derived from the cell of origin or from the PU.1 point mutation. 
   Some cases of rAML do not have Sfpi1 deletions or point mutations (Silver et al., 
1999, Suraweera et al., 2005) and alternative mechanisms of the disease development 
are yet to be demonstrated. Mutations in the FMS-like tyrosine kinase 3 (Flt3) gene 
can lead to dysregulation of proliferation and leukaemia (Meshinchi and Appelbaum, 
2009). One type of mutation associated with the gene is an internal tandem 
duplication (ITD) in the gene leading to a duplication of a fragment in the 
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juxtamembrane domain of the protein, which has been found in 15-35 % of cases of 
human AML (Kiyoi et al., 1998; Meshinchi and Appelbaum, 2009). Interestingly, 
recently Flt3-ITD mutations have been found in some cases of rAML in C57BL/6 x 
CBA/H F1 and CBA/H animals (Finnon et al., 2011 submitted). An inverse 
relationship between the expression of the gene Flt3 and Sfpi1 has also been observed 
(Inomata et al., 2006; Brown et al., 2011; Finnon et al., 2011 submitted).  
    The results in this chapter are derived from a study of 100 male CBA mice, 50 
Sfpi1 GFP/+ and 50 Sfpi1 GFP/GFP and a further 15 CBA/H Sfpi1 GFP/GFP female mice 
that were exposed to a total body dose (3 Gy) of x-rays. Of the animals that developed 
rAML, 9 cases have been analysed in this chapter. The study aimed to investigate 
links between the expression of Sfpi1, PU.1 protein expression and point mutations of 
the Sfpi1 DNA binding domain, chromosome 2 deletions with Sfpi1 copy loss and the 
surface marker expression in rAML blasts. The rAML samples were also screened for 
the presence of Flt3-ITDs and genotyped by PCR. 
  
3.3.2 GFP expression analysis of rAML cases using flow cytometry 
    Animals that needed to be euthanised for humane reasons according to institutional 
regulations were investigated for signs of leukaemia. Tissue samples were collected 
and processed for further analysis as described in material and methods. Spleen, blood 
and bone marrow cells from suspected rAMLs were phenotyped by flow cytometry. 
The samples included cells from 6 male CBA/H Sfpi1 GFP/+ animals, 2 male Sfpi1 
GFP/GFP animals and 1 female Sfpi1 GFP/GFP animal. The antibody panel used for 
phenotyping (Table 3.3.1) was based on recommendations from the hematopathology 
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Antibody Cell type expression References 
Gr-1 (Ly6G, clone 1A8) Granulocytes Hestdal et al., 1991 
Mac-1 (CD11b) Monocytes/macrophages Arnaout, 1990 
CD31 (PECAM-1) Myeloid progenitors, 
dendritic cell precursors 
and macrophages 
van der Loo et al., 1995 
Ly6c (CD59) Myeloid progenitors, 
dendritic cell precursors 
and macrophages 
van der Loo et al., 1995 
Sca-1 HSCs in combination with 
c-Kit 
Spangrude et al., 1988 
c-Kit (CD117) HSCs in combination with 
Sca-1, myeloid progenitors 
Spangrude et al., 1988 
CD3 T-cells Dave, 2009 
B220 (CD45R) B-cells Hardy and Hayakawa, 
2001 
CD34 Committed progenitor 
cells 
Iwasaki and Akashi, 2007b 
CD38 Long-term HSCs in the 
LSK fraction 
Iwasaki and Akashi, 2007b 
Flt3 Flt3 expression defines 
certain progenitors in 
conjunction with VCAM-1 
expression 
Iwasaki and Akashi, 2007b 
VCAM-1 (CD106) VCAM-1 expression 
defines certain myeloid 
progenitors in conjunction 
with Flt3 expression 
Iwasaki and Akashi, 2007b 
Thy-1 (CD90) Thy-1 low expressing cells 
indicate HSCs when 
expressed together with 
other surface markers 
Spangrude et al., 1988 
FcγR II/II (CD16/32) Myeloid progenitors and 
macrophages 
Iwasaki and Akashi, 2007b 
 
Table 3.3.1. Surface marker antibodies used for phenotyping of suspected rAML 
cases. 
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subcommittee of the Mouse Models of Human Cancers Consortium (Kogan et al., 
2002) and further antibodies that were thought to be useful in identifying early and 
myeloid progenitors (Iwasaki and Akashi, 2007b).  
    A notable difference between normal and leukaemic samples is the presence of 
immature forms/blast cells (Figure 3.3.1). It is particularly noticeable in the spleen 
samples (Figure 3.3.1 B and E), where a region with medium forward scatter (FSC) 
and low side scatter (SSC), lymphocytes in green, is present in normal spleen, 
whereas in leukaemic samples a blast region with high SSC (purple) is present. The 
forward FSC/SSC profile of BMCs (Figure 3.3.1 A and D) changes from 5 regions, of 
which 3 are analysed (representing lymphocytes, blue; monocytes, orange and 
granulocytes, green), and replaced by one blast region (green). In some cases, the 
bone marrow had a very distorted FSC/SSC, resulting in samples that were difficult to 
analyse. WBCs (Figure 3.3.1 C and F) change from containing a region of medium 
FSC and low SSC (lymphocytes, red) and one with higher SSC (monocytes and 
granulocytes, green) to a region of high FSC and SSC. If more than 20% of cells in a 
sample are immature forms/blasts, one defining criteria for a leukaemia is met (Kogan 
et al., 2002). This criterion was met in all cases (Table 3.3.2), although 2 cases 
contained only just over 20% of immature forms/blasts. Blood smears were prepared 
for further characterisation to confirm the findings, but analysis of these blood smears 
is not included. 
    All flow cytometry analysis was performed on the gated region with immature 
forms/blast from spleen cells (Figure3.3.1G). Total bone marrow cells were used as 
control cells, gated on the regions marked as blue, orange and green (Figure 3.3.1A). 
Total bone marrow was chosen as a control since the majority of cells in the rAML 
spleen will be infiltrating leukaemic BMCs. The spleen tissue was chosen for analysis 
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Figure 3.3.1. FSC/SSC profile of samples from control and cases of rAML. 
 A. Normal BMCs. Cells are analysed in the blue(lymphocyte), orange (monocyte) 
and green (granulocytic) regions. B. Normal spleen cells. Cells in the green 
(lymphocytes) region are analysed. C. Normal WBCs. Cells in the red (lymphocytes) 
and green (monocytes and granulocytes) region are analysed. D. AML BMCs. 
Immature forms/blasts in the green region.E. AML spleen cells. Immature 
forms/blasts in the pink region. F. AML WBCs. Immature forms/blasts in the green 
region. G. Gating strategy for analysing the GFP expression of immature 
forms/blasts. Regions were created around major populations of cells on a forward 
scatter/side scatter (FSC/SSC) dot plot. Events with low FSC/SSC were assumed to 
be dead cells and debris and were excluded from analysis. In leukaemic samples the 
analysis was performed on the region was with high FSC/SSC, which is not normally 
present in spleen. Leukamic samples were compared to the combined major regions in 
BMCs. The GFP expression was defined as mean fluorescence level, which is the 
geometric mean channel number on a log scale x-axis on the lower right quadrant on a 
dot plot. 
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due to the large number of cells possible to extract in rAML spleen. The bone marrow 
from femur had in some cases a low cellularity and was therefore not as easy to 
analyse. The GFP levels are expressed as the geometric mean of the mean channel 
number for the quadrant on a dot plot that is defined as GFP+ compared to non-GFP 
control mice. 
    In 4 out of 9 cases (58.2c, 58.1f, 61.2g and 61.3d), the geometric mean of the GFP 
expression levels were higher compared to the equivalent control Sfpi1 GFP/+ or Sfpi1 
GFP/GFP BMC levels (Table 3.3.2). However, the actual percentages of GFP+ cells 
were higher in 6 out of 9 cases (58.2c, 58.1f, 61.2g, 61.3d, 62.2d and 57.b). Three 
Sfpi1 GFP/+ cases (52.1f, 61.2f and 51.1c) had a low percentage GFP positive cells 
combined with a low GFP geometric mean, which is likely to be the result of the loss 
of the GFP construct combined with the Sfpi1 gene. Correspondingly, the Sfpi1 GFP/+ 
mice positive for GFP most likely had lost the non-GFP allele. One Sfpi1 GFP/GFP 
mouse (57.3b) had a high percentage of GFP+ cells but a relatively low geometric 
mean.  
 
3.3.3 Genotyping of rAML cases and analysis of Sfpi1 deletion on chromosome 2 
 As mentioned previously, the original mice carrying the GFP construct were 
produced in C57BL/6 mice (Dakic et al., 2005; Nutt et al, 2005). During the process 
of backcrossing the mice onto a CBA/H genetic background, the mice were 
genotyped so as to distinguish which animals to use for further breeding. As was 
shown previously (Figure 3.2.16), CBA/H WT and CBA/H Sfpi1 GFP/GFP mice carry 
different sized alleles that give different sized bands when PCR products amplifying 
the region where the construct is situated are analysed on an agarose gel. Knowing 
that it is possible to distinguish between the three genotypes (WT, Sfpi1 GFP/+ and 
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Sfpi1 GFP/GFP) by PCR genotyping using primers specific for exon 5 in Sfpi1 and the 
GFP construct, it was thought that it might be possible to detect partial deletions on 
chromosome 2 by using this PCR reaction. Due to the size of the minimal deleted 
region (Silver et al., 1999) and the location of the GFP construct, the construct would 
be lost together with the rest of the Sfpi1 allele. However, since Sfpi1 GFP/GFP mice 
carry two copies of the GFP construct, the PCR assay cannot be used to detect 
deletions in these cases. That is, irrespective of the deletion status of the sample there 
will always be DNA from the GFP construct to amplify and the product will always 
be the same size when analysed on an agarose gel. DNA was extracted from spleen 
material of CBA/H WT, CBA/H Sfpi1 GFP/+ and CBA/H Sfpi1 GFP/GFP control mice as 
well as the 9 rAML cases presented previously. The extracted DNA from the enlarged 
spleen of animals with rAML might also contain splenocyte DNA where no deletions 
would be present, as well as infiltrating leukaemic cells. A series with DNA mixes 
(Clark et al., 1996) of known ratios of DNA from WT and Sfpi1 GFP/GFP mice were 
used to calibrate the assay and determine the approximate amount of splenocyte DNA 
present. This made it possible to distinguish contaminating normal spleen DNA from 
leukaemic cell DNA. The PCR amplified the section of the DNA containing the GFP 
construct and products were analysed on an agarose gel (Figure 3.3.2).  
    Interestingly, 2 of the Sfpi1 GFP/+ mice (61.3d and 61.2g) showed an imbalance in 
the bands that is similar to that seen in the 1:9 WT/ Sfpi1 GFP/GFP standard. 3 mice 
(52.1f, 61.2f and 51.1c) showed an imbalance in the bands similar to the 9:1 WT/ 
Sfpi1 GFP/GFP standard. When the cases were grouped according to whether they 
showed GFP positivity by FACS analysis, it became clear that the imbalance is likely  
indicated a loss of one allele of Sfpi1. The case 61.2g was confirmed by FISH to have 
lost one allele of Sfpi1. The case that were weakly positive for GFP by FACS but 
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showed a normal Spi1 GFP/+ genotype (62.2d), as assessed by PCR, was confirmed by 
FISH to be a case where no deletion of Sfpi1 could be detected. All three cases that 
were GFP negative by FACS analysis (52.1f, 61.2f and 51.1c) had a preferential 
amplification of the WT allele and one of those cases (61.2f) was confirmed by FISH 
to have lost a copy of Sfpi1. Furthermore, in two cases where FISH analysis was not 
done (52.1f, and 58.1f), a point mutation (Table 3.3.3) suggested a loss of one allele 
of Sfpi1 since the mutation is not seen in cases with two intact alleles (Suraweera et 
al., 2005). In three cases, 51.1c, 61.3 d and 57.3b no point mutations were detected 
and FISH was not used to determine whether a deletion was present or not. However, 
the PCR results convincingly demonstrated deletions of the WT allele (61.3d) and of 
GFP allele (51.1c). The reason for not determining the copy loss by FISH in all 
samples was due to a lack of time. 
    Combining the flow cytometry data of the GFP expression with the PCR 
genotyping data (Figure 3.3.3 and Table 3.3.2) further emphasises the correlation 
between loss of GFP expression and the change in the expected product size in the 
PCR assay. That is, loss of GFP expression assessed by flow cytometry in Sfpi1 GFP/+ 
mice correlates with the PCR verification of GFP allele loss. Sfpi1 GFP/+ mice without 
a loss of an Sfpi1 allele retain a low GFP expression and the expected Sfpi1 GFP/+ PCR 
products with two bands. Sfpi1 GFP/+ mice that have a loss of the non-GFP carrying 
allele of Sfpi1 show GFP expression as measured by flow cytometry and the PCR 
product is that expected from a Sfpi1 GFP/GFP mouse. These results further validate the 
use of the transgenic mouse model as a valuable tool to study loss of an allele of Sfpi1 
in rAML and to assess the relative level of PU.1 protein. 
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Figure 3.3.2. Genotyping of AMLs.  
DNA was extracted from spleen material of control mice (CBA WT, CBA Sfpi1 GFP+/- 
and CBA Sfpi1 GFP+/+) and AMLs. PCR were set up amplifying the region containing 
the GFP construct. Products were analysed on an agarose gel. A mix of known 
concentrations of WT and Sfpi1 GFP+/+ DNA was used to estimate potential 
contamination of spleen tissue. From left to right, (parts WT/Sfpi1 GFP/GFP), 9:1. 7:3, 
1:1, 3:7, 1:9. The case names are above each lane and are the same as in table 3.3.2. 
 denotes cases where the deletion status has been confirmed by FISH. See table 
3.3.2 for deletion status.  
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Figure 3.3.3. Overlay histogram of the GFP expression in the rAML cases.  
The GFP expression as measured by flow cytometry is visualised in 3D in an overlay 
histogram. The identifier colour and the corresponding case name are found in table 
3.3.3. 
 
AML case GFP expression by 
flow cytometery 
Original GFP 
genotype 
PCR product from 
leukaemic spleen cells 
Sfpi1 copy 
loss by 
FISH 
Histogram 
identifier 
 WT GFP   
58.2c High Sfpi1 GFP/GFP - + Yes  
58.1f High Sfpi1 GFP/GFP - + Not done  
61.2g High Sfpi1 GFP/+ - + Yes  
52.1f Negative Sfpi1 GFP/+ + - Not done  
61.2f Negative Sfpi1 GFP/+ + - Yes  
51.1c Negative Sfpi1 GFP/+ + - Not done  
61.3d Low Sfpi1 GFP/+ - + Not done  
62.2d Low Sfpi1 GFP/+ + + No  
57.3b Low Sfpi1 GFP/GFP - + Not done  
 
Table 3.3.2. Colour identifiers for the flow cytometry data in Figure 3.3.5.  
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3.3.4 Phenotyping of rAML cases using flow cytometry 
    Overall, the rAML cases had a Gr-1lo/+ Mac-1lo/+ CD31+ Ly6C+ Sca-1lo CD3- B220- 
CD34- CD38lo Flt3-/lo VCAM-1+ Thy-1lo/+ FcγRIII/II+ (Figure 3.3.4). This gives the 
majority of the cases a non-lymphocytic leukaemia phenotype, where the granulocytic 
and monocytic component varies. The expression of Ly6C, CD31, VCAM-1 and 
FcγRIII/II further emphasizes the myeloid component of the leukaemia. The detailed 
surface marker expression of the samples can be seen in Table 3.3.3.  
    Overall, all cases were positive for Gr-1, although with varying levels of positivity. 
The higher levels of Gr-1 would indicate cells with more granulocytic phenotype 
(Hestdahl et al., 1991) than those cases with low levels. A higher Mac-1 expression 
would mean a more monocytic cell component (Arnaout, 1990). Together, Gr-1 and 
Mac-1 would classify the immature forms/blast as being a granulocytic leukaemia, 
whereas low-negative Gr-1 and positive Mac-1 is a monocytic leukaemia (Kogan et 
al., 2002). In general, most cases showed positivity for both markers, but three cases 
(58.1f, 52.1f and 61.2f) had low Gr-1 expression with a very low Mac-1 expression. 
The low expression could mean these cases had immature forms/blasts that were less 
differentiated compared to the other cases.  
    Cases of non-lymphoid leukaemia do not express markers for T- and B-cells 
(Kogan et al., 2002), such as CD3 (Dave, 2009) and B220 (Hardy and Hayakawa, 
2001) respectively, to a high degree. For the majority of cases this was true, however 
two cases (62.2d and 57.3b) showed co-expression of B220 with both Gr-1 and Mac-
1, indicating these cases were biphenotypic leukaemias. This is still classified as a 
non-lymphoid leukaemia (Kogan et al., 2002), although the majority of cases of 
rAML are not of this type (Major, 1979). One of the proposed biphenotypic cases was 
a female mouse. Since only a small amount of female animals were irradiated, it is not  
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 Figure 3.3.4. Representative plots for analysis of surface marker 
expression by flow cytometry in rAML cases.  
The plots were gated as described in figure 3.3.1 G.   
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possible to say at the moment how typical the phenotype is of the disease in female 
mice. 
    All cases were more highly positive than normal for CD31 and Ly6C that are 
markers for myeloid progenitor cells (van der Loo et al., 1995), apart from the female 
mouse (57.3b) that was Ly6C negative/low. Furthermore, all cases were positive for 
FcγRIII/II, further showing that the cells had a myeloid lineage phenotype (Iwasaki 
and Akashi, 2007b). VCAM-1 is another marker of myeloid progenitors (Iwasaki and 
Akashi, 2007b) and all cases but one (62.2d) had an increase compared to control 
BMCs. The differing case was the presumed male biphenotypic leukaemia. The 
expression of Flt3 is used for separating different subsections of multi-potent 
progenitors (MPPs) (Iwasaki and Akasi, 2007b). The marker was generally not 
expressed or very lowly expressed apart from the male mouse with biphenotypic 
characteristics (62.2d).  
    Sca-1 and c-Kit are markers for HSCs when they are expressed together 
(Spangrude et al., 1988). Cells only expressing c-Kit are considered to be myeloid 
progenitors (Iwasaki and Akashi, 2007b). In general, all cases showed low expression 
of Sca-1 in line with control mice, whereas the c-Kit expression was increased and 
generally quite high. The female mouse (57.3b) had a high Sca-1 expression and c-Kit 
expression. Other markers for immature cells at the stage of HSCs or MPPs are CD34 
and CD38 (Iwasaki and Akashi, 2007b). CD34 was not expressed higher in the cases 
compared to the control bone marrow and CD38 expression was significantly. The 
female mouse (57.3b) however showed a very high expression of CD38 even 
compared to control BMCs. 
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  R235H R235C R235 (Wild type) 
  Control 
total BMC 
58.2c (m)     
Sfpi1 GFP/GFP 
58.1f (m)  
Sfpi1 GFP/GFP     
61.2g (m)     
Sfpi1 GFP/+ 
52.1f (m) 
Sfpi1 GFP/+      
61.2f (m)     
Sfpi1 GFP/+ 
 51.1c (m)  
Sfpi1 GFP/+ 
61.3d (m)    
Sfpi1 GFP/+ 
62.2d (m)    
Sfpi1 GFP/+ 
57.3b (f) 
Sfpi1 GFP/GFP       
GFP+  geo 
mean 13/35/57a 130 80 78 24 28 22 50 31 37 
GFP % 0/49/68a 92 89 88 1 2 9 85 79 74 
% immature 
forms/blasts   64 55 45 61 24 59 36 34 23 
Sfpi1 copy 
loss by FISH   Yes  Not done Yes Not done Yes Not done Not done No  Not done 
Gr-1 50 74 22 46 29 14 49 42 66 51 
Mac-1 44 59 1 50 1 6 13 41 29 51 
CD31 58 96 92 90 86 92 65 79 46 80 
Ly6C 53 97 75 89 77 90 87 86 79 1 
Sca-1 4 7 4 2 3 0 10 5 14 65 
c-Kit 29 78 57 52 82 61 56 64 42 41 
CD3 1 0 1 1 0 0 3 1 0 3 
B220 26 8 3 2 3 2 4 6 31 77 
CD34 0 1 0 0 0 0 1 0 0 0 
CD38 52 0 3 4 0 1 8 8 15 81 
Flt3 3 0 0 3 0 0 7 0 9 1 
VCAM-1 29 58 42 59 53 48 64 45 11 41 
Thy-1  7 32 2 2 7 2 23 4 7 33 
FcγRIII/II  80 96 91 89 85 92 84 77 92 77 
Table 3.3.3. Surface marker expression of rAML cases.  
The cases are grouped according to point mutation status. Apart from the geometric mean, which is based on statistics from Cellquest, the 
numbers refer to percentages. a: The numbers refer to CBA/H WT/ CBA/H Sfpi1 GFP/+/ CBA/H Sfpi1 GFP/GFP mice respectively. Male mice have 
(m) after the case name and the female mouse (f).
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In summary, from just looking at the surface marker expression, most rAML cases 
seemed to be leukaemias of a granulocytic type and two cases seemed to be 
biphenotypic. Interestingly compared to the other cases, the female mouse (57.3b) had 
the surface marker phenotype Sca-1hi CD38hi Ly6C-/lo phenotype. Otherwise, the 
immature forms/blasts expressed markers for immature cells, particularly of myeloid 
progenitors. To complement the analysis blood smears would need to be looked at. 
 
3.3.5 PU.1 point mutation status 
    The level of PU.1 protein has been found to be important to lineage commitment of 
bone marrow cells and also for the induction of AML (Rosenbauer et al., 2004; Dakic 
et al., 2007). Point mutations have been described in the exon encoding the DNA 
binding domain of the PU.1 protein in mouse rAML and it is believed that these point 
mutation affects the functionality of PU.1 as a transcription factor (Cook et al., 2004; 
Suraweera et al., 2005; Hirouchi et al., 2008). Analysis of the point mutation status of 
the Sfpi1 gene in rAMLs, would allow investigation of the impact of the specific 
mutations on the development of rAML immature forms/blasts. DNA was extracted 
from the leukaemic spleen cells of the 9 rAMLs used for cell surface marker analysis. 
After DNA extraction, PCR reactions were set up using primers specific for exon 5 of 
Sfpi1which encodes the DNA binding domain of the PU.1 protein. The amplified 
PCR products were sequenced and then after in silico conversion to protein sequence 
analysed for point mutations in the DNA binding domain (Figure 3.3.5). According to 
the results, three cases (58.2c, 58.1f and 61.2g) had a point mutation that led to an 
Arginine (R) to Histidine (H) substitution (R235H), two cases (52.1f and 61.2f) had 
an R to Cysteine (C) (R235C) substitution and four cases had no point 
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Figure 3.3.5. Example of point mutation in exon 5 of the Sfpi1 gene.  
DNA was extracted from the spleen cells of rAML cases and exon 5 of the Sfpi1 gene 
was amplified by PCR. The PCR product was then sent for sequencing at the 
sequencing facility at University of Oxford. The sequencing file was then aligned and 
analysed using the 4Peaks software. A. Example of a DNA sequence with a CAC 
point mutation (compared the to normal CGC sequence) resulting in an R to H amino 
acid replacement. B. The 4Peaks analysis software used Basic Logical Alignment 
Search Tool (BLAST) at the website of the National Center for Biotechnology 
Information (NCBI) to align the protein sequences. This example, the same sequence 
as used in A, shows the amino acid replacement of residue R235 to a Histidine 
residue (red, top sequence) compared to the reference sequence (blue, bottom 
sequence). 
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mutation, wild type (Table 3.3.3). A small number of R to Serine (R235S) 
substitutions have also been observed previously varying from 3-19%, but the R235S 
variant was not found in the samples analysed here. The occurrence of point 
mutations in the current rAML cases is 5/9 or 44%. Since all cases have not had their 
Sfpi1 deletion status confirmed, it is difficult to compare directly with previously 
published data. Other reported cases of R235 point mutations are 87 % (Cook et al., 
2004), 67 % (Suraweera et al., 2005) and 74 % (Hirouchi et al., 2008) of rAML 
carrying Sfpi1 copy deletions. No cases have been observed with a point mutation but 
no Sfpi1 deletion in these publications. Therefore it is most plausible that all Sfpi1 
mutants are also carrying Sfpi1 copy deletions. The R235H substitution is not usually 
as commonly found (16-19 %) (Suraweera et al., 2005, Hirouchi et al., 2008) and in 
these rAML cases it was more common than the R235C substitution, which is usually 
the most frequent type (49-73 %).  
 
3.3.6 The gene expression of Sfpi1 in cases of rAML 
    A further factor that could affect the activity of the protein is the expression of the 
gene Sfpi1. The transcriptional activity of the gene (mRNA level) will to a degree 
affect the amount of protein that is present and further influence the development and 
lineage commitment of myeloid cells. Since not all cases of rAML have a point 
mutation, other factors such as the expression of the gene could be important for 
progression of the disease. RNA was extracted from the leukaemic spleen material of 
the rAML cases used for point mutation analysis above. The level of mRNA 
transcript was then assessed by multiplex-quantitative PCR. 
   All cases with a point mutation had no change or a slight increase in the Sfpi1 
expression compared to bone marrow cells from control mice (Figure 3.3.6, blue and 
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red bars). The point mutation does not therefore influence the level of Sfpi1 mRNA. 
Interestingly, cases with a wild type Sfpi1 allele (Figure 3.3.6 green bars) showed a 
clear reduction in the expression of the gene. A reduction of the Sfpi1 gene to 
approximately 20% of normal level has previously been shown to lead to AML 
(Rosenbauer et al., 2004), as well as complete abrogation of Sfpi1 expression (Metcalf 
et al., 2006). The progression to rAML in these cases is potentially due to reduction 
of the gene expression at the mRNA level. In the rAML cases where a point mutation 
is present in the DNA binding domain, a defect in binding of the transcription factor 
to its target genes is a likely cause of dysregulation of the gene expression that could 
lead to leukaemia. It is also known that Sfpi1 autoregulation through an upstream 
regulatory element is needed for normal expression of the gene (Okuno et al., 2005). 
In all cases where no point mutation could be found the expression of Sfpi1 was 
reduced compared to in normal bone marrow. Repression of the expression of Sfpi1 
has previously been found to be due to mutated upstream regulatory elements in cases 
of human AML (Bonadies et al., 2010). Epigenetic modifications of gene expression 
through methylation of CpG dinucleotides (Das and Singal, 2004) or modifications of 
histones (Cheung et al., 2011) are further mechanisms for silencing or reduction of 
Sfpi1 gene expression in rAML that could be investigated by further work.  
 
3.3.7 Investigation of potential Flt3-ITD mutations 
    The internal tandem duplication of part of the gene Flt3 is a common mutation in 
human AML (Kiyoi et al., 1998; Meshinchi and Appelbaum, 2009). The mutation 
causes duplication of the juxtamembrane domain of the protein and leads to
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Figure 3.3.6. The Sfpi1 expression in rAML cases. 
 RNA was extracted from spleen of suspected rAML cases and the mRNA expression 
analysed by multiplex-quantitative PCR. Samples were run in triplicate and Ct values 
were first normalised to the reference gene HPRT1 and converted to transcript 
quantity using a standard curve. The mRNA expression is shown normalised to the 
expression of total bone marrow from control mice. The cases are grouped according 
to the point mutation status. Blue: R235H substitution. Red: R235C substitution. 
Green: Wild type Sfpi1 allele. The case names are shown above or below each bar on 
the chart. The results are from one experiment. 
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constitutive activation of the receptor (Meshinchi and Appelbaum, 2009). The Flt3-
ITD has recently been discovered in rAML cases in the mouse model used for this 
project (Finnon et al., 2011 submitted). Furthermore, the cases carrying the Flt3-ITD 
mutation showed an inverse relationship between the expression of Sfpi1 and Flt3 
(Finnon et al, 2011 submitted). The exact cause for this is not known. To investigate 
whether the reduction in Sfpi1 expression in rAML cases with no amino acid 
substitution was related to the presence of Flt3-ITD mutations, DNA from the 9 cases 
were extracted from leukaemic spleen cells and analysed by PCR. Primers for 
detection of ITDs in exon 14 and 15 of Flt3 were used for detecting any alterations. A 
333 bp band in size is expected for wild type alleles and where Flt3-ITDs are present 
larger products would be detected as additional bands on the gel.  
    In these cases shown here, the band size expected for the wild type allele was 
detected and no Flt3-ITDs were present (Figure 3.3.7). It can therefore be concluded 
that the reduction in Sfpi1 expression in the cases without a point mutation is not  
related to the presence of Flt3-ITDs.  
 
3.3.8 Conclusions 
    The surface marker phenotypes of the rAMLs studied here does not seem to be 
dependent on the type of point mutation in the PU.1 protein and is somewhat 
heterogeneous. For example, most rAML cases expressed Mac-1 and Gr-1, but the 
cases 58.1f, 52.1f and 61.2f showed a low Mac-1 expression and a lowered Gr-1 
expression compared to the other cases. The case 58.2c, 51.1c and 57.3b had higher 
Thy-1 expression compared to other cases, but otherwise no particular similarities that 
would group them together.  
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Figure 3.3.7. PCR analysis of the presence of Flt3-ITDs.  
DNA was extracted from the spleen cells of a control CBA/H Sfpi1 GFP/GFP mouse and 
spleen cells from the 9 cases described above. A PCR reaction was set up with 
primers that amplify exon 14 and 15 of the Flt3 gene. Wild type alleles give product 
of 333 bp whereas a presence of Flt3-ITDs would show up as additional larger 
products when present. Lane 1: 1 kB ladder. Lane 2: CBA/H Sfpi1 GFP/GFP control. 
Lane 3: 61.3d*. Lane 4: 61.2g. Lane 5: 62.2d*. Lane 6: 52.1f. Lane 7: 61.2f. Lane 
8: 51.1c*. Lane 9: 58.2c. Lane 10: 58.1f. Lane 11: 57.3b*. Lane 12: H2O blank. 
Lane 13: 1 kB ladder. Samples with an asterisk (*) denote samples with no point 
mutation. 
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Likewise the level of GFP expression as assessed by flow cytometry is independent of 
the type of point mutation. However, in cases where a point mutation is present the 
level of Sfpi1 gene expression as assessed by MQ-RT-PCR is slightly increased or the 
same as innormal BMCs. Therefore, since the gene expression is similar to the normal 
level in BMCs from control mice, but the amount of protein is high, as assessed by 
the high level of the GFP expression (eg 58.2c and 58.1f in Table 3.3.3) the function 
of the PU.1 protein is likely to be compromised, specifically since the point mutation 
is situated in the DNA binding domain (Cook et al,. 2005; Suraweera et al., 2005). 
Whether the actual binding properties of the protein to DNA target sequences, the 
conformation of the protein has changed, or both, is not known and further research 
would need to be done to investigate. This could for example be done by a gel 
retardation assay.  
    In the cases presented here, none has an Flt3-ITD mutation. Cases with Flt3-ITDs 
and no point mutations or partial deletion of chromosome 2 have been found to have a 
reduced Sfpi1 expression (Finnon et al., 2011 submitted). The exact relationship 
between the genes is not yet established, however recent results show that Sfpi1 can 
directly regulate Flt3 expression (Carotta et al., 2010).  
    Since the reduction in Sfpi1 gene expression in some cases is not dependent on a 
deletion event, other mechanisms of repression of the gene are implied such as 
mutations in upstream regulatory elements and epigenetic modifications (Das and 
Singal, 2004; Bonadies et al., 2010; Cheung and So, 2011). Overall, the in vivo results 
presented here confirm data from cell line studies (Brown et al., 2011) where the 
point mutation type did not drive the expression of the surface marker phenotype. 
However, according to the results from the cell lines (Brown et al., 20011) the type of 
point mutation affected the mRNA expression of Sfpi1. In the current results the 
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presence of any point mutation was associated with unchanged or slightly increased 
Sfpi1 mRNA expression compared to cases of with no point mutation, where the 
mRNA levels were reduced.  Further work would need to be done to investigate the 
expression of PU.1 target genes in these primary rAML cases and also investigate 
cases with different types of point mutations (eg R235S substitution) that were not 
represented in the cases presented here. The transcription factor PU.1 has already 
been confirmed to regulate the expression of genes such as c-myc (Hirouchi et al., 
2008), c-fms (Krysinka et al., 2007), c-Jun, GATA-2 and Flt3 (Brown et al, 2011). 
Other genes where a PU.1 promoter binding sequence is present are for example c-
myb, Csf3 (G-CSF) and Csf2 (GM-CSF) (Szcymczyna and Arrowsmith, 2000).
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Chapter 4. General discussion 
4.1 Introduction 
 
    The aim of the current work was to investigate the consequences copy loss of the 
gene Sfpi1, leading to a lack of function or loss of function of PU.1, in relation to 
early post-irradiation events, to define a target cell population for the initial copy loss 
and relate these to the manifestation of rAML. This was achieved using a transgenic 
CBA/H mouse model that expresses a GFP reporter gene under the transcriptional 
control of the Sfpi1 promoter (Nutt et al., 2005). 
    A difference in the cell survival was found in the Lin- of immature bone marrow 
progenitor cells between the CBA/H strain and the C57BL/6 strain, where the former 
is susceptible to rAML and the latter is not. No difference between the strains could 
be seen in the Lin- c-kit+ fraction of immature bone marrow progenitor cells.  
    The use of a transplantation model to investigate the target cell of the initial Sfpi1 
copy loss was found to have potential, but need further refinement to ensure a higher 
frequency of long-term reconstitution of the irradiated cells. Without long-term 
reconstitution with irradiated cells, there will be a very low chance of rAML 
developing in transplanted animals. 
    Using the transgenic mouse model expressing GFP under the control of the Sfpi1 
promoter, it was for the first time possible to use flow cytometry to detect a copy loss 
of Sfpi1 in live cells. The copy loss can also alternatively be detected using a 
genotyping PCR when Sfpi1 GFP/+ mice are used. 
    The analysis of Sfpi1 gene expression in rAML cases suggests two different ways 
the gene Sfpi1 can be involved in the induction of rAML. One mechanism is through 
the loss of PU.1 transcription factor function due to a point mutation in the DNA 
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sequence coding for the DNA binding domain of the protein, or the reduction of Sfpi1 
expression due to currently unknown reasons. 
    The work in this thesis therefore presents novel ways of studying early events in 
rAML induction and of the analysis of the leukaemic cells in the CBA/H mouse 
through the use of the transgenic mouse model. Furthermore the work gave new 
insights into the mechanisms of leukaemogenesis in the model. 
 
4.2 Differences in cell survival after exposure to ionising radiation between 
CBA/H and C57BL/6 mice when using in vitro colony forming assays 
    In vitro colony forming unit cells assays were performed to determine if there was 
a difference in survival in different populations of immature BMCs between the two 
strains CBA/H and C57BL/6 (Figure 3.1.7 A). The results showed a difference in 
survival in Lin- cells, a trend that was also observed, but not as marked, after in vivo 
irradiation (Figure 3.1.10). The difference in cell survival was seen in the Lin- 
fraction, but not in the Lin- c-Kit+ fraction (Figure 3.1.7 B). The Lin- c-Kit+ fraction is 
more selected for committed myeloid progenitors (Iwasaki and Akashi, 2007b) 
whereas the Lin- fraction also contains HSCs and multi-potent progenitors (Spangrude 
et al. 1988; Iwasaki and Akashi 2007b). It has previously been reported that cells in 
the C57BL/6 strain undergo apoptosis at a higher rate than in the CBA/H strain 
(Lindsay et al., 2007). The relevance to rAML induction is that immature bone 
marrow cells in CBA/H strain carrying copy deletions of Sfpi1 might therefore have a 
higher chance of surviving and through secondary events become leukaemic, 
compared to the C57BL/6 strain where such cells would undergo apoptosis. The level 
of apoptosis in immature bone marrow cells were not investigated in these sets of 
experiments and would therefore need to be confirmed for this theory to be proven.   
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Recent work found that HSCs, in contrast to myeloid progenitors, use non-
homologous end joining (NHEJ) as a repair mechanism after exposure to ionising 
radiation, which makes HSCs more prone to acquire mutations (Mohrin et al., 2010). 
Together with the results from the cell survival assays, an interesting potential 
explanation for the susceptibility to rAML in the CBA/H strain and the target cell for 
the leukaemic events can be suggested. Due to HSCs being more quiescent and long 
lived than myeloid progenitors, they are more likely to accumulate mutations through 
misrepair of DNA damage through the more error prone process of NHEJ. The gene 
Rbbp8 has been found to be upregulated in the CBA/H strain, but not in the C57BL/6 
strain after exposure to ionising radiation (Darakhshan et al., 2006). The product of 
the gene is the protein CtIP that is involved in NHEJ of DNA double-strand breaks 
(You et al., 2010). More importantly, CtIP has very recently been found to be 
specifically involved in an alternative type of NHEJ that is implicated in the 
formation of chromosome translocations (Zhang and Jasin, 2010). Further 
experiments comparing the activity of CtIP in HSCs and multi-potent progenitors 
between the CBA/H strain and C57BL/6 strain would therefore be interesting to 
perform. For example, in vitro experiments exploring DNA repair capabilities in cells 
from CBA/H and C57BL/6 mice after exposure to ionising radiation. 
    Unpublished results by Dr Munira Kadhim contradicts the findings in this thesis by 
showing a reduction in survival of bone marrow cells from the CBA/H strain 
compared to the C57BL/6 strain after exposure to comparable doses of ionising 
radiation (x-rays) (http://www.osti.gov/bridge/purl.cover.jsp?purl=/973040-0nILG5/). 
Notably though, the experiments used unfractionated BMCs. Since the experiments 
presented in this thesis show the importance of what cell population is exposed, this 
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could explain the difference in results between these results and the experiments by 
Kadhim.   
    Flow cytometric analysis of pooled colonies grown in semi-solid media from Lin- 
cells showed a majority of the colonies consisted of cells committed to the myeloid 
lineage, as seen by their high expression of Mac-1 and Gr-1 (Figure 3.1.14 and 
3.1.15). A proportion of cells expressed the marker c-Kit and could be more immature 
cells although further analysis using a combination of antibodies is needed to 
determine the stage of development of these cells. Interestingly, cultures from CBA/H 
mice had about twice the frequency of c-Kit positive cells compared to cultures from 
C57BL/6 mice (Figure 3.1.12). The difference was not specific to irradiated cultures 
so the effect is not caused by exposure to irradiation as such. These results further 
emphasised there might be a difference between the CBA/H and C57BL/6 strains 
with regards to in an immature subpopulations of BMCs, although the phenotype of 
the sensitive population has not been fully characterised in these experiments so far. 
Work by Jawad et al. (Jawad et al., 2007) suggested that the target cell frequency 
could affect the susceptibility to rAML. Further work by the same group (Jawad et al., 
2008) concluded that the number of LSK cells in bone marrow with a high expression 
of Sca-1 and c-Kit were almost 4 times higher, whereas the difference between Lin- c-
Kit+ cells (myeloid progenitors) was not significant. The difference in c-Kit+ cells in 
the cultures established from Lin- cells could therefore due to a difference in the 
potential of Lin- cells to differentiate between the strains rather than the difference in 
the number of c-Kit+ cells within the Lin- fraction that were plated. The difference in 
cell survival after exposure to ionising radiation was seen in the Lin- population and 
not the more defined Lin- c-Kit+ fraction, which would contain more myeloid 
progenitors. This suggests that the myeloid progenitor component of the Lin- 
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population was not the major contributor to the difference in survival. Further 
investigation of the frequency of HSCs and myeloid progenitors and the possibility of 
a link to rAML susceptibility would therefore be interesting to pursue. 
 
4.3 Developing a transplant model for determining the target cell for the initial 
Sfpi1 copy deletion using FACS-sorted LSK cells 
    The next part of the project aimed to use a novel approach to isolate target cells 
carrying radiation-induced partial deletions of chromosome 2 and to detect copy loss 
of the gene Sfpi1. Two different transplantation assays were used, one long-term and 
one short-term. In the long-term assay, the goal was to identify and sort a population 
enriched for HSCs with partial deletions of chromosome 2 and then inject them into 
myeloablated hosts. It was anticipated that these stem cells would then form progeny 
that also carried the deletion and form a pool of pre-leukaemic stem cells (LSCs). By 
sorting the LSK population, which is enriched for HSCs, and selecting cells in this 
population that is GFP-/lo it was expected to be possible to obtain cells carrying a 
chromosome deletion with copy loss of Sfpi1. By transplanting these sorted cells at 
higher numbers than there normally are cells with Sfpi1 copy loss in the bone marrow, 
it was expected the hosts might develop rAML at a higher frequency and shorter 
latency.  
     There was some success in reconstituting the host hematopoietic system with 
unirradiated GFP + LSK cells, whereas unirradiated GFP -/lo LSK cells did not manage 
to show long-term reconstitution. Similarly, one mouse was reconstituted with in vivo 
irradiated GFP + LSK cells, but no mice that received in vivo irradiated GFP -/lo LSK 
cells. The low reconstitution frequency of irradiated LSK cells was similarly seen by 
Otsuka and colleagues (Otsuka et al., 2010). Their results also how that the capacity 
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for unirradiated LSK cells to maintain reconstitution over a period up to 9 months is 
relatively low (approximately 15 % in Otsuka et al., 2010), showing that a more 
defined phenotype than LSK than the one used in the experiments presented in this 
thesis might be needed for maintaining reconstitution over the time period required 
for rAML induction. Successful long-term reconstitution has been found 8-10 months 
after transplant with Lin- Sca-1+ Thy-1.1lo Rhodamine-123lo cells (Spangrude et al., 
1995) and up to 9 months with LSK Thy1.1lo Flk2- CD150+ cells (Papathanasiou et 
al., 2009). Due to a lack of time, only the LSK phenotype was injected in the work 
presented in this thesis.  
    Furthermore, Marusyk et al. (Marusyk et al., 2009) found that unirradiated total 
BMCs cells can outcompete irradiated BMCs in a transplantation model even when 
the ratio of irradiated: unirradiated cells is 9:1 and suggested this effect is caused by 
reactive oxygen species (ROS). Their conclusion was based on the fact that plasma 
levels of markers of oxidative stress were found up to three weeks after radiation 
exposure. Furthermore, competitive repopulation assays using scavengers for ROS 
showed improved competition compared to mice not treated with ROS scavengers.  
Wang et al., 2006 furthermore found that irradiated HSCs had increased expression of 
genes related to senescence (Wang et al., 2006). The failure of LSK cells to 
reconstitute after exposure to ionising radiation could therefore be a combination of 
these factors. That is, LSK cells have a reduced fitness due to damage caused by ROS 
and cannot therefore compete with the helper cells and some LSK cells are 
furthermore potentially either senescent at the time of transplant or become senescent 
after transplant. However, the level of senescence or the presence of ROS in LSK 
cells was not analysed at the time of cell sorting. Cells that were sorted as GFP -/lo 
failed to graft whereas successfully reconstituted mice had received GFP+ donor cells. 
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As was seen in the results (Figure 3.2.9), the cells sorted as GFP -/lo expressed GFP at 
similar levels to cells sorted as GFP + after 9 days in culture. Since the cells grew in 
culture, the majority of cells could not have been senescent at the time of sorting, but 
more likely senescence occurred some time after transplant. Further investigation is 
therefore needed to determine what the negative/low GFP expression actually 
represents. Since the Sfpi1 GFP/GFP mice have not been used for analysing the Sfpi1 
expression after exposure to ionising radiation before, it is not possible to compare 
with previous research.  
    The reduction of fitness of HSCs after irradiation exposure is long lasting (Marusyk 
et al., 2009; 2010), but it is possible that choosing a time-point for isolating LSK 
cells, likely several months after radiation exposure, might make the GFP expression 
a more robust indicator of Sfpi1 loss. The expression of Sfpi1 is intimately linked to 
haematopoiesis and, after exposure to radiation, the haematopoietic system is in a 
state of rapid renewal. Several different levels of GFP expression from different cell 
types within the LSK fraction may mask the small shifts in the level of GFP 
expression associated with Sfpi1 copy number, when sorting the cells by FACS. 
Therefore, to refine the phenotype of the sorted population might make it easier to 
sort cells as GFP-/lo or GFP+. Nutt et al. (Nutt et al., 2005), using the same model as 
was used in this work, isolated various immature bone marrow progenitor cells 
according to defined surface marker phenotypes. The GFP expression was uniform in 
most populations, although they did not define HSCs as more than LSK IL7Rα-. 
Another research group (Back et al., 2004; Back et al., 2005) used GFP as a reporter 
gene for Sfpi1 expression, but the modification was initially derived using a slightly 
different targeting vector. In their results, it can be seen that the GFP expression in 
LSK CD34- cells (defined as long-term reconstituting HSCs) has quite a broad 
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distribution of the GFP expression that would be difficult to sort cells as GFP+ or 
GFP-/lo and obtain a pure fraction. Their results confirms the potential difficulties of 
using the GFP expression linked to Sfpi1 expression for sorting according to changes 
on GFP fluorescence intensity as attempted in this thesis. The surface marker 
phenotype chosen for HSCs could therefore be crucial and need significant 
optimisation to achieve several objectives at once, ie. a surface marker phenotype 
representing a cell type with long-term reconstitution potential, a narrow distribution 
of GFP expression that makes it possible to sort a pure population of GFP+ or GFP-/lo 
cells and the actual cell number needed for subsequent transplantation and long-term 
reconstitution. 
    In previous studies, an experiment was performed where total BMCs from mice 
exposed to a total body dose of 3 Gy of ionising radiation were isolated 40 weeks 
after exposure and transplanted into sublethally (4.5 Gy) irradiated hosts (Riches, 
1995). In contrast to control mice receiving unirradiated bone marrow, 40-60% of 
mice receiving irradiated BMCs developed rAML within 20 weeks. This is compared 
to a frequency of 25 % when mice were irradiated with a normal leukaemogenic dose 
(3 Gy) according to standard protocol without transplantation of irradiated cells. 
Interestingly, when total BMCs were isolated and transplanted at earlier time-points 
(1, 4 and 7 months after irradiation exposure) very low incidences of leukaemia were 
seen. These experiments show it is possible to transplant pre-leukaemic cells that will 
later become leukamic. The time-point of isolating the cells in these experiments 
coincides with the time where the clonal expansion of cell with chromosome 2 
deetions was seen (12-15 months post exposure) in CBA/H mice exposed to 3 Gy of 
ionising radiation (Bouffler et al. 1997). Further work is therefore necessary for 
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finding the best time-point for isolating and transplanting irradiated LSK GFP -/lo or 
GFP + cells for a successful repopulation and further development to rAML. 
 
4.4 Developing a transplant model for determining the target cell for the initial 
Sfpi1 copy deletion using cultured, FACS-sorted LSK cells 
    No mice with cultured LSK cells were found to have been reconstituted with host 
cells. In contrast, mice transplanted with Lin- Sca-1+ CD34- cells cultured for 10 days 
showed a similar average long-term reconstitution to mice transplanted with cells of 
the same phenotype but injected fresh without culturing. The level of reconstitution 
was monitored for a total of 52 weeks after transplantation (Miller et al., 1997). The 
main difference between the experiments in his thesis is the phenotype of the input 
cells. Potentially, similarly to freshly transplanted LSK cells, the phenotype does not 
contain enough HSCs to sustain reconstitution over the time period required for the 
experiments. Cultured LSK cells have shown long-term reconstitution up to a period 
of 4 months (Audet et al., 2001). In both these publications, the same concentrations 
of cytokines were used. The cell cultures in this thesis were expanded for 9 days, 
compared to 5 or 10 days (Miller et al., 1997) or 10 days (Audet et al., 2001). The 
cells in the previously cited publications were cultured at 33 °C. However, other 
investigators (Brown et al. 1997) have used the same temperature (37 °C) as in the 
experiments described here and succeeded in maintaining reconstitution for 
approximately 6 months. The total time for the expansion is therefore relatively 
similar, but the exact same culture time should be tested to see how it affects the rate 
of long-term reconstitution. Similarly, the lower temperature could be tested, but due 
to a lack of available incubators this was not possible to test for this project. Even 
though cells were cultured under normal oxygen conditions, there are some 
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suggestions that culturing under low oxygen conditions could be beneficial (Csete 
2005). The low oxygen conditions would reduce oxidative stress to the cells, which 
could for example lead to senescence or loss of fitness due to DNA damage. The 
reason for cultured cells failing to reconstitute hosts, apart from due to radiation 
exposure and culture the conditions, could be a reduced fitness caused by a period of 
culture. As noted above, it is possible that senescence plays a part. LSK cells in 
culture divide at a very high rate and HSCs can undergo a limited number of divisions 
before they become exhausted and senescent (Orford and Scadden, 2008). Therefore, 
the graft failure could, in this case, be due to the fact that HSCs become senescent 
after transplant although they initially might have contributed to some level of 
reconstitution. The possibility of partial short-term reconstitution can be investigated 
by tail vein bleeding the transplanted animals at an earlier time point after the 
procedure as well as at 9-12 months post transplant. Additionally, it was noted that 8-
9 % of cells in some cultures were found to have an unidentified chromosome 
aberration or chromosomes that had not separated properly (Figure 3.2.13 and Table 
3.2.13), and this could affect the ability of the cells to survive long-term. Short-term 
cultures have previously shown to increase the frequency of chromosome aberrations 
in cells and also transplantation of the cultured cells. Furthermore, the more cells were 
stimulated to grow and divide, the more aberrations were seen (Bouffler et al., 2001). 
     Finally, lack of reconstitution could be due to cells with long-term reconstituting 
activity failing to home to the bone marrow (Szilvassy et al., 1999). Changes in 
surface marker expression on cultured HSCs have been described, although no 
difference in the ability to reconstitute host animals short-term was observed (Zhang 
and Lodish, 2005). In all, further work is needed to demonstrate that cultured cells can 
be used for reconstituting host animals. In the work described here the LSK cells 
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injected on the same day as they were isolated so far has shown more promise. 
However, further optimisation of this protocol is needed to achieve reconstitution at 
high frequency in host animals. 
 
4.5 Cytogenetic studies on cultured LSK cells to detect Sfpi1 copy loss 
     Retrospective cytogenetic studies on the cultured LSK cells sorted as GFP + or 
GFP –/lo allowed estimation of the frequency of partial chromosome 2 deletions and 
Sfpi1 copy loss in the injected cells. This further made it possible to investigate any 
differences between in vivo and in vitro exposure to ionising radiation in relation to 
the frequency of partial deletions of chromosome 2. Deletions could be detected in in 
vivo irradiated LSK cells sorted as GFP + (12 %), but not in those sorted as GFP -/lo, 
which was unexpected. A small number of deletions (2 out of 30, 7 %) could be seen 
in in vitro irradiated cells that after 9 days in culture were sorted as GFP -/lo. However, 
since the background rate for deletions in unirradiated control cells was 1 out of 67 
(1.5 %) cells, the frequency of deletions for the in vitro irradiated cells needs more 
investigation to be confirmed. These results are the first to show copy loss of Sfpi1 in 
LSK cells since previous research of copy loss at early time points after exposure to 
ionising radiation used total BMCs (Bouffler et al., 1997; Peng et al., 2009). The 
work should therefore continue to look at more phenotypically defined populations of 
HSCs and bone marrow progenitor cells to investigate potential differences in the 
frequency of Sfpi1 copy loss.  
    The results overall suggests that some cells with chromosome 2 interstitial 
deletions were injected into host animals. However, the results also show that with 
regards to cell sorting, the time point chosen (7-9 days after irradiation), the GFP 
expression is not always indicative of retained Sfpi1 alleles or deletion events. 
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Referring back to a previous point, the time at which HSCs should be sorted might 
need to be changed. It is possible that a better time would be when the haematopoietic 
system has normalised after the exposure to ionising radiation, approximately 1-2 
months depending on the dose received. 
    The culturing of irradiated and unirradiated control cells also allowed comparison 
of LSK cells and c-Kit+ progenitor cell frequency after expansion. Interestingly, the 
irradiated cells that were sorted as GFP + seemed to have less Sca-1+ c-Kit+ cells 
compared to the cells sorted as GFP -/lo (Figure 3.2.9 and 3.2.10). Since cultured cells 
from 3 Gy in vivo irradiated mice after the 9 day had more Sca-1+ c-Kit+ cells than 
cells in the GFP -/lo fraction from the same mice it is tempting to make a link between 
the presence of cells with Sfpi1 deletions and a reduction in Sca+ c-Kit+ cells since the 
GFP + cells had a higher frequency of Sfpi1 deletions (Table 3.2.7). However, the 
cytogenetic analysis could only be done on some of the cultures due to difficulties in 
obtaining enough cells from the experiments. The results are only from two 
experiments and therefore more work is needed before a definite conclusion of the 
results can be made.  
 
 
4.6 The CFU-S12 assay 
    The short-term colony forming unit-spleen assay at day 12 (CFU-S 12) was used to 
try and identify progeny of immature BMCs with partial chromosome 2 deletions and 
Sfpi1 copy loss through the use of flow cytometry. The overall result by the flow 
cytometric analysis of individual colonies did not detect any significant reduction in 
the geometric mean of the GFP expression levels. The total number of colonies were 
12 derived from BMCs of in vivo irradiated and 25 (total of 2 experiments) derived 
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from in vitro irradiated BMCs. All colonies were GFP positive by FACS analysis, 
meaning that no endogenous colonies formed from the WT host animals. The donor 
cells were all derived from CBA Sfpi1 GFP/GFP animals and the expected outcome was 
for some colonies to show a reduction in the geometric mean of the GFP expression 
level, which would indicate a loss of one Sfpi1 allele. For an example of a reduction 
in the level of GFP expression, see Figure 3.1.2 or 3.1.9. Based on the number of 
colonies analysed, at least one or two colonies should, on average, have a loss since 
previous work showed that the level of Sfpi1 deletions was approximately 10-15 % 
when analysed 7-30 days post irradiation (Peng et al., 2009). Although how well the 
data from total BMCs can be applied to colony forming cells is not clear. Previous 
experiments on CFU-S 8 and CFU-S 11 showed copy loss of Sfpi1 in 1/42 colonies 
and 0/82 colonies (assessed by PCR) when total BMCs were used as donor cells 
(Rigat et al., 2001). The number of colonies screened in the experiments presented 
here might therefore be statistically too low to detect Sfpi1 copy loss. To achieve a 
higher number of colonies with Sfpi1 copy loss, potentially using Lin- cells or other 
immature bone marrow cells could increase frequency. This is based on the 
assumption that the initial copy loss is concentrated in an immature cell population. 
However, it is currently not known whether the initial deletion events are 
concentrated in cell populations particularly sensitive to ionising radiation or whether 
the copy loss events are uniformly distributed in all BMCs.  
As was seen in the cases of rAML, in Sfpi1 GFP/+ mice, a partial chromosome 2 
deletion can be detected on a histogram plot by flow cytometry or by genotyping 
using PCR (Figure 3.3.2). Therefore, using Sfpi1 GFP/+ mice it might be possible to 
detect a deletion event, whereas using the Sfpi1 GFP/GFP mice it is not possible even by 
PCR. For cell sorting of LSK cells, the GFP expression does not correlate with 
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deletion events since Sfpi1 is involved in haematopoiesis, particularly when a rapid 
expansion and differentiation of cells are occurring. In the rAML cases it was possible 
to detect the deletion of Sfpi1 as an almost complete reduction of GFP expression is 
seen, if the deletion event has occurred on the allele carrying the GFP construct. 
Therefore, the most likely way of detecting deletion events in isolated spleen colonies 
is probably a combination of flow cytometry and PCR in Sfpi1 GFP/+ mice. That is, 
colonies derived from cells of Sfpi1 GFP/+mice with a deletion will appear GFP -/lo by 
FACS if there is a deletion of the Sfpi1 allele carrying the GFP construct. If there is a 
deletion of the WT allele, the loss could still be detected by the genotyping PCR, 
although not by FACS. The data from the genotyping PCR of the leukaemia cases 
suggests that this approach is promising. Furthermore, FISH analysis of the remaining 
cases would need to be done to completely establish the relationship between deletion 
events, GFP expression assessed by flow cytometry and the size of PCR products.  
 
4.7 Flow cytometry analysis of rAML cases 
    Overall, it was demonstrated that flow cytometry can be used to infer partial 
chromosome 2 deletions in live blast cells in this mouse model, but the analysis has to 
be done when either the BMCs are in a steady-state of haematopoiesis and not 
expected to coincide with stress, such as exposure to irradiation, shortly before the 
analysis. While a mouse with leukaemia obviously cannot be said to have a 
haematopoietic system in a steady state, there is some consistency in the expression of 
Sfpi1. The leukaemic blasts have a relatively homogenous expression of Sfpi1, as 
evidenced by very high percentage of cells that are GFP + (Table 3.3.3). However, it 
should be noticed that if the level of expression of PU.1 is of greater interest, the Sfpi1 
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GFP/GFP mice are easier to use since they will always have at least one copy of the GFP 
construct remaining.  
    The surface marker expression of immature forms/blasts in cases of leukaemia is 
relatively heterogeneous when it comes to the actual levels of expression (Table 
3.3.3). The immature forms/blasts in general had a myeloid or granulocytic phenotype 
although two cases (62.2d and 57.3b) had a biphenotypic phenotype (both non-
lymphocytic and B-lymphocytic surface markers). Even when the cases were grouped 
according to their amino acid substitution at R235, there was no obvious link between 
the type of point mutation and the phenotype of the immature forms/blasts. Therefore, 
even if the point mutation is involved in the triggering of the leukaemic process by 
affecting the function of the PU.1 protein, the type of point mutation does not seem to 
directly affect the surface marker phenotype. Therefore, there is no evidence from 
these results that a specific amino acid replacement drives the development of the 
immature haematopoietic cells to a particular subtype of leukaemia.  
    The common phenotype of the immature forms/blasts is CD31+ Ly6c+ c-Kit+ Sca-
1lo VCAM-1+ FcγRIII/II+ CD3- B220- CD34- CD38lo (Table 3.3.3). In general, the 
expression levels for all these surface markers are high. The differing case is 
particularly 57.3b that has a low expression of CD31 and a high expression of CD38. 
The level of Gr-1 and Mac-1 expression varies depending on whether the leukaemia 
has a more granulocytic or monocytic component. A high expression of both markers 
is typical of a granulocytic leukaemia whereas a low expression of Gr-1 and positivity 
for Mac-1 corresponds to a monocytic leukaemia (Kogan et al., 2002). Both markers 
define the leukaemia as myeloid. Therefore, 7 out of 9 cases of leukaemia presented 
here can be classified as myeloid, whereas two (62.2.d and 57.3b, Table 3.2.2) are 
biphenotypic since they also express the marker B220 as well as myeloid markers 
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(Kogan et al., 2002). The expression of Mac-1 is variable between the cases. When 
the expression of PU.1 has been conditionally deleted, the expression of Mac-1 is 
abrogated (Dakic et al., 2005). Therefore, it is possible that in the rAML cases, the 
level of Mac-1 expression is reflecting the level of functionality of the mutated PU.1 
protein. From analysis of the crystal structure of PU.1 it was suggested that any 
replacement of an amino acid in the critical residue R235 in the DNA binding domain 
would result in loss of DNA binding (Pio et al., 1996). However, the actual ability of 
PU.1 protein in this model of rAML to bind to its target sequence is not known. Since 
some immature forms/blasts expressed Mac-1 and also had a point mutation in the 
DNA sequence encoding the DNA binding domain, resulting in an R235 substitution, 
means that some functionality of the PU.1 protein must have remained at the time the 
samples were analysed by flow cytometry. In a mouse model with conditional 
deletion of PU.1 expression, the expression of Mac-1 disappeared almost completely 
2 weeks after the conditional inactivation, but started to reappear in a low frequency 
at 8 weeks after (Dakic et al., 2005). A similar pattern was seen in a different model 
at 3 weeks and 6 weeks, respectively (Iwasaki et al., 2005). In the model that 
Rosenbauer and colleagues used, where PU.1 expression is suppressed to about 20% 
of normal expression, some expression of Mac-1 was seen (Rosenbauer et al., 2004). 
Low levels of Mac-1 expression therefore mean some functionality of the PU.1 
protein, although at much lower levels than needed for normal expression of Mac-1. 
As the PU.1 protein is expressed in a high proportion of the immature forms/blasts, 
the surface Mac-1 phenotypes observed suggest the transcription factor is present but 
not functional.   
    Sca-1, CD34, CD38 and Thy-1 are other markers associated with HSCs (Spangrude 
et al. 1988; Randall et al. 1996), where HSCs are Sca-1+ and Thy-1 lo. Cells that are in 
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the LSK fraction, CD34- CD38+ and Thy-1lo are considered to be HSCs with long-
term reconstitution ability whereas the cells with the CD34+ CD38- and Thy-1- 
phenotype are multi-potent progenitors (Randall et al., 1996). Most immature 
forms/blasts express Sca-1 and are CD34-. The expression of Thy-1 is in general quite 
low, but was expressed in some cases that were otherwise not completely similar in 
phenotype (eg case 58.2c and 51.1c, Table 3.3.3). The marker cannot therefore be 
considered to be of particular interest for differentiating LSC sub-populations in this 
model. In human leukaemias, Thy-1 is normally not expressed on leukaemic cells 
with reconstitution potential (Blair et al., 1997), but has been implicated in patients 
with a poor survival prognosis (Buccisano et al., 2004).  
    The expression of CD34 and CD38 in immature forms/blast in the presented cases 
was in general negative or low for both markers. However, the two cases of 
biphenotypic leukaemia were both postitive for CD38, which if found in future 
similar cases might be of significance.  
    The expression of Flt3 was in general negative on the immature forms/blasts, but 
two cases had a phenotype with a low expression (cases 51.1c and 62.2d, Table 
3.3.3). As there was no obvious connection between the cases, this expression might 
therefore be of no particular significance for the classification of the leukaemias in 
this model. However, the expression of the Flt3 gene has been found to be 
upregulated in cases where an Flt3-ITD is present (Finnon et al. 2011 submitted for 
publication). The surface marker expression of Flt3 in cases with Flt3-ITDs could 
potentially be more upregulated, however none of the present cases have an Flt3-ITD 
mutation so this cannot be confirmed. 
In summary, the surface marker phenotype is relatively heterogeneous in the nine 
rAMLs studied, but all have the phenotype characteristic of non-lymphocytic 
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leukaemia. The small differences between cases could be due to general abnormalities 
of leukaemic cells. The phenotype of the rAML cases is in agreement with previous 
results from CBA WT rAML cases (Finnon, R. unpublished results). Some further 
results have been reported from the C3H/He mouse model, where the phenotype of 
BMCs from rAML cases generally agree with the results presented in this thesis 
(Hirouchi et al., 2011). The results from Hirouchi and colleagues are reported as 
number of cells in femur, which makes a direct comparison more difficult. However, 
the cells are Gr-1+ and Mac-1+ (low frequency), whereas in CBA/H the results show a 
variable but generally high frequency. This could be due to differences between the 
mouse strains, but without further results from the C3H/He strain it is not possible to 
say.   
The phenotyping could potentially be used to define a LSC phenotype for this model. 
This would be achieved by sorting primary rAML cells or passaged cells according to 
a specific phenotype and then using an in vivo transplantation assays to find which 
phenotype is the most likely in LSCs (Blair et al., 1997; Bonnet and Dick, 1997). For 
this model, a starting point would be to look in the c-Kit+ Sca-1lo CD34- CD38lo 
fraction since in general this seems to be a common phenotype of immature 
haematopoietic cells. The would be done by passaging cells selected for the potential 
phenotypes at limiting dilutions into host animals and comparing the cell numbers 
necessary to induce leukaemia. The phenotype consistently able to induce leukaemia 
with the lowest amount of cells would be the phenotype containing the most LSCs.         
    Hirouchi and colleagues (Hirouchi et al., 2011) very recently reported their 
findings of a CMP-like LSC for the C3H/He model (Lin- Sca-1- c-Kit+ CD34+) and it 
would therefore be interesting by further work confirm this in the CBA/H strain.     
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    An improvement that could be made for further phenotyping work in the model 
would be to combine the analysis of several surface markers in one sample. For 
example, combining Gr-1 and Mac-1 would make it possible to better distinguish the 
proportion of cells the are Gr-1+ only, Mac-1+ only or express both (Gr-1+ Mac-1+). 
Since the flow cytometer (FACS Calibur) used only had 3 channels available for 
analysis, this was not possible and is a limitation of the presented phenotyping results. 
The antibody fluorochromes used for the analysis (PE and PE-Cy5) have emission 
spectra that overlap significantly and therefore the fluorescence compensation was too 
difficult with those conjugates and would lead to unreliable results. However, a flow 
cytometer with more channels available would allow for this type of analysis and 
would be possible in the future since multiparametric. 
 
 
4.8 Analysis of the point mutation in the sequence for the DNA binding domain 
of PU.1 in rAML cases 
    The point mutations found in the DNA sequence encoding the DNA binding 
domain of PU.1 (at R235) in the leukaemia cases were observed at different 
frequency compared to previously published results (Cook et al., 2004; Suraweera et 
al., 2005; Hirouchi et al., 2008). The R235H substitution was the most frequent in the 
present set (3/9; 33 % of cases, Table 3.3.3) and has previously been reported in 
around 2-3 % of cases (Suraweera et al., 2005; Hirouchi et al., 2008) or 18 % of cases 
(Cook et al., 2004). There was furthermore no R235S substitution seen in the samples 
presented here, previously seen to e present in 16-19 % of cases. The current data set 
is from a very small sample of rAMLs while prior studies were based on a minimum 
of 30 cases, and it is therefore possible that this has affected the results. Another 
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difference is the strains used for the induction of rAML. The strains used were F1 
hybrids (CBA/H X C57BL/6 and C3H/He X C57BL/Lia) and C3H/He (Suraweera et 
al., 2005), F1 hybrids (CBA X SJL) and cell lines from the same mice (Cook et al., 
2004) and C3H/He where some samples were from transplanted AMLs (Hirouchi et 
al., 2008). While data from cell lines could be affected by some types of point 
mutations adapting more readily to culture (Brown et al., 2011), the remaining 
primary rAML differences seem to be strain dependent between CBA/H and C3H/He. 
The fact that the mice used in the current study originated from a (C57BL/6 Sfpi1 
GFP/GFP X CBA WT) cross should not affect the results since the mice used for the 
induction experiment were used at minimum backcross F10 where C57BL/6 DNA 
would be a very small fraction of the genome compared to the 50% as in the F1 
hybrids.   
 
4.9 The Sfpi1 gene expression in rAML cases 
Difference in Sfpi1 gene expression between cases with a point mutation and those 
that are WT was interesting and gives a new line of investigation for the induction of 
rAML in relation to Sfpi1 in the CBA/H mouse model. As previously mentioned, the 
rAML cases with a point mutation are known to express Sfpi1, but due to the point 
mutation the PU.1 protein is not sufficiently functional leading to the development of 
leukaemia. Supporting this is the expression of PU.1 protein by assessing GFP 
expression by flow cytometry and also the fact that the expression of Sfpi1 was 
normal or slightly increased in cases of rAML compared to BMC control cells. In 
cases without a point mutation, the expression of Sfpi1 was consistently down 
regulated (Figure 3.3.6), suggesting the suppression of Sfpi1 is due to different factors 
in these cases. In contrast in the C3H/He strain, the point mutation did not affect the 
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expression of Sfpi1, but the presence of a copy loss or not determined the level of the 
expression (Hirouchi et al., 2008). To completely validate the results presented here, 
all the rAML cases need to be analysed for Sfpi1 copy loss, sequenced for point 
mutations and the level of Sfpi1 determined by MQ-RT_PCR. If confirmed, it would 
show a potential difference in the mechanism of rAML in two different strains 
susceptible to the disease. The suppression of the gene was not due to the presence of 
Flt3-ITD mutations, where the expression of Sfpi1 is down regulated (Finnon, et al. 
2011 submitted for publication). Further work is therefore needed in analysing the 
cause of the down regulation of Sfpi1 in rAMLs without R235 mutations, nonetheless 
these cases are consistent with the current thinking that a reduction of Sfpi1 
expression below a critical level eventually leads to leukaemia. The suppression of 
gene expression could for example either be by Sfpi1 promoter methylation (Tatetsu 
et al., 2007) or by a mutation of an upstream regulatory element (Bonadies et al., 
2010). 
 
4.10 Experimental limitations in the thesis 
    While the CBA Sfpi1 GFP/+ and Sfpi1 GFP/GFP mouse model has proved useful to 
study rAML, there are currently some limitations to how it can be used to study early 
events in the leukaemogenesis of the disease. The gene Sfpi1 is expressed at several 
different stages of haematopoiesis. Therefore the expression of the reporter gene 
seems to not be sensitive enough to be able to detect the small amount of cells that 
have an Sfpi1 copy loss at an early time point after exposure to ionising radiation 
when using flow cytometry. As was suggested previously, using a later time point 
after radiation exposure might be possible. A solution for the earlier time point could 
potentially be to identify another gene in the minimal deleted region on chromosome 
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2 that is expressed at a suitable level, ie expressed in haematopoietic cells and more 
specifically HSCs and progenitor cells. The gene should not involved in 
haematopoiesis as such and the expression should not change due to ionising 
irradiation or be involved in DNA damage and repair.  
    Another limitation to the results is the few experimental repeats in some cases, 
which could make the results either difficult to interpret if there is variability or a 
result could be found not to be significant if further repeats were made. In some cases, 
the lack of repeats means the results should be seen as provisional until further work 
has been done. The main reason for lack of experimental repeats was due to time 
constraints.  
     
4.11 Main conclusions and their implications for further work 
    The early work investigating in vitro radiation sensitivity of different populations 
of immature BMCs gave the first indication of where a potential target cell for the 
leukaemic events might be found. Lin- c-Kit+ cell populations, a fraction containing a 
high proportion of myeloid progenitors showed no difference in radiation sensitivity 
between the two mouse strains CBA/H and C57BL/6. The former strain is susceptible 
to rAML, whereas the latter is not. The Lin- fraction however, showed a significant 
difference in radiation sensitivity, with cells from the CBA/H strain being less 
radiosensitive. This suggested that a subpopulation within the Lin- fraction surviving 
exposure to ionising radiation is able to survive and carry potentially leukaemic 
mutations forming LSCs in CBA/H mice but not in C57BL/6 mice. 
    12 % of in vivo irradiated LSK cells were shown to contain chromosome 2 
interstitial deletions with Sfpi1 copy loss. The surface marker phenotype of immature 
forms/blasts in cases of leukaemia indicates that the LSC in the mouse model is 
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potentially a myeloid progenitor, which might be different to the target cell. The 
target cell has not yet been definitely identified. That is, the initial damage could 
occur in HSCs but a potential differentiation block at a later stage of development, 
presumably in a myeloid progenitor, leads to the development of rAML. A good 
starting point for further work would be to investigate a subpopulations of leukaemic 
cells in the LSK fraction and further make use of the surface markers CD34 and 
CD38.   
     Transplantation assays of immature haematopoietic cells, while needing further 
refinement, have shown to have potential for further use with refinement of the assay 
conditions.  Potentially, the assay would be of use for characterising and finding a 
target cell and to study early events in leukemic development of these cells. While 
using the transplant model, connections to recent publications regarding reduction of 
fitness of HSCs after exposure to ionising radiation were found (Marusyk et al., 2009; 
Fleenor et al., 2010). This raises interesting questions regarding the molecular 
mechanisms of leukaemic induction in the mouse model and how the chromosomal 
damage, deletion of a tumour suppressor gene and further mutations eventually give 
LSCs the proliferative advantage to take over the haematopoietic system of the 
affected animal. Fleenor and colleagues (Fleenor et al., 2010) have suggested that the 
connection between ionising radiation and carcinogenesis could be more complex 
than previously thought. Apart from ionising radiation causing oncogenic mutations, 
it also reduces the fitness of HSCs, that is, the irradiated cells become less 
competitive compared to unirradiated cells. An example is the fact that when 
irradiated HSCs are transplanted at a ratio of 9:1 with unirradiated cells, the 
unirradiated cells will preferentially reconstitute the host animal (Marusyk et al., 
2009). Some oncogenic mutations have been shown to be more likely to be selected 
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for than others, specifically following exposure to ionising radiation (Marusyk et al., 
2009). Furthermore exposure to radiation alters the microenvironment of the bone 
marrow. Stromal cells in the bone marrow can either increase proliferative signals, 
having a positive impact on LSCs or have a inhibitory affect on normal HSCs 
compared to LSCs (Fleenor et al., 2010). These complex relations could eventually 
lead to some cells becoming leukaemic. Further experiments are therefore also needed 
to study these relationships in relation to leukemic induction.  
    With regards to the CBA/H mouse model of rAML, it would be interesting to 
define exactly how the partial deletion of chromosome 2 could ultimately lead to 
increased fitness and competitive advantage. The gene Sfpi1 is likely to be one of the 
genes with oncogenic mutations that give a proliferative advantage compared to 
normal HSCs. The point mutation in the DNA sequence of the DNA binding domain 
is of interest as a cause for the proliferative advantage, presumably by the fact that it 
reduces the functionality of the transcription factor PU.1. At which point after 
radiation exposure this mutation occurs is still not known. To investigate the time 
point at which the LSC pool starts to expand, a systematic analysis of blood samples 
from irradiated animals could be undertaken, starting approximately 6 months after 
exposure as the earliest cases of rAML present around 9 months post irradiation 
exposure. Flow cytometric analysis could make use of the upregulation of the surface 
marker c-Kit and any other potential surface markers that might have been connected 
to the LSC in the model.  
    Since a direct down regulation of Sfpi1 gene expression also seems to be lead to the 
development of leukaemia in this model, future work could be done to investigate the 
causes, such as suppression of Sfpi1 promoter activity or how regulation by other 
mutations such as Flt3-ITDs lead to leukaemia in this model.  
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     The transgenic mouse model expressing GFP driven by the Sfpi1 promoter has 
proved to be useful in studying molecular events in BMCs after exposure to ionising 
radiation. In cases of rAML, the model allowed for the first time the detection of 
partial deletions of chromosome 2 and copy loss of Sfpi1 in live cells by flow 
cytometry.  
 
4.12 Summary of suggestions for further work 
 
Defining LSCs in the CBA/H mouse model through in vivo limiting dilution 
assays on leukaemic blasts. 
    Defining a leukaemic stem cell would make it possible to study the gene 
expression in LSCs and in so doing identify the molecular events that contribute 
to malignancy, particularly changes in gene expression (Passegue et al., 2003). In 
a wider context, this work would ultimately be aimed in human AML to find 
potential treatment targets. For human AML, immunocompromised mice are 
usually used for transplanting limiting dilutions of defined cell populations, but a 
CBA/H WT mouse could be used for the experiments using leukaemic blasts from 
the CBA Sfpi1 GFP/+ and Sfpi1 GFP/GFP. The phenotype of the LSC is the phenotype 
that would give the highest amount of cases of leukaemia in the recipients using 
the lowest number of cells. A LSC has been proposed for the C3H/He strain in 
rAML, with a CMP phenotype (Hirouchi et al., 2011). Since some differences 
was seen between the C3H/He strain and the CBA/H strain regarding the surface 
marker phenotype and gene expression of Sfpi1 in the leukaemic blasts, similar 
work in the CBA/H strain would establish whether there are differences between 
the strains regarding the LSC in rAML. 
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Investigation of the DNA binding properties of PU.1 protein with a point mutation 
in the DNA binding domain. 
    It is thought that the point mutation leads to the PU.1 protein not being able to 
bind to its target genes and function properly (Cook et al., 2004; Suraweera et al., 
2005), but the exact difference in binding properties have not been established. 
One way of establishing what difference point mutations located in the sequence 
coding for the DNA binding domain make would be to use an electrophoretic 
mobility shift assay (Hellman and Fried, 2007). 
 
Find alternative causes for Sfpi1 down regulation in some cases of rAML. 
    To further understand how the gene Sfpi1 is involved in leukaemogenesis in the 
model, the cases where the gene is downregulated and without a point mutation of 
the remaining copy. Methylation of the Sfpi1 promoter has been found to reduce 
the expression of the gene in a human myeloma cell line (Tatetsu et al., 2007). 
This can be investigated using bisulfate sequencing and a DNAseI 
hypersensitivity assay (Lu and Richardson, 2004). A point mutation in an 
upstream regulatory element was found in a small amount of patients with AML 
(Bonadies et al., 2010). To investigate the potential of similar point mutations in 
the mouse model of rAML, sequencing of known promoters and regulatory 
elements would confirm whether this is one of the mechanisms behind the 
downregulation of Sfpi1.  
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Assess Sfpi1 loss after in vitro exposure to ionising radiation. 
    It is not known exactly how much the microenvironment in the bone marrow 
contributes to early events of Sfpi1 copy loss and future leukaemogenesis. By 
assessing the frequency of copy loss after in vitro irradiation as was perfomed in 
this thesis, it would be possible to establish whether there are any differences to in 
vivo exposure. Furthermore, if there are no differences detected by in vivo and in 
vitro exposure, early events can be studied in cell cultures and therefore minimise 
the number of licensed scientific procedures that are performed. 
 
Repeating the CFU-S 12 assay using Sfpi1 GFP/+ mice. 
    The results did not show any CFU-S with copy loss of Sfpi1, which could 
partially have been because more colonies needed to be investigated. As was 
shown, when a large amount of cells carry a copy loss it is possible to detect by 
flow cytometry and also by PCR genotyping if Sfpi1 GFP/+ mice are used. 
Potentially, this might also work in the CFU-S assay and would make it possible 
to identify colonies with Sfpi1 copy loss that would be possible to investigate 
further, for example gene expression studies of potential target genes. 
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